As filed with the Securities and Exchange Commission on August 4, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
NextCure, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
|
|
47-5231247
(I.R.S. Employer
Identification Number)
|
|
9000 Virginia Manor Road, Suite 200
Beltsville, Maryland 20705
(240) 399-4900
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Michael Richman
Chief Executive Officer
NextCure, Inc.
9000 Virginia Manor Road, Suite 200
Beltsville, Maryland 20705
(240) 399-4900
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Asher M. Rubin, Esq.
Istvan Hajdu, Esq.
Kostian Ciko, Esq.
Sidley Austin LLP
787 Seventh Avenue
New York, New York 10019
(212) 839-5300
Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement.
If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐
If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer
☐
|
|
|
Accelerated filer
☐
|
|
|
Non-accelerated filer
☒
|
|
|
Smaller reporting company
☒
|
|
|
|
|
|
Emerging growth company
☒
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐
The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
EXPLANATORY NOTE
This registration statement contains two prospectuses:
•
a base prospectus which covers the offering, issuance and sale by the Registrant of up to a maximum aggregate offering price of $180,000,000 of the Registrant’s common stock, preferred stock, debt securities, warrants, and units from time to time in one or more offerings; and
•
a sales agreement prospectus covering the offering, issuance and sale by the Registrant of up to a maximum aggregate offering price of $16,762,573 of shares of the Registrant’s common stock that may be offered, issued, and sold from time to time under a sales agreement, dated August 4, 2023, with Leerink Partners LLC.
The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement to the base prospectus. The sales agreement prospectus immediately follows the base prospectus. The common stock that may be offered, issued, and sold by the Registrant under the sales agreement prospectus is included in the $180,000,000 of securities that may be offered, issued, and sold by the Registrant under the base prospectus. Upon termination of the sales agreement with Leerink Partners LLC, any portion of the $16,762,573 included in the sales agreement prospectus that is not sold pursuant to such sales agreement will be available for sale in other offerings pursuant to the base prospectus and a corresponding prospectus supplement.
The information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED AUGUST 4, 2023.
PROSPECTUS
NextCure, Inc.
$180,000,000
Common Stock
Preferred Stock
Debt Securities
Warrants
Units
We may offer and sell up to an aggregate of $180,000,000 of the securities identified above from time to time in one or more offerings. This prospectus provides you with a general description of the securities. We refer to the securities identified above as the “securities.” We may offer any combination of the securities, in separate series or classes and in amounts, at prices and on terms described in one or more supplements to this prospectus. In addition, this prospectus may be used to offer securities for the account of persons other than us.
This prospectus describes some of the general terms that may apply to the securities we may offer and sell and the general manner in which they may be offered. Each time we offer securities pursuant to this prospectus, we will provide one or more supplements to this prospectus or free writing prospectuses that contain specific information about the offering and the terms of any securities being sold. Prospectus supplements or free writing prospectuses may also add, update, or change information contained in this prospectus.
We may offer and sell these securities to or through agents, underwriters, dealers, or directly to purchasers, or through a combination of these methods, on a continuous or delayed basis. The names of any agents, underwriters or dealers and the terms of the arrangements with them will be stated in the applicable prospectus supplement or free writing prospectus.
Our common stock is listed on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “NXTC.” On August 3, 2023, the last reported sale price of our common stock on Nasdaq was $1.72 per share.
As of August 3, 2023, the aggregate market value of our common stock held by our non-affiliates, as calculated pursuant to the rules of the Securities and Exchange Commission, was approximately $50.3 million, based upon 27,330,283 shares of our outstanding common stock held by non-affiliates at the per share price of $1.84, the closing sale price of our common stock on Nasdaq on July 18, 2023. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public offering with a value exceeding more than one-third of our “public float” (i.e., the market value of our common stock held by our non-affiliates) in any 12-month period so long as our public float remains below $75.0 million. We have not sold any securities in reliance on General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this prospectus.
You should read carefully this prospectus, the applicable prospectus supplement, the information incorporated herein and therein by reference, and any free writing prospectus before you invest in any of our securities. Investing in our securities involves risks. See “Risk Factors” beginning on page 6.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The date of this prospectus is , 2023.
TABLE OF CONTENTS
|
|
|
|
|
|
1 |
|
|
|
|
|
|
|
|
2 |
|
|
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
4 |
|
|
|
|
|
|
|
|
6 |
|
|
|
|
|
|
|
|
7 |
|
|
|
|
|
|
|
|
9 |
|
|
|
|
|
|
|
|
10 |
|
|
|
|
|
|
|
|
14 |
|
|
|
|
|
|
|
|
22 |
|
|
|
|
|
|
|
|
24 |
|
|
|
|
|
|
|
|
25 |
|
|
|
|
|
|
|
|
26 |
|
|
|
|
|
|
|
|
26
|
|
|
ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement that we have filed with the U.S. Securities and Exchange Commission, or the SEC, under the Securities Act of 1933, as amended, or the Securities Act, using a “shelf” registration process. By using a shelf registration statement, we may sell securities from time to time and in one or more offerings as described in this prospectus up to an aggregate dollar amount of $180,000,000 of securities. Each time that we offer and sell securities, we will provide a prospectus supplement to this prospectus that contains specific information about the securities being offered and sold and the specific terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement or free writing prospectus may also add, update or change information contained in this prospectus with respect to that offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or free writing prospectus, you should rely on the prospectus supplement or free writing prospectus, as applicable. Before purchasing any securities, you should carefully read this prospectus, the applicable prospectus supplement, and any applicable free writing prospectuses, together with the additional information described under “Where You Can Find More Information” and “Incorporation by Reference.”
We have not authorized anyone to provide you with information other than that contained in this prospectus, any applicable prospectus supplement or free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We will not make an offer to sell or solicit any offer to buy these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus and the applicable prospectus supplement is accurate only as of the date on its respective cover, that the information appearing in any applicable free writing prospectus is accurate only as of the date of that free writing prospectus, and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise. Our business, financial condition, results of operations and prospects may have changed since those dates.
This prospectus, the information incorporated herein by reference, and any prospectus supplement or free writing prospectus contain or may contain references to trademarks, service marks, and trade names owned by us or other companies. Solely for convenience, trademarks, service marks, and trade names, including logos, artwork, and other visual displays, may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, service marks, and trade names. We do not intend our use or display of other companies’ trade names, service marks, or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Other trademarks, trade names, and service marks appearing in this prospectus are the property of their respective owners.
When we refer to “NextCure,” “we,” “our,” “us” and “Company” in this prospectus or any prospectus supplement, we mean NextCure, Inc., unless otherwise specified. When we refer to “you,” we mean the potential holders of the applicable series of securities.
WHERE YOU CAN FIND MORE INFORMATION
We file reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements, and other information about issuers, such as us, who file electronically with the SEC. The address of that website is www.sec.gov. We make available, free of charge, on our website at www.nextcure.com, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to such reports as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the SEC. Information on or accessible through our website is not incorporated by reference herein and does not form a part of this prospectus.
This prospectus and any prospectus supplement are part of a registration statement that we have filed with the SEC and do not contain all of the information in the registration statement. The full registration statement may be obtained through the SEC’s website, as provided above, or from us, as provided below under “Incorporation by Reference.” Certain documents establishing the terms of the offered securities are or may be filed as exhibits to the registration statement or documents incorporated by reference in the registration statement. Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is subject, and qualified in all respects by reference, to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters.
INCORPORATION BY REFERENCE
The SEC’s rules allow us to “incorporate by reference” information into this prospectus, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, and subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained in this prospectus or a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or a subsequently filed document incorporated by reference modifies or replaces that statement.
This prospectus and any accompanying prospectus supplement incorporate by reference the documents set forth below that have previously been filed with the SEC (other than those documents or the portions of those documents not deemed to be filed):
•
•
•
•
All reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, prior to the termination of this offering, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such reports and documents. We are not, however, incorporating by reference any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed “filed” with the SEC, including any information furnished pursuant to Items 2.02 or 7.01 of Form 8-K or related exhibits furnished pursuant to Item 9.01 of Form 8-K.
We will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, upon written or oral request of such person, a copy of any or all of the documents incorporated by reference in this prospectus, other than exhibits to such documents unless such exhibits are specifically incorporated by reference into such documents. Requests may be made in writing or by telephone at:
NextCure, Inc.
9000 Virginia Manor Road, Suite 200
Beltsville, Maryland 20705
(240) 399-4900
THE COMPANY
We are a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or “FIND-IO”, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. We are committed to discovering and developing first-in-class immunomedicines, which are immunomedicines that use new or unique mechanisms of action to treat a medical condition.
Our product candidate NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1. In June 2020, we initiated a Phase 1/2 clinical trial of NC410 in patients with advanced or metastatic solid tumors. The Phase 1 dose-escalation portion of this open-label trial was designed to evaluate the safety and tolerability of NC410 and determine its pharmacologically active and/or maximum tolerated dose. In October 2022, we announced the initiation of a Phase 1b/2 clinical trial to evaluate NC410 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in immune checkpoint refractory patients (colorectal, esophageal, endometrial and head and neck cancers) or immune checkpoint naïve solid tumor patients (colorectal and ovarian cancers).
Our product candidate NC762 is a monoclonal antibody that binds specifically to human B7 homolog 4 protein, or “B7-H4”, a protein expressed on multiple tumor types. In July 2021, we initiated a Phase 1/2 clinical trial of NC762 in patients with lung cancer, breast cancer, ovarian cancer or potentially other tumor types. The Phase 1 dose-escalation portion of this open-label trial was designed to evaluate the safety and tolerability of NC762 and determine its pharmacologically active and/or maximum tolerated dose. In November 2022, we announced initial data from the Phase 1 portion of this trial which indicate that NC762 appears to be well tolerated. Safety expansion studies are ongoing with the intent of selecting a recommended Phase 2 dose.
Our product candidate NC525 (LAIR-1 mAb) is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia, or “AML”, blast cells and leukemic stem cells, or “LSCs.” Preclinical data show that NC525 kills AML blast cells and LSCs while sparing hematopoietic stem and progenitor cells, or “HSPCs.” In February 2023, we initiated a Phase 1 trial for NC525 to evaluate the safety and preliminary efficacy of NC525 in AML, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia (CMML).
Implications of Being an Emerging Growth Company and Smaller Reporting Company
We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We may take advantage of certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm under Section 404 of the Sarbanes-Oxley Act of 2002 reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments. We may take advantage of these exemptions until December 31, 2024 or until we are no longer an “emerging growth company,” whichever is earlier. We will cease to be an emerging growth company prior to the end of such period if certain earlier events occur, including if we become a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, or Exchange Act, our annual gross revenues exceed $1.235 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period.
In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of accounting standards that have different effective dates
for public and private companies until those standards would otherwise apply to private companies. We have not elected to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not “emerging growth companies.”
We are also a “smaller reporting company” as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.
Corporate Information
We are a Delaware corporation formed in September 2015. Our primary executive offices are located at 9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705 and our telephone number is (240) 399-4900. Our website address is www.nextcure.com. Additionally, our filings with the SEC are posted on our website at www.nextcure.com. The information found on or accessible through our website is not part of this or any other report we file with or furnish to the SEC. The public can also obtain copies of these filings by accessing the SEC’s website at http://www.sec.gov.
RISK FACTORS
Investment in any securities offered pursuant to this prospectus and the applicable prospectus supplement involves significant risks. You should carefully consider the risk factors incorporated by reference to the 2022 Annual Report and any subsequent reports we file with the SEC after the date of this prospectus, and all other information contained or incorporated by reference into this prospectus, as updated by our subsequent filings under the Exchange Act, and the risk factors and other information contained in the applicable prospectus supplement and any applicable free writing prospectus before making a decision about investing in our securities. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business, financial condition, and results of operations. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus, the applicable prospectus supplement and any free writing prospectus may contain forward-looking statements, including with respect to our plans, objectives, and expectations for our business, operations, and financial performance and condition. Any statements contained herein or therein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “due,” “estimate,” “expect,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language. Forward-looking statements include, but are not limited to, statements about:
•
our expectations regarding the timing, progress, and results of preclinical studies and clinical trials for NC410, NC762, NC525 and any other product candidates we develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;
•
the timing or likelihood of regulatory filings for NC410, NC762, NC525 and any other product candidates we develop and our ability to obtain and maintain regulatory approvals for such product candidates for any indication;
•
the identification, analysis and use of biomarkers and biomarker data;
•
development of patient selection assays and companion or complementary diagnostics for NC410, NC762, NC525 or any other product candidates we develop;
•
our manufacturing capabilities and strategy, including the scalability of our manufacturing methods and processes;
•
our expectations regarding the potential benefits, activity, effectiveness, and safety of NC410, NC762, NC525 and any other product candidates we develop;
•
our intentions and ability to successfully commercialize our product candidates;
•
our expectations regarding the nature of the biological pathways we are targeting;
•
our expectations for our FIND-IO platform, including our ability to discover and advance product candidates using our FIND-IO platform;
•
the potential benefits of and our ability to maintain our relationship and collaboration with Yale University;
•
our estimates regarding our expenses, future revenues, capital requirements, our needs for or ability to obtain additional financing, and the period over which we expect our current cash, cash equivalents, and marketable securities to be sufficient to fund our operations;
•
our intended reliance on and the performance of third parties, including collaborators, contract research organizations, and third-party manufacturers;
•
our ability to protect and enforce our intellectual property protection and the scope and duration of such protection;
•
any failure of our information technology systems such as security breaches, loss of data and other disruptions;
•
developments and projections relating to our competitors and our industry, including competing therapies;
•
the impact of current and future laws and regulations; and
•
our intended use of proceeds from this offering.
These statements are based on management’s current expectations, estimates, forecasts, and projections about our business and industry, are not guarantees of future performance and involve known and unknown
risks, uncertainties and other factors that are in some cases beyond our control and that may cause our actual results, levels of activity, performance, or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in greater detail under “Risk Factors” and elsewhere in this prospectus and any related free writing prospectus, and in any other documents incorporated herein or therein (including in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings we make with the SEC pursuant to Section 13(a), 13(c), 14, or 15(d) of the Exchange Act). You should read these factors and the other cautionary statements made in this prospectus, the applicable prospectus supplement, and any free writing prospectus as being applicable to all related forward-looking statements wherever they appear herein or therein. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, levels of activity, performance, or achievements may vary materially from any future results, activity, performance, or achievements expressed or implied by these forward-looking statements. We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they were made. We undertake no obligation to publicly update any forward-looking statements after the date of this prospectus supplement, whether as a result of new information, future events or otherwise, except as required by law.
You should read this prospectus, the applicable prospectus supplement and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by the foregoing cautionary statements.
USE OF PROCEEDS
Unless we specify otherwise in a prospectus supplement, we intend to use the net proceeds from sales of securities by us for general corporate purposes. These purposes may include clinical trials, research and development expenditures, potential strategic acquisitions or licensing of complementary businesses, assets, services or technologies, expenditures to build our development and commercialization capabilities, further expansion of our manufacturing capacity, working capital and capital expenditures, and any other corporate purpose. As of the date of this prospectus, we cannot specify with certainty all of the particular uses of the net proceeds from the sale of securities under this prospectus. Accordingly, we will retain broad discretion over the use of such proceeds. Pending the use of the net proceeds described above, we plan to invest any net proceeds from sales of securities by us in a variety of capital preservation investments, including short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. We will not receive proceeds from sales of securities by persons other than us except as may otherwise be stated in an applicable prospectus supplement.
DESCRIPTION OF CAPITAL STOCK
The following description summarizes certain information about our capital stock. The summary does not purport to be complete and is subject, and qualified in its entirety by reference, to our amended and restated certificate of incorporation, or certificate of incorporation, and our amended and restated bylaws, or bylaws, each of which is incorporated by reference as an exhibit to the registration statement of which this prospectus is a part, and the applicable provisions of Delaware law. See “Incorporation by Reference.”
General
Our authorized capital stock under our certificate of incorporation consists of
•
100,000,000 shares of common stock, par value $0.001 per share; and
•
10,000,000 shares of preferred stock, par value $0.001 per share.
Common Stock
Voting Rights
Holders of our common stock are entitled to one vote for each share on all matters submitted to a vote of our stockholders, including the election of directors. Holders of our common stock do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of our directors. In addition, the affirmative vote of holders of 662∕3% of the voting power of all of the then outstanding voting stock will be required to take certain actions, including amending certain provisions of our certificate of incorporation, such as the provisions relating to the classified board.
Dividends
Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.
Liquidation
In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.
Other Rights and Preferences
Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future.
Fully Paid and Nonassessable
All of our outstanding shares of common stock are fully paid and nonassessable.
Preferred Stock
Under the terms of our certificate of incorporation, our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. For example, the issuance of our preferred stock could
adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation.
Registration Rights
Under the terms of our amended and restated investors’ rights agreement, holders of certain shares of our common stock, or their transferees, have the right to require us to register their shares under the Securities Act so that those shares may be publicly resold, and the right to include their shares in any registration statement we file, subject to certain limitations. These rights will expire, with respect to any particular stockholder, upon the earlier of May 13, 2024 and when that stockholder can sell all of its shares under Rule 144 under the Securities Act without limitation during any three-month period without registration.
Anti-Takeover Effects of Provisions of Our Certificate of Incorporation, Our Bylaws and Delaware Law
Certain provisions of Delaware law and our certificate of incorporation and our bylaws could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for our shares.
These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.
Delaware Anti-Takeover Statute
We are subject to Section 203 of the Delaware General Corporation Law, which prohibits persons deemed “interested stockholders” from engaging in a “business combination” with a publicly traded Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an “interested stockholder” is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation’s voting stock. Generally, a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by our board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock.
Undesignated Preferred Stock
The ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could have the effect of delaying, deferring, preventing or otherwise impeding any attempt to change control of us.
Special Stockholder Meetings
Our certificate of incorporation and our bylaws provide that a special meeting of stockholders may be called only by or at the direction of our board of directors or by the Chair of our board of directors.
Requirements for Advance Notification of Stockholder Nominations and Proposals
Our bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of our board of directors or a committee of our board of directors.
Elimination of Stockholder Action by Written Consent
Our certificate of incorporation and our bylaws do not permit stockholders action by written consent without a meeting.
Classified Board; Election and Removal of Directors; Filling Vacancies; Board Size
Our board of directors is divided into three classes. The directors in each class serve for a three-year term, one class being elected each year by our stockholders, with staggered three-year terms. Only one class of directors is elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, holders of a majority of the shares of common stock outstanding will be able to elect all of our directors. Our certificate of incorporation provides for the removal of any of our directors only for cause and requires a stockholder vote by the holders of at least a 662∕3% of the voting power of the then outstanding voting stock. Any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of the board, may only be filled by a resolution of our board of directors unless our board of directors determines that such vacancies shall be filled by our stockholders. Furthermore, the authorized number of directors may be changed only by a resolution of our board of directors. This system of electing and removing directors, filling vacancies and fixing the size of the board may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.
Choice of Forum
Our bylaws provide that unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware or, if subject matter jurisdiction of such action is vested exclusively in the federal courts, the United States District Court for the District of Delaware will, to the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers and employees, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws, (iv) any action or proceeding to interpret, apply, enforce, or determine the validity of our certificate of incorporation or bylaws or (v) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery or the United States District Court for the District of Delaware, as applicable, having personal jurisdiction over the indispensable parties named as defendants therein. In addition, any person holding, owning, or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and to have consented to this provision of our bylaws. The choice of forum provision does not apply to any actions arising under the Securities Act or the Exchange Act. Although our bylaws contain the choice of forum provision described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable.
Amendment of Charter Provisions
The amendment of any of the above provisions that are in our certificate of incorporation, except for the provision making it possible for our board of directors to issue undesignated preferred stock, would require approval by a stockholder vote by the holders of at least a 662∕3% of the voting power of our then outstanding voting stock.
The provisions of the Delaware General Corporation Law, our certificate of incorporation and our bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.
Limitation on Liability and Indemnification Matters
Our certificate of incorporation contains provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for:
•
any breach of the duty of loyalty to us or our stockholders;
•
any act or omission not in good faith that involves intentional misconduct or a knowing violation of law;
•
unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or
•
any transaction from which the director derived an improper personal benefit.
Our bylaws provide that we are required to indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. Our bylaws also obligate us to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of such person’s actions in that capacity regardless of whether we would otherwise be permitted to indemnify such person under Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. These indemnification agreements generally require us, among other things, to indemnify our directors, executive officers, and these employees against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements also generally require us to advance any expenses incurred by the directors, executive officers and employees as a result of any proceeding against them as to which they could be indemnified. We believe that these provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain directors’ and officers’ liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment in some circumstances.
The limitation of liability and indemnification provisions in our certificate of incorporation and bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. Further, a stockholder’s investment may be adversely affected to the extent that we pay the costs of settlement and damage.
Listing
Our common stock is listed on Nasdaq under the symbol “NXTC.”
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company, LLC. The transfer agent and registrar’s address is 6201 15th Avenue, Brooklyn, New York 11219.
DESCRIPTION OF DEBT SECURITIES
The following description summarizes certain terms and conditions of the debt securities that we may offer and sell pursuant to this prospectus. When we offer to sell a particular series of debt securities, we will describe the specific terms and conditions of the series in a prospectus supplement to this prospectus. We will also indicate in the applicable prospectus supplement whether the general terms and conditions described in this prospectus apply to the series. The terms and conditions of the series may be different in one or more respects from the terms and conditions described below. If so, those differences will be described in the applicable prospectus supplement. We urge you to read the applicable prospectus supplement and any related free writing prospectus, as well as the indenture, which may be amended or supplemented from time to time, that contains the terms of the debt securities.
The following summary of provisions of the indenture does not purport to be complete and is subject, and qualified in its entirety by reference, to the complete text of the indenture, including, but not limited to, definitions therein of certain terms. This summary may not contain all of the information that you may find useful. The terms and conditions of the debt securities of each series will be set forth in those debt securities and in the indenture and in the applicable prospectus supplement.
The form of indenture has been filed as an exhibit to the registration statement of which this prospectus forms a part. A form of each debt security, reflecting the specific terms and provisions of that series of debt securities, will be filed with the SEC in connection with each offering and will be incorporated by reference in the registration statement of which this prospectus forms a part.
General
We may offer the debt securities from time to time in as many distinct series as we may determine. The indenture does not limit the amount of debt securities that we may issue thereunder. We may, without the consent of the holders of the debt securities of any series, issue additional debt securities ranking equally with, and otherwise similar in all respects to, the debt securities of the series (except for the public offering price and the issue date) so that those additional debt securities will be consolidated and form a single series with the debt securities of the series previously offered and sold.
The debt securities of each series will be issued in fully registered form without interest coupons. We currently anticipate that the debt securities of each series offered and sold pursuant to this prospectus will be issued as global debt securities as described under “Global Debt Securities” and will trade in book-entry form only.
Debt securities denominated in U.S. dollars will be issued in denominations of $2,000 and any integral multiple of $1,000 in excess thereof, unless otherwise specified in the applicable prospectus supplement. If the debt securities of a series are denominated in a foreign or composite currency, the applicable prospectus supplement will specify the denomination or denominations in which those debt securities will be issued.
Unless otherwise specified in the applicable prospectus supplement, we will repay the debt securities of each series at 100% of their principal amount, together with any premium and accrued and unpaid interest thereon at maturity, except if those debt securities have been previously redeemed or purchased and cancelled.
Unless otherwise specified in the applicable prospectus supplement, the debt securities of each series will not be listed on any securities exchange.
Provisions of Indenture
A prospectus supplement, the indenture, and a supplemental indenture or authorizing resolution of our board of directors (including any related officer’s certificate or Company order), if any, relating to any series of debt securities being offered will include specific terms relating to the offering. These terms will include some or all of the following:
•
the form and title of the debt securities;
•
the aggregate principal amount of the debt securities and any limit on the aggregate principal amount, provided, however, that such amount may from time to time be increased by a resolution of our board of directors;
•
the price or prices at which the debt securities will be sold;
•
the person to whom any interest on a debt security of the series will be payable, if other than the person in whose name that debt security is registered;
•
the date or dates on which the principal of the debt securities will be payable;
•
the rate or rates (fixed or variable, or combination thereof) at which the debt securities shall bear interest, if any, or the method of determining such rate or rates;
•
the date or dates on which any such interest shall be payable, the date or dates on which payment of any such interest shall commence and the record dates, if any, for such payment date or dates, or the method of determining such date or dates, and the basis upon which interest shall be calculated if other than that of a 360-day year of twelve 30-day months, the right, if any, to extend or defer interest payments and the duration of such extension or deferral;
•
any optional or mandatory redemption or repayment option, including any sinking fund, amortization or analogous provisions;
•
if other than a minimum denomination equal to $2,000 or an integral multiple of $1,000 in excess thereof, the denominations in which any debt securities of the series will be issuable;
•
any special tax implications of the debt securities, including provisions for original issue discount securities, if offered;
•
any provisions granting special rights to holders when a specified event occurs;
•
the percentage of the principal amount at which the debt securities will be issued and any payments due if the maturity of the debt securities is accelerated;
•
any Events of Default or covenants with respect to the debt securities that differ from, or are in addition to, those set forth in the indenture;
•
if other than U.S. dollars, the currency or currencies for which the debt securities will be issued or in which the principal thereof, any premium thereon and any interest thereon will be payable;
•
provisions regarding the convertibility or exchangeability of the debt securities;
•
provisions pertaining to the issuance of debt securities in the form of global debt securities, as described below;
•
provisions relating to the satisfaction and discharge of the indenture;
•
the form of and conditions to issuance of debt securities issuable in definitive form, other than as described below;
•
if other than the trustee, the identity of any other trustee, the registrar for the debt securities and any paying agent;
•
whether the debt securities of the series will be guaranteed by any persons and, if so, the identity of such persons, the terms and conditions upon which such debt securities will be guaranteed and, if applicable, the terms and conditions upon which such guarantees may be subordinated to other indebtedness of the respective guarantors;
•
whether the debt securities of the series will be secured by any collateral and, if so, the terms and conditions upon which such debt securities will be secured and, if applicable, upon which such liens may be subordinated to other liens securing other indebtedness of us or of any guarantor;
•
whether the debt securities will be issued in a transaction exempt from registration under the Securities Act and any restriction or condition on the transferability of the debt securities of such series;
•
the exchanges, if any, on which the debt securities may be listed;
•
the terms of any right to convert or exchange debt securities of such series into any other securities or property of ours or of any other corporation or person, and the additions or changes, if any, to the indenture with respect to the debt securities of such series to permit or facilitate such conversion or exchange; and
•
any other terms not prohibited by the provisions of the indenture.
Global Debt Securities
Certain series of the debt securities may be issued as permanent global debt securities to be deposited with a depositary with respect to that series. Unless otherwise indicated in the applicable prospectus supplement, the following is a summary of the depository arrangements applicable to debt securities issued in permanent global form and for which The Depository Trust Company, or DTC, acts as depositary.
Each global debt security will be deposited with, or on behalf of, DTC, as depositary, or its nominee and registered in the name of a nominee of DTC. Except under the limited circumstances described below, global debt securities are not exchangeable for definitive certificated debt securities.
Ownership of beneficial interests in a global debt security is limited to institutions that have accounts with DTC or its nominee, or participants, or persons that may hold interests through participants. In addition, ownership of beneficial interests by participants in a global debt security will be evidenced only by, and the transfer of that ownership interest will be effected only through, records maintained by DTC or its nominee for a global debt security. Ownership of beneficial interests in a global debt security by persons that hold through participants will be evidenced only by, and the transfer of that ownership interest within that participant will be effected only through, records maintained by that participant. DTC has no knowledge of the actual beneficial owners of the debt securities. Beneficial owners will not receive written confirmation from DTC of their purchase, but beneficial owners are expected to receive written confirmations providing details of the transaction, as well as periodic statements of their holdings, from the participants through which the beneficial owners entered the transaction. The laws of some jurisdictions require that certain purchasers of securities take physical delivery of such securities in definitive form. Such laws may impair the ability to transfer beneficial interests in a global debt security.
Payments on debt securities represented by a global debt security registered in the name of or held by DTC or its nominee will be made to DTC or its nominee, as the case may be, as the registered owner and holder of the global debt security representing the debt securities. We expect that upon receipt of any payments with respect to a global debt security, DTC will immediately credit accounts of participants on its book-entry registration and transfer system with payments in amounts proportionate to their respective beneficial interests in the principal amount of that global debt security as shown in the records of DTC. Payments by participants to owners of beneficial interests in a global debt security held through those participants will be governed by standing instructions and customary practices, as is now the case with securities held for the accounts of customers in bearer form or registered in “street name,” and will be the sole responsibility of those participants, subject to any statutory or regulatory requirements that may be in effect from time to time.
Neither we, any trustee nor any of our respective agents will be responsible for any aspect of the records of DTC, any nominee or any participant relating to, or payments made on account of, beneficial interests in a permanent global debt security or for maintaining, supervising or reviewing any of the records of DTC, any nominee or any participant relating to such beneficial interests.
A global debt security is exchangeable for definitive debt securities registered in the name of, and a transfer of a global debt security may be registered to, any person other than DTC or its nominee, only if:
•
DTC notifies us that it is unwilling or unable to continue as depositary for that global debt security or at any time DTC ceases to be registered under the Exchange Act, and a successor depositary is not appointed by us within 90 days after our receipt of such notice;
•
there shall have occurred and be continuing an event of default under the debt securities and the registrar shall have received a request from the depositary to issue certificated securities;
•
we determine in our sole discretion that the global debt security will be exchangeable for definitive debt securities in registered form; or
•
as may be provided in any applicable prospectus supplement.
Any global debt security that is exchangeable pursuant to the preceding sentence will be exchangeable in whole for definitive debt securities in registered form, of like tenor and of an equal aggregate principal amount as the global debt security. The definitive debt securities will be registered by the registrar in the name
or names instructed by DTC. We expect that these instructions may be based on directions received by DTC from its participants with respect to ownership of beneficial interests in the global debt security.
Except as provided above, owners of the beneficial interests in a global debt security will not be entitled to receive physical delivery of debt securities in definitive form and will not be considered the holders of debt securities for any purpose under the indenture. No global debt security will be exchangeable except for another global debt security of like denomination and tenor to be registered in the name of DTC or its nominee. Accordingly, each person owning a beneficial interest in a global debt security must rely on the procedures of DTC and, if that person is not a participant, on the procedures of the participant through which that person owns its interest, to exercise any rights of a holder under the global debt security or the indenture.
We understand that, under existing industry practices, in the event that we request any action of holders, or an owner of a beneficial interest in a global debt security desires to give or take any action that a holder is entitled to give or take under the debt securities or the indenture, DTC would authorize the participants holding the relevant beneficial interest to give or take that action, and those participants would authorize beneficial owners owning through those participants to give or take that action or would otherwise act upon the instructions of beneficial owners owning through them.
DTC is a limited purpose trust company organized under the laws of the State of New York, a “banking organization” within the meaning of the New York Banking Law, a member of the Federal Reserve System, a “clearing corporation” within the meaning of the New York Uniform Commercial Code and a “clearing agency” pursuant to the provisions of Section 17A of the Exchange Act. DTC was created to hold securities of its participants and to facilitate the clearance and settlement of securities transactions among its participants in those securities through electronic book-entry changes in accounts of the participants, thereby eliminating the need for physical movement of securities certificates. DTC’s participants include securities brokers and dealers, banks, trust companies, clearing corporations and certain other organizations. DTC is a wholly owned subsidiary of The Depository Trust & Clearing Corporation, or DTCC. DTCC is the holding company for DTC, National Securities Clearance Corporation and Fixed Income Clearing Corporation, all of which are registered clearing agencies. DTCC is owned by the users of its regulated subsidiaries. Access to the DTC system is also available to others, such as banks, brokers, dealers, trust companies and clearing corporations that clear through or maintain a custodial relationship with a participant, either directly or indirectly. The rules applicable to DTC and its participants are on file with the SEC. More information about DTC can be found at www.dtcc.com; the information contained on that website is not incorporated in this prospectus or in any prospectus supplement.
Certain Covenants
The indenture sets forth limited covenants that will apply to each series of debt securities issued under the indenture, unless otherwise specified in the applicable prospectus supplement. Under the indenture, we will agree to:
•
pay the principal of, and interest and any premium on, the debt securities when due;
•
maintain a place of payment;
•
deliver an officer’s certificate to the trustee within 120 days after the end of each fiscal year regarding our review of compliance with our obligations under the indenture;
•
maintain our corporate existence; and
•
deposit sufficient funds with any paying agent on or before the due date for any payment of principal, interest or premium.
Consolidation, Merger or Asset Sale
The indenture generally will allow us to consolidate with or merge into any other person, association or entity. The indenture will also allow us to convey, transfer or lease our property and assets as, or substantially as, an entirety to a person, association or entity.
However, we will only consolidate with or merge into any other person, association or entity or convey, transfer or lease our properties and assets as, or substantially as, an entirety according to the terms and conditions of the indenture, including the following requirements:
•
(i) we are the surviving person or (ii) the remaining or acquiring person, association or entity is a corporation or partnership organized under the laws of the United States, any state or the District of Columbia and expressly assumes all of our responsibilities and liabilities under the indenture, including the punctual payment of all amounts due on the debt securities and performance of the covenants in the indenture;
•
immediately after giving effect to the transaction, no Event of Default, and no event which, after notice or lapse of time or both, would become an Event of Default, as defined below, exists; and
•
delivery to the trustee of an officer’s certificate and an opinion of counsel, each stating that all related conditions have been satisfied.
The remaining or acquiring person, association or entity will be substituted for us in the indenture with the same effect as if it had been an original party to the indenture. Thereafter, the successor may exercise our rights and powers under the indenture, in our name or in its own name. If we sell or transfer our assets substantially as an entirety, we will be released from all our liabilities and obligations under the indenture and the debt securities. If we lease our assets substantially as an entirety, we will not be released from our obligations under the indenture and the debt securities.
Events of Default
Unless otherwise specified in the applicable prospectus supplement, each of the following events will be an Event of Default under the indenture with respect to any series of debt securities issued under the indenture:
•
failure to pay any interest on any debt security of the series when due, continued for 30 days;
•
failure to pay principal of (or premium, if any, on) any debt security of the series when due;
•
failure to deposit a sinking fund payment when and as due by the terms of a debt security of the series;
•
failure to perform or comply with any covenant in the indenture or related supplemental indenture, continued for 90 days after written notice as provided in the indenture;
•
certain events in bankruptcy, insolvency or reorganization affecting us; and
•
any other Event of Default set forth in the indenture or supplemental indenture relating to the debt securities of that series.
An Event of Default for a particular series of debt securities does not necessarily constitute an Event of Default for any other series of debt securities issued under the indenture. The trustee may withhold notice to the holders of a series of debt securities of any default, except payment defaults of principal or interest or any premium on those debt securities, if it considers such withholding to be in the interest of the holders.
If an Event of Default occurs and is continuing, then the trustee or the holders of 25% in aggregate principal amount of the outstanding debt securities of that series may declare the entire principal amount of the debt securities of that series to be due and payable immediately; provided, however, that the holders of a majority of the aggregate principal amount of the debt securities of that series may, under certain circumstances, rescind and annul the declaration.
Subject to provisions in the indenture relating to its duties in case an Event of Default shall have occurred and be continuing, the trustee will not be under an obligation to exercise any of its rights or powers under the indenture at the request, order or direction of any holders of debt securities then outstanding under the indenture, unless the holders shall have offered to the trustee reasonable indemnity. If such reasonable indemnity is provided, the holders of a majority in aggregate principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any power conferred on the trustee, for any series of debt securities.
Defeasance
Debt securities of a series may be defeased at any time in accordance with their terms and as set forth in the indenture and described briefly below, unless the securities resolutions or supplemental indenture establishing the terms of the series provides otherwise. Any defeasance may terminate all of our obligations (with limited exceptions) with respect to a series of debt securities and the indenture, or Legal Defeasance, or it may terminate only our obligations under any restrictive covenants which may be applicable to a particular series, or Covenant Defeasance.
We may exercise our Legal Defeasance option even though we have also exercised our Covenant Defeasance option. If we exercise the Legal Defeasance option with respect to a series of debt securities, that series may not be accelerated because of an Event of Default. If we exercise the Covenant Defeasance option, that series of debt securities may not be accelerated by reference to any restrictive covenants which may be applicable to that particular series.
To exercise either defeasance option as to a series of debt securities, we must:
•
irrevocably deposit in trust with the trustee or another trustee money or U.S. government obligations in an amount to pay and discharge the principal of and any premium and interest on the debt securities on the stated maturities or redemption dates therefor and any mandatory sinking fund payments;
•
deliver a certificate from an independent public accountant or financial advisor expressing its opinion that the payments of principal and interest when due on the deposited U.S. government obligations, without reinvestment, plus any deposited money without investment, will provide cash at the times and in the amounts necessary to pay the principal of and premium and interest when due on all debt securities of the series to maturity or redemption, as the case may be, and any mandatory sinking fund payments; and
•
comply with certain other conditions, including that there be no Event of Default at the time of deposit or Event of Default due to bankruptcy on or prior to the 90th day after the deposit date. In particular, we must obtain an opinion of tax counsel that the defeasance will not result in recognition of any gain or loss to holders for federal income tax purposes as a result of the deposit.
Discharge
We may discharge all our obligations under the indenture with respect to the notes of any series, other than our obligation to register the transfer of and to exchange notes of that series, when either:
•
all outstanding notes of that series (except (i) mutilated, destroyed, lost or stolen notes that have been replaced or paid and notes for whose payment money has been deposited in trust and thereafter repaid to us and (ii) notes for whose payment money has theretofore been deposited in trust or segregated and held in trust by us and thereafter repaid to us or discharged from such trust) have been delivered to the trustee cancelled or for cancellation; or
•
all such notes not so delivered for cancellation have either become due and payable or will become due and payable at their stated maturity within one year or are to be called for redemption within one year, and we have deposited with the trustee in trust an amount of cash sufficient to pay the entire indebtedness of such notes, including interest to the stated maturity or applicable redemption date; and
•
we have paid all other sums due under the indenture and delivered an officer’s certificate and opinion of counsel to the trustee stating that all related conditions have been satisfied.
Modification of the Indenture
Under the indenture, generally we and the trustee may modify our rights and obligations and the rights of the holders with the consent of the holders of not less than a majority in aggregate principal amount of the outstanding debt securities of each series affected by the modification.
No modification of the principal or interest payment terms, no modification reducing the percentage required for any waiver or modifications and no modification impairing the right to institute suit for the enforcement of any payment on debt securities of any series when due, is effective against any holder without its consent.
In addition, we and the trustee may amend the indenture without the consent of any holder of the debt securities to make certain changes, such as:
•
curing ambiguities or correcting defects or inconsistencies;
•
otherwise adding or changing provisions with respect to matters or questions arising under the indenture relating to a particular series of debt securities that does not adversely affect the rights of any holder in any material respect;
•
evidencing the succession of another person to us, and the assumption by that successor of our obligations under the indenture and the debt securities of any series;
•
providing for the acceptance of appointment by a successor trustee;
•
qualifying the indenture under the Trust Indenture Act, or TIA;
•
complying with the rules and regulations of any securities exchange or automated quotation system on which debt securities of any series may be listed or traded or any applicable depositary;
•
adding, changing or eliminating provisions relating to a particular series of debt securities to be issued, provided that any such addition, change or elimination (1) shall neither (i) apply to any debt security of any series created prior to the execution of such supplemental indenture and entitled to the benefit of such provision nor (ii) modify the rights of the holders of any such debt security with respect to such provision or (2) shall become effective only when there is not such debt security outstanding;
•
to establish the form or terms of any debt securities of any series under the indenture; or
•
to provide for the issuance of additional debt securities of any series.
No Individual Liability of Officers, Directors, Employees or Stockholders
No director, officer, employee or stockholder, as such, of ours or any of our affiliates will have any personal liability in respect of our obligations under the indenture or the debt securities by reason of his, her or its status as such.
Governing Law
The indenture and all the debt securities will be governed by, and construed in accordance with, the laws of the State of New York.
Regarding the Trustee
The indenture provides that there may be more than one trustee thereunder, each with respect to one or more series of debt securities. If there are different trustees for different series of debt securities, each trustee will be a trustee of a trust or trusts separate and apart from the trust or trusts administered by any other trustee under the indenture. Unless otherwise indicated in any applicable prospectus supplement, any action permitted to be taken by a trustee may be taken by such trustee only with respect to the one or more series of debt securities for which it is the trustee under the indenture. Any trustee under the indenture may resign or be removed with respect to one or more series of debt securities. All payments of principal of, and premium, if any, and interest on, and all registration, transfer, exchange, authentication and delivery (including authentication and delivery on original issuance of the debt securities) of, the debt securities of a series will be effected by the trustee with respect to that series at an office designated by the trustee.
We may maintain corporate trust relationships in the ordinary course of business with the trustee. The trustee shall have and be subject to all the duties and responsibilities specified with respect to an indenture trustee under the TIA. Subject to the provisions of the TIA, the trustee is under no obligation to exercise any
of the powers vested in it by the indenture at the request of any holder of debt securities, unless offered satisfactory indemnity by the holder against the costs, expense and liabilities which might be incurred thereby.
Under the TIA, the indenture is deemed to contain limitations on the right of the trustee, should it become a creditor of our company, to obtain payment of claims in some cases or to realize on certain property received in respect of any such claim as security or otherwise. The trustee may engage in other transactions with us. If it acquires any conflicting interest under the TIA relating to any of its duties with respect to the debt securities, however, it must eliminate the conflict or resign as trustee.
DESCRIPTION OF WARRANTS
The following description summarizes certain terms and conditions of the warrants that we may offer and sell pursuant to this prospectus. When we offer to sell a particular series of warrants, we will describe the specific terms and conditions of the warrants in a prospectus supplement to this prospectus. We will also indicate in the applicable prospectus supplement whether the general terms and conditions described in this prospectus apply to the series of warrants. The terms and conditions of the warrants may be different in one or more respects from the terms and conditions described below. If so, those differences will be described in the applicable prospectus supplement. We urge you to read the applicable prospectus supplement and any related free writing prospectus, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants.
We may issue warrants for the purchase of shares of our common stock or preferred stock or of debt securities. We may issue warrants independently or together with other securities, and the warrants may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and the investors or a warrant agent. The terms of any warrants offered under a prospectus supplement may differ from the terms described below.
The particular terms of any issue of warrants will be described in the prospectus supplement relating to the issue. Those terms may include:
•
the number of shares of common stock or preferred stock issuable upon the exercise of warrants to purchase such shares and the price at which such number of shares may be purchased upon such exercise;
•
the designation, stated value and terms (including, without limitation, liquidation, dividend, conversion, and voting rights) of the series of preferred stock issuable upon exercise of warrants to purchase preferred stock;
•
the principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise price for the warrants, which may be payable in cash, securities or other property;
•
the date, if any, on and after which the warrants and the related debt securities, preferred stock or common stock will be separately transferable;
•
the terms of any rights to redeem or call the warrants;
•
the date on which the right to exercise the warrants will commence and the date on which the right will expire;
•
U.S. federal income tax consequences applicable to the warrants; and
•
any additional terms of the warrants, including terms, procedures and limitations relating to the exchange, exercise and settlement of the warrants.
Each warrant will entitle its holder to purchase the principal amount of debt securities or the number of shares of preferred stock or common stock at the exercise price set forth in, or calculable as set forth in, the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void.
A holder of warrant certificates may exchange them for new warrant certificates of different denominations, present them for registration of transfer and exercise them at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement. Until any warrants to purchase debt securities are exercised, the holder of the warrants will not have any rights of holders of the debt securities that can be purchased upon exercise, including any rights to receive payments of principal, premium or interest on the underlying debt securities or to enforce covenants in the applicable indenture. Until any warrants to purchase common stock or preferred stock are exercised, the holders of the warrants will not have any rights of holders of the underlying common stock or preferred stock, including any rights to receive dividends or payments upon any liquidation, dissolution or winding up on the common stock or preferred stock, if any.
This description and the description in the applicable prospectus supplement and any free writing prospectus of any warrants that we may offer is not and will not necessarily be complete and will be subject, and qualified in its entirety by reference, to the applicable warrant agreements and warrant certificates, which will be filed with the SEC.
DESCRIPTION OF UNITS
We may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series. We may evidence each series of units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of any unit agent in the applicable prospectus supplement relating to a particular series of units.
The following description summarizes certain features of the units that we may offer under this prospectus. When we offer to sell any units, we will describe the specific terms and conditions of the units in a prospectus supplement to this prospectus. We urge you to read the applicable prospectus supplement and any related free writing prospectus, as well as the complete unit agreements that contain the terms of the units. If we offer any units, certain terms of that series of units will be described in the applicable prospectus supplement, including, without limitation, the following, as applicable:
•
the title of the series of units;
•
identification and description of the separate constituent securities comprising the units;
•
the price or prices at which the units will be issued;
•
the date, if any, on and after which the constituent securities comprising the units will be separately transferable;
•
a discussion of certain U.S. federal income tax considerations applicable to the units; and
•
any other terms of the units and their constituent securities.
The description in the applicable prospectus supplement and any free writing prospectus of any units that we may offer will not necessarily be complete and will be subject, and qualified in its entirety by reference, to the unit agreement and, if applicable, collateral arrangements and depositary arrangements relating to such units, which will be filed with the SEC.
PLAN OF DISTRIBUTION
We may sell the offered securities from time to time:
•
through underwriters or dealers;
•
through agents;
•
directly to one or more purchasers; or
•
through a combination of any of these methods of sale.
We will identify the specific plan of distribution, including any underwriters, dealers, agents, or direct purchasers and their compensation in the applicable prospectus supplement.
LEGAL MATTERS
Certain legal matters relating to the issuance and sale of the securities offered hereby will be passed upon for us by our counsel, Sidley Austin LLP, New York, New York. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.
EXPERTS
The financial statements of NextCure, Inc. appearing in NextCure, Inc.’s Annual Report (Form 10-K) for the year ended December 31, 2022, have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.
The information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED AUGUST 4, 2023.
PROSPECTUS
Up to $16,762,573
Common Stock
We have entered into a sales agreement (the “sales agreement”) with Leerink Partners LLC (“Leerink Partners”) relating to shares of our common stock, par value $0.001 per share, offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $16,762,573 from time to time through Leerink Partners acting as our agent.
Our common stock is listed on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “NXTC.” On August 3, 2023, the last reported sale price of our common stock on Nasdaq was $1.72 per share.
As of August 3, 2023, the aggregate market value of our common stock held by our non-affiliates, as calculated pursuant to the rules of the Securities and Exchange Commission, was approximately $50.3 million, based upon 27,330,283 shares of our outstanding common stock held by non-affiliates at the per share price of $1.84, the closing sale price of our common stock on Nasdaq on July 18, 2023. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public offering with a value exceeding more than one-third of our “public float” (i.e., the market value of our common stock held by our non-affiliates) in any 12-month period so long as our public float remains below $75.0 million. We have not sold any securities in reliance on General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this prospectus.
Sales of our common stock, if any, under this prospectus will be made in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Leerink Partners is not required to sell any specific amount of securities, but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Leerink Partners and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.
The compensation to Leerink Partners for sales of common stock sold pursuant to the sales agreement will be an amount equal to 3.0% of the gross proceeds of any shares of common stock sold under the sales agreement. In connection with the sale of the common stock on our behalf, Leerink Partners will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of Leerink Partners will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Leerink Partners with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended (the “Exchange Act”). See “Plan of Distribution” beginning on page S-14 for additional information regarding the compensation to be paid to Leerink Partners.
We are an “emerging growth company” and a “smaller reporting company” under federal securities laws and as such, have elected to comply with reduced public company reporting requirements for this prospectus and the documents incorporated by reference herein and may elect to comply with reduced public company reporting requirements in future filings. See “Prospectus Summary — Implications of Being an Emerging Growth Company and Smaller Reporting Company.”
Our business and an investment in our common stock involve significant risks. Before making an investment decision, you should review carefully and consider all of the information set forth in this prospectus and the documents incorporated by reference. These risks are described under the caption “Risk Factors” beginning on page S-4 of this prospectus and in the documents incorporated by reference into this prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
Leerink Partners
The date of this prospectus is , 2023.
TABLE OF CONTENTS
|
|
|
|
|
|
S-ii |
|
|
|
|
|
|
|
|
S-1 |
|
|
|
|
|
|
|
|
S-3 |
|
|
|
|
|
|
|
|
S-4 |
|
|
|
|
|
|
|
|
S-7 |
|
|
|
|
|
|
|
|
S-9 |
|
|
|
|
|
|
|
|
S-10 |
|
|
|
|
|
|
|
|
S-14 |
|
|
|
|
|
|
|
|
S-16 |
|
|
|
|
|
|
|
|
S-16 |
|
|
|
|
|
|
|
|
S-16
|
|
|
ABOUT THIS PROSPECTUS
This prospectus is part of a shelf registration statement on Form S-3 that we filed with the Securities and Exchange Commission (the “SEC”). Under this shelf registration process, we may sell any combination of the securities described in our base prospectus included in the shelf registration statement in one or more offerings up to a total aggregate offering price of $180,000,000, subject to the limitations of General Instruction I.B.6 of Form S-3, described on the cover of that prospectus. The $16,762,573 of common stock that may be offered, issued and sold under this prospectus is included in the $180,000,000 of securities that may be offered, issued and sold by us pursuant to our shelf registration statement.
You should rely only on the information contained in, or incorporated by reference into, this prospectus and in any free writing prospectus that we may authorize for use in connection with this offering. We have not, and Leerink Partners has not, authorized any other person to provide you with different or additional information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and Leerink Partners is not, making an offer to sell or soliciting an offer to buy our securities in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus, the documents incorporated by reference into this prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus, the documents incorporated by reference into this prospectus, and any free writing prospectus that we may authorize for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the section of this prospectus entitled “Incorporation of Certain Documents by Reference” and in the section of the accompanying base prospectus entitled “Where You Can Find More Information.”
We are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus and the offering of our common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of our common stock and the distribution of this prospectus outside the United States. This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.
In this prospectus, the terms “NextCure,” “Company,” “we,” “us,” “our” and similar terms refer to NextCure, Inc., a Delaware corporation, and its subsidiaries unless the context otherwise requires.
This prospectus and the information incorporated herein or therein by reference include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference in this prospectus are the property of their respective owners.
PROSPECTUS SUMMARY
This summary highlights selected information contained elsewhere in this prospectus or incorporated by reference in this prospectus, and does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus and any related free writing prospectus, including the risks of investing in our securities discussed under the heading “Risk Factors” contained in this and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.
Overview
We are a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or “FIND-IO”, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. We are committed to discovering and developing first-in-class immunomedicines, which are immunomedicines that use new or unique mechanisms of action to treat a medical condition.
Our product candidate NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1. In June 2020, we initiated a Phase 1/2 clinical trial of NC410 in patients with advanced or metastatic solid tumors. The Phase 1 dose-escalation portion of this open-label trial was designed to evaluate the safety and tolerability of NC410 and determine its pharmacologically active and/or maximum tolerated dose. In October 2022, we announced the initiation of a Phase 1b/2 clinical trial to evaluate NC410 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in immune checkpoint refractory patients (colorectal, esophageal, endometrial and head and neck cancers) or immune checkpoint naïve solid tumor patients (colorectal and ovarian cancers).
Our product candidate NC762 is a monoclonal antibody that binds specifically to human B7 homolog 4 protein, or “B7-H4”, a protein expressed on multiple tumor types. In July 2021, we initiated a Phase 1/2 clinical trial of NC762 in patients with lung cancer, breast cancer, ovarian cancer or potentially other tumor types. The Phase 1 dose-escalation portion of this open-label trial was designed to evaluate the safety and tolerability of NC762 and determine its pharmacologically active and/or maximum tolerated dose. In November 2022, we announced initial data from the Phase 1 portion of this trial which indicate that NC762 appears to be well tolerated. Safety expansion studies are ongoing with the intent of selecting a recommended Phase 2 dose.
Our product candidate NC525 (LAIR-1 mAb) is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia, or “AML”, blast cells and leukemic stem cells, or “LSCs”. Preclinical data show that NC525 kills AML blast cells and LSCs while sparing hematopoietic stem and progenitor cells, or “HSPCs”. In February 2023, we initiated a Phase 1 trial for NC525 to evaluate the safety and preliminary efficacy of NC525 in AML, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia (CMML).
Implications of Being an Emerging Growth Company and Smaller Reporting Company
We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We may take advantage of certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm under Section 404 of the Sarbanes-Oxley Act of 2002 reduced disclosure obligations regarding executive compensation in our periodic reports and proxy
statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments. We may take advantage of these exemptions until December 31, 2024 or until we are no longer an “emerging growth company,” whichever is earlier. We will cease to be an emerging growth company prior to the end of such period if certain earlier events occur, including if we become a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, or Exchange Act, our annual gross revenues exceed $1.235 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period.
In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of accounting standards that have different effective dates for public and private companies until those standards would otherwise apply to private companies. We have not elected to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not “emerging growth companies.”
We are also a “smaller reporting company” as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.
Corporate Information
We are a Delaware corporation formed in September 2015. Our primary executive offices are located at 9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705 and our telephone number is (240) 399-4900. Our website address is www.nextcure.com. Additionally, our filings with the SEC are posted on our website at www.nextcure.com. The information found on or accessible through our website is not part of this or any other report we file with or furnish to the SEC. The public can also obtain copies of these filings by accessing the SEC’s website at http://www.sec.gov.
The Offering
Common stock offered by us
Shares of common stock having an aggregate offering price of up to $16,762,573.
“At the market” offering that may be made from time to time through our sales agent, Leerink Partners. See “Plan of Distribution” on page S-14 of this prospectus.
Our management will retain broad discretion regarding the allocation and use of the net proceeds from this offering. We currently intend to use the net proceeds from this offering, if any, for general corporate purposes and working capital, including for preclinical studies and clinical trials and the advancement of our product candidates. See “Use of Proceeds” on page S-9 of this prospectus.
Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page S-4 of this prospectus and the other information included in, or incorporated by reference into, this prospectus for a discussion of certain factors that you should carefully consider before deciding to invest in shares of our common stock.
Nasdaq Global Select Market symbol
“NXTC”
RISK FACTORS
Investing in our common stock involves risk. You should carefully consider the specific risks discussed below, together with all the other information contained in the prospectus or incorporated by reference into this prospectus. You should also consider the risks, uncertainties and assumptions discussed under the caption “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2022 and in our Quarterly Report on Form 10-Q for the period ended June 30, 2023, and in subsequent filings, which are incorporated by reference into this prospectus. These risk factors may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future. These risks and uncertainties are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us, or that we currently view as immaterial, may also impair our business. If any of the risks or uncertainties described in our SEC filings or any additional risks and uncertainties actually occur, our business, financial condition and results of operations could be materially and adversely affected. In that case, the trading price of our securities could decline and you might lose all or part of your investment.
Risks Related to This Offering
We have broad discretion in the use of the net proceeds from this offering.
Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways with which you may not agree. Accordingly, you will be relying on the judgment of our management with regard to the use of the net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the net proceeds will be invested or otherwise used in a way that does not yield a favorable, or any, return for the Company.
Investors in this offering may experience immediate and substantial dilution in the net tangible book value per share of the common stock they purchase.
The price per share of our common stock being offered may be higher than the net tangible book value per share of our common stock, and as such, you may suffer substantial dilution in the net tangible book value of the common stock you purchase in this offering. In addition, we have a significant number of options outstanding. If the holders of these options exercise such options, you may incur further dilution.
Our stockholders may experience significant dilution as a result of future equity offerings and exercise of outstanding options.
In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price per share in this offering.
In addition, we have a number of securities allowing the purchase of, our common stock. As of March 31, 2023, 741,097 shares of common stock were reserved for future issuance under our 2019 Employee Stock Purchase Plan. As of that date, there were also options to purchase 7,030,160 shares of our common stock outstanding. The exercise of outstanding options having an exercise price per share that is less than the offering price per share in this offering will increase dilution to investors in this offering.
It is not possible to predict the actual number of shares we will sell under the sales agreement or aggregate proceeds resulting from sales made under the sales agreement.
Subject to certain limitations in the sales agreement and compliance with applicable law, we have the discretion to deliver a placement notice to Leerink Partners at any time throughout the term of the sales agreement. The number of shares that are sold through or to Leerink Partners after delivering a placement notice will fluctuate based on a number of factors, including the market price of our common stock during the
sales period, any limits we may set with Leerink Partners in any applicable placement notice and the demand for our common stock. Because the price per share of each share sold pursuant to the sales agreement will fluctuate over time, it is not currently possible to predict the actual number of shares that will be sold or the aggregate proceeds to be raised in connection with sales under the sales agreement.
The common stock offered hereby will be sold in “at-the-market offerings” and investors who buy shares at different times will likely pay different prices.
Investors who purchase shares in this offering at different times will likely pay different prices, and accordingly may experience different levels of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices and number of shares sold in this offering. In addition, subject to the final determination by our board of directors or any restrictions we may place in any applicable placement notice, there is no minimum or maximum sales price for shares to be sold in this offering. Investors may experience a decline in the value of the shares they purchase in this offering as a result of sales made at prices lower than the prices they paid.
We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.
We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.
The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock in this offering.
Our stock price has been and is likely to remain volatile. The stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme volatility that has often been unrelated to the operating performance or prospects of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above a recently reported price, or at all. The market price for our common stock may be influenced by many factors, including:
•
the commencement, enrollment or results of our ongoing or future clinical trials, or changes in the development status of our product candidates;
•
any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority’s review of such filings, including without limitation the FDA’s issuance of a “refusal to file” letter or a request for additional information;
•
adverse results or delays in clinical trials;
•
our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;
•
adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;
•
our failure to commercialize our product candidates;
•
unanticipated serious safety concerns related to the use of our product candidates;
•
the size and growth of our target markets;
•
the success of competitive products or technologies;
•
regulatory actions with respect to our product candidates or our competitors’ products or product candidates;
•
announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;
•
regulatory or legal developments in the United States and other countries applicable to our product candidates, including but not limited to clinical trial requirements for approvals;
•
our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;
•
developments or disputes concerning patent applications, issued patents or other proprietary rights;
•
the recruitment or departure of key personnel;
•
the level of expenses related to our product candidates or clinical development programs;
•
the results of our efforts to discover, develop, acquire or in-license product candidates;
•
actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts or publications of research reports about us or our industry;
•
variations in our annual or quarterly financial results or those of companies that are perceived by investors to be similar to us;
•
our cash position;
•
fluctuations in the valuation of companies perceived by investors to be comparable to us;
•
share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
•
announcement or expectation of additional financing efforts
•
sales of our common stock by us, our directors, officers or their affiliated funds or our other stockholders;
•
changes in the structure of healthcare payment systems;
•
significant lawsuits, including intellectual property or stockholder litigation;
•
market conditions in the pharmaceutical and biotechnology sectors;
•
general economic, industry and market conditions;
•
other events or factors, many of which are beyond our control, or unrelated to our operating performance or prospects; and
•
the other factors described in the “Risk Factors” sections of our Annual Report on Form 10-K for the year ended December 31, 2022 and in our Quarterly Report on Form 10-Q for the period ended June 30, 2023 and in subsequent filings, which are incorporated by reference into this prospectus.
In addition, the stock market in general, and Nasdaq and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus includes and incorporates by reference “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and releases issued by the SEC and within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements.
In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “due,” “estimate,” “expect,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language. Forward-looking statements include, but are not limited to, statements about:
•
our expectations regarding the timing, progress, and results of preclinical studies and clinical trials for NC410, NC762, NC525 and any other product candidates we develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;
•
the timing or likelihood of regulatory filings for NC410, NC762, NC525 and any other product candidates we develop and our ability to obtain and maintain regulatory approvals for such product candidates for any indication;
•
the identification, analysis and use of biomarkers and biomarker data;
•
development of patient selection assays and companion or complementary diagnostics for NC410, NC762, NC525 or any other product candidates we develop;
•
our manufacturing capabilities and strategy, including the scalability of our manufacturing methods and processes;
•
our expectations regarding the potential benefits, activity, effectiveness, and safety of NC410, NC762, NC525 and any other product candidates we develop;
•
our intentions and ability to successfully commercialize our product candidates;
•
our expectations regarding the nature of the biological pathways we are targeting;
•
our expectations for our FIND-IO platform, including our ability to discover and advance product candidates using our FIND-IO platform;
•
the potential benefits of and our ability to maintain our relationship and collaboration with Yale University;
•
our estimates regarding our expenses, future revenues, capital requirements, our needs for or ability to obtain additional financing, and the period over which we expect our current cash, cash equivalents, and marketable securities to be sufficient to fund our operations;
•
our intended reliance on and the performance of third parties, including collaborators, contract research organizations, and third-party manufacturers;
•
our ability to protect and enforce our intellectual property protection and the scope and duration of such protection;
•
any failure of our information technology systems such as security breaches, loss of data and other disruptions;
•
developments and projections relating to our competitors and our industry, including competing therapies;
•
the impact of current and future laws and regulations; and
•
our intended use of proceeds from this offering.
These statements are based on management’s current expectations, estimates, forecasts and projections about our business and industry, are not guarantees of future performance and involve known and unknown
risks, uncertainties and other factors that are in some cases beyond our control, and that may cause our actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in greater detail in the section entitled “Risk Factors” and elsewhere in this prospectus. You should read these factors and the other cautionary statements made in this prospectus as being applicable to all related forward-looking statements wherever they appear herein or therein. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, levels of activity, performance, or achievements may vary materially from any future results, activity, performance, or achievements expressed or implied by these forward-looking statements. We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they were made. We undertake no obligation to publicly update any forward-looking statements after the date of this prospectus, whether as a result of new information, future events or otherwise, except as required by law.
You should read this prospectus and documents we have filed with the SEC that are incorporated by reference and any free writing prospectus that we may authorize for use in connection with this offering completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements.
USE OF PROCEEDS
We may issue and sell shares of our common stock having an aggregate sales proceeds of up to $16,762,573 from time to time. The amount of proceeds from this offering will depend upon the number of shares of our common stock sold and the market price at which they are sold. There can be no assurance that we will be able to sell any shares under, or fully utilize, the sales agreement with Leerink Partners as a source of financing.
As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received. We currently intend to use the net proceeds from this offering, if any, for general corporate purposes and working capital, including for preclinical studies and clinical trials and the advancement of our product candidates.
The amounts and timing of our actual expenditures and the extent of our research and development activities may vary significantly depending on numerous factors, including the progress of our development efforts, the timing and costs associated with the manufacture and supply of any of our product candidates and any unforeseen cash needs. As a result, our management will have broad discretion over the use of the net proceeds from this offering.
Pending the uses described above, we intend to invest the net proceeds from this offering in interest-bearing, investment-grade securities, certificates of deposit or government securities.
DESCRIPTION OF CAPITAL STOCK
The following description summarizes certain information about our capital stock. The summary does not purport to be complete and is subject, and qualified in its entirety by reference, to our amended and restated certificate of incorporation, or certificate of incorporation, and our amended and restated bylaws, or bylaws, each of which is incorporated by reference as an exhibit to the registration statement of which this prospectus is a part, and the applicable provisions of Delaware law. See “Incorporation by Reference.”
General
Our authorized capital stock under our certificate of incorporation consists of
•
100,000,000 shares of common stock, par value $0.001 per share; and
•
10,000,000 shares of preferred stock, par value $0.001 per share.
As of June 30, 2023, 27,839,968 shares of common stock were outstanding and no shares of preferred stock were outstanding.
Common Stock
Voting Rights
Holders of our common stock are entitled to one vote for each share on all matters submitted to a vote of our stockholders, including the election of directors. Holders of our common stock do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of our directors. In addition, the affirmative vote of holders of 662∕3% of the voting power of all of the then outstanding voting stock will be required to take certain actions, including amending certain provisions of our certificate of incorporation, such as the provisions relating to the classified board.
Dividends
Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.
Liquidation
In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.
Other Rights and Preferences
Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future.
Fully Paid and Nonassessable
All of our outstanding shares of common stock are fully paid and nonassessable.
Preferred Stock
Under the terms of our certificate of incorporation, our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences,
sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. For example, the issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation.
Registration Rights
Under the terms of our amended and restated investors’ rights agreement, holders of certain shares of our common stock, or their transferees, have the right to require us to register their shares under the Securities Act so that those shares may be publicly resold, and the right to include their shares in any registration statement we file, subject to certain limitations. These rights will expire, with respect to any particular stockholder, upon the earlier of May 13, 2024 and when that stockholder can sell all of its shares under Rule 144 under the Securities Act without limitation during any three-month period without registration.
Anti-Takeover Effects of Provisions of Our Certificate of Incorporation, Our Bylaws and Delaware Law
Certain provisions of Delaware law and our certificate of incorporation and our bylaws could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for our shares.
These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.
Delaware Anti-Takeover Statute
We are subject to Section 203 of the Delaware General Corporation Law, which prohibits persons deemed “interested stockholders” from engaging in a “business combination” with a publicly traded Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an “interested stockholder” is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation’s voting stock. Generally, a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by our board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock.
Undesignated Preferred Stock
The ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could have the effect of delaying, deferring, preventing or otherwise impeding any attempt to change control of us.
Special Stockholder Meetings
Our certificate of incorporation and our bylaws provide that a special meeting of stockholders may be called only by or at the direction of our board of directors or by the Chair of our board of directors.
Requirements for Advance Notification of Stockholder Nominations and Proposals
Our bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of our board of directors or a committee of our board of directors.
Elimination of Stockholder Action by Written Consent
Our certificate of incorporation and our bylaws do not permit stockholders action by written consent without a meeting.
Classified Board; Election and Removal of Directors; Filling Vacancies; Board Size
Our board of directors is divided into three classes. The directors in each class serve for a three-year term, one class being elected each year by our stockholders, with staggered three-year terms. Only one class of directors is elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, holders of a majority of the shares of common stock outstanding will be able to elect all of our directors. Our certificate of incorporation provides for the removal of any of our directors only for cause and requires a stockholder vote by the holders of at least a 662∕3% of the voting power of the then outstanding voting stock. Any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of the board, may only be filled by a resolution of our board of directors unless our board of directors determines that such vacancies shall be filled by our stockholders. Furthermore, the authorized number of directors may be changed only by a resolution of our board of directors. This system of electing and removing directors, filling vacancies and fixing the size of the board may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.
Choice of Forum
Our bylaws provide that unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware or, if subject matter jurisdiction of such action is vested exclusively in the federal courts, the United States District Court for the District of Delaware will, to the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers and employees, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws, (iv) any action or proceeding to interpret, apply, enforce, or determine the validity of our certificate of incorporation or bylaws or (v) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery or the United States District Court for the District of Delaware, as applicable, having personal jurisdiction over the indispensable parties named as defendants therein. In addition, any person holding, owning, or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and to have consented to this provision of our bylaws. The choice of forum provision does not apply to any actions arising under the Securities Act or the Exchange Act. Although our bylaws contain the choice of forum provision described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable.
Amendment of Charter Provisions
The amendment of any of the above provisions that are in our certificate of incorporation, except for the provision making it possible for our board of directors to issue undesignated preferred stock, would require approval by a stockholder vote by the holders of at least a 662∕3% of the voting power of our then outstanding voting stock.
The provisions of the Delaware General Corporation Law, our certificate of incorporation and our bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.
Limitation on Liability and Indemnification Matters
Our certificate of incorporation contains provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by Delaware law. Consequently, our directors will not be personally
liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for:
•
any breach of the duty of loyalty to us or our stockholders;
•
any act or omission not in good faith that involves intentional misconduct or a knowing violation of law;
•
unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or
•
any transaction from which the director derived an improper personal benefit.
Our bylaws provide that we are required to indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. Our bylaws also obligate us to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of such person’s actions in that capacity regardless of whether we would otherwise be permitted to indemnify such person under Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. These indemnification agreements generally require us, among other things, to indemnify our directors, executive officers, and these employees against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements also generally require us to advance any expenses incurred by the directors, executive officers and employees as a result of any proceeding against them as to which they could be indemnified. We believe that these provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain directors’ and officers’ liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment in some circumstances.
The limitation of liability and indemnification provisions in our certificate of incorporation and bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. Further, a stockholder’s investment may be adversely affected to the extent that we pay the costs of settlement and damage.
Listing
Our common stock is listed on Nasdaq under the symbol “NXTC.”
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company, LLC.
PLAN OF DISTRIBUTION
We have entered into a sales agreement (the “sales agreement”) with Leerink Partners LLC (“Leerink Partners”) under which we may issue and sell from time to time our common stock through Leerink Partners as our sales agent. Pursuant to this prospectus we may issue and sell shares of our common stock having an aggregate offering price of $16,762,573. Sales of our common stock, if any, will be made at market prices by any method that is deemed to be an “at the market” offering as defined in Rule 415(a)(4) under the Securities Act, including sales made directly on Nasdaq or any other trading market for our common stock. The sales agreement is filed as an exhibit to this registration statement, of which this prospectus forms a part and is incorporated herein by reference. The below description of the material provisions of the sales agreement does not purport to be a complete statement of its terms and conditions.
Leerink Partners will offer our common stock subject to the terms and conditions of the sales agreement on a daily basis or as otherwise agreed upon by us and Leerink Partners. We will designate the maximum amount of common stock to be sold through Leerink Partners on a daily basis or otherwise determine such maximum amount together with Leerink Partners. Subject to the terms and conditions of the sales agreement, Leerink Partners will use its commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us. We may instruct Leerink Partners not to sell common stock if the sales cannot be effected at or above the price designated by us in any such instruction. Leerink Partners or we may suspend the offering of our common stock being made through Leerink Partners under the sales agreement upon proper notice to the other party. Leerink Partners and we each have the right, by giving written notice as specified in the sales agreement, to terminate the sales agreement in each party’s discretion at any time.
The aggregate compensation payable to Leerink Partners as sales agent is equal to 3.0% of the gross sales price of the shares sold through it pursuant to the sales agreement. We have also agreed to reimburse Leerink Partners up to $75,000 of Leerink Partners’ actual outside legal expenses incurred by Leerink Partners in connection with this offering. We estimate that the total expenses of the offering payable by us, excluding commissions payable to Leerink Partners under the sales agreement, will be approximately $300,000.
The remaining sales proceeds, after deducting any expenses payable by us and any transaction fees imposed by any governmental, regulatory, or self-regulatory organization in connection with the sales, will equal our net proceeds for the sale of such common stock.
Leerink Partners will provide written confirmation to us following the close of trading on Nasdaq on each day in which common stock is sold through it as sales agent under the sales agreement. Each confirmation will include the number of shares of common stock sold through it as sales agent on that day, the volume weighted average price of the shares sold, the percentage of the daily trading volume and the net proceeds to us.
To the extent any sales are made, we will report at least quarterly the number of shares of common stock sold through Leerink Partners under the sales agreement, the net proceeds to us and the compensation paid by us to Leerink Partners in connection with the sales of common stock.
Settlement for sales of common stock will occur, unless the parties agree otherwise, on the second business day that is also a trading day following the date on which any sales were made in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.
In connection with the sales of our common stock on our behalf, Leerink Partners will be deemed to be an “underwriter” within the meaning of the Securities Act, and the compensation paid to Leerink Partners will be deemed to be underwriting commissions or discounts. We have agreed in the sales agreement to provide indemnification and contribution to Leerink Partners against certain liabilities, including liabilities under the Securities Act. As sales agent, Leerink Partners will not engage in any transactions that stabilizes our common stock.
Our common stock is listed on Nasdaq and trades under the symbol “NXTC.” The transfer agent of our common stock is American Stock Transfer & Trust Company, LLC.
Leerink Partners and/or its affiliates have provided, and may in the future provide, various investment banking and other financial services for us for which services they have received and, may in the future receive, customary fees.
LEGAL MATTERS
Certain legal matters in connection with the securities offered hereby will be passed upon for us by Sidley Austin LLP, New York, New York. Leerink Partners LLC is being represented in connection with this offering by Cooley LLP, New York, New York.
EXPERTS
The financial statements of NextCure, Inc. appearing in NextCure, Inc.’s Annual Report (Form 10-K) for the year ended December 31, 2022, have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
SEC rules permit us to incorporate information by reference in this prospectus. This means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be part of this prospectus, except for information superseded by information contained in this prospectus itself or in any subsequently filed incorporated document. This prospectus incorporates by reference the documents set forth below that we have previously filed with the SEC (Commission File No. 001-38905), other than information in such documents that is deemed to be furnished and not filed:
•
•
•
•
•
the description of our Common Stock contained in our Registration Statement on Form 8/A, dated May 8, 2019, including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.2 to the Annual Report on Form 10-K for the year ended December 31, 2022.
All documents that we file (but not those that we furnish) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus and prior to the termination of the offering of any of the securities covered under this prospectus shall be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus and any previously filed documents.
Any statement contained herein or in a document incorporated or deemed to be incorporated by reference in this prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this prospectus, modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.
You can obtain any of the filings incorporated by reference into this prospectus through us or from the SEC through the SEC’s website at http://www.sec.gov. Upon request, we will provide, without charge, a copy of any or all of the reports and documents referred to above which have been incorporated by reference into this prospectus. Prospective investors may obtain documents incorporated by reference in this prospectus by requesting them in writing or by telephone from us at our executive offices at:
NextCure, Inc.
9000 Virginia Manor Road
Beltsville, MA 20705
(240) 399-4900
Our reports and documents incorporated by reference herein may also be found in the “Investor Relations” section of our website at www.nextcure.com. The content of our website and any information that is linked to or accessible from our website (other than our filings with the SEC that are incorporated by reference, as set forth under “Incorporation of Certain Documents by Reference”) is not incorporated by reference into this prospectus and you should not consider it a part of this prospectus or the registration statement.
Up to $16,762,573
Common Stock
PROSPECTUS
Leerink Partners
August , 2023
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution
The following table sets forth the costs and expenses, other than the underwriting discounts and commissions, payable by us in connection with the sale of common stock being registered. All amounts are estimates except for the SEC registration fee and the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee.
|
|
|
Amount to
be Paid
|
|
SEC registration fee
|
|
|
|
$ |
19,638(1) |
|
|
FINRA filing fee
|
|
|
|
$ |
27,500(1) |
|
|
Printing and engraving expenses
|
|
|
|
$ |
(2)
|
|
|
Legal fees and expenses
|
|
|
|
$ |
(2)
|
|
|
Accounting fees and expenses
|
|
|
|
$ |
(2)
|
|
|
Transfer agent and registrar fees and expenses
|
|
|
|
$ |
(2)
|
|
|
Miscellaneous expenses
|
|
|
|
$ |
(2)
|
|
|
Total
|
|
|
|
$ |
(2)
|
|
|
(1)
In accordance with Rule 415(a)(6) under the Securities Act, the filing fee was previously paid in connection with the securities registered in the registration statement on Form S-3 (File Number 333-241706), all of which remain unsold, will continue to be applied to the securities registered under this Registration Statement. Please see the registration fee table contained in Exhibit 107 to this registration statement for more information.
(2)
These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be estimated at this time.
Item 15. Indemnification of Directors and Officers
We are incorporated under the laws of the State of Delaware. As permitted by Section 102 of the Delaware General Corporation Law, we have adopted provisions in our certificate of incorporation and bylaws that limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for:
•
any breach of the duty of loyalty to us or our stockholders;
•
any act or omission not in good faith that involves intentional misconduct or a knowing violation of law;
•
unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or
•
any transaction from which the director derived an improper personal benefit.
These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Our certificate of incorporation also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law.
As permitted by Section 145 of the Delaware General Corporation Law, our bylaws provide that:
•
we will indemnify our directors and officers to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions;
•
we will advance expenses to our directors in connection with legal proceedings to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and
•
the rights provided in our bylaws are not exclusive.
Our certificate of incorporation, attached as Exhibit 3.1 hereto, and our bylaws, attached as Exhibit 3.2 hereto, provide for the indemnification provisions described above and elsewhere herein.
We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. These indemnification agreements generally require us, among other things, to indemnify our directors, executive officers, and these employees against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements also generally require us to advance any expenses incurred by the directors, executive officers, and employees as a result of any proceeding against them as to which they could be indemnified. We also maintain directors’ and officers’ liability insurance that insures our directors and officers against the cost of defense, settlement, or payment of a judgment in some circumstances.
Any underwriting agreement or distribution agreement that we enter into with any underwriters or agents involved in the offering or sale of any securities registered hereby may require such underwriters or dealers to indemnify the registrant, some or all of its directors and officers and its controlling persons, if any, for specified liabilities, which may include liabilities under the Securities Act.
The sales agreement filed as Exhibit 1.2 to this registration statement provides for indemnification of us and our directors and officers by Leerink Partners against certain liabilities under the Securities Act and the Exchange Act.
See the undertakings set forth in response to Item 17 herein.
Item 16. Exhibits
|
Exhibit
Number
|
|
|
Description
|
|
|
23.1
|
|
|
|
|
|
23.2
|
|
|
Consent of Sidley Austin LLP (included in Exhibit 5.1 and Exhibit 5.2).
|
|
|
24.1
|
|
|
|
|
|
25.1**
|
|
|
Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939.
|
|
|
107
|
|
|
|
|
*
To be filed by amendment or incorporated by reference in connection with the offering of the securities.
**
To be filed in accordance with the requirements of Section 305(b)(2) of the Trust Indenture Act of 1939.
***
Previously filed.
Item 17. Undertakings
(a)
The undersigned registrant hereby undertakes:
(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
provided, however, that paragraphs (a)(1)(i), (a)(1)(ii), and (a)(1)(iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(5)
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
(A)
Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and
(B)
Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.
(6)
That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities:
The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
(i)
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;
(ii)
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;
(iii)
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
(iv)
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
(b)
The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(h)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
(j)
The undersigned registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the Commission under Section 305(b)(2) of the Act.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Beltsville, State of Maryland, on the 4th day of August, 2023.
NEXTCURE, INC.
By:
/s/ Michael Richman
Michael Richman
President and Chief Executive Officer
POWER OF ATTORNEY
Each person whose individual signature appears below hereby authorizes and appoints Michael Richman and Steven P. Cobourn and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place, and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this registration statement, including any and all post-effective amendments and amendments thereto, and any subsequent registration statement relating to the same offering as this registration statement that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated:
|
Signature
|
|
|
Title
|
|
|
Date
|
|
|
/s/ Michael Richman
Michael Richman
|
|
|
President, Chief Executive
Officer and Director
(Principal Executive Officer)
|
|
|
August 4, 2023
|
|
|
/s/ Steven P. Cobourn
Steven P. Cobourn
|
|
|
Chief Financial Officer
(Principal Financial and
Accounting Officer)
|
|
|
August 4, 2023
|
|
|
/s/ David Kabakoff, Ph.D.
David Kabakoff, Ph.D.
|
|
|
Chair of the Board
|
|
|
August 4, 2023
|
|
|
/s/ Anne Borgman, M.D.
Anne Borgman, M.D.
|
|
|
Director
|
|
|
August 4, 2023
|
|
|
/s/ Ellen G. Feigal, M.D.
Ellen G. Feigal, M.D.
|
|
|
Director
|
|
|
August 4, 2023
|
|
|
/s/ John G. Houston, Ph.D.
John G. Houston, Ph.D.
|
|
|
Director
|
|
|
August 4, 2023
|
|
|
Signature
|
|
|
Title
|
|
|
Date
|
|
|
/s/ Elaine V. Jones, Ph.D.
Elaine V. Jones, Ph.D.
|
|
|
Director
|
|
|
August 4, 2023
|
|
|
/s/ Chau Q. Khuong
Chau Q. Khuong
|
|
|
Director
|
|
|
August 4, 2023
|
|
|
/s/ Garry Nicholson
Garry Nicholson
|
|
|
Director
|
|
|
August 4, 2023
|
|
|
/s/ Stephen Webster
Stephen Webster
|
|
|
Director
|
|
|
August 4, 2023
|
|
Exhibit 1.2
NEXTCURE, INC.
Shares of Common Stock
($0.001 par value per share)
SALES
AGREEMENT
August 4, 2023
LEERINK PARTNERS LLC
1301 Avenue of the Americas, 12th
Floor
New York, New York 10019
Ladies and Gentlemen:
NextCure, Inc., a Delaware corporation (the “Company”),
confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”),
as follows:
1. Issuance
and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the
conditions set forth herein, it may issue and sell through the Agent up to $75,000,000 of shares of common stock, $0.001 par value per
share, of the Company (the “Common Stock”), subject to the limitations set forth in Section 6(c) (the
“Placement Shares”). Notwithstanding anything to the contrary contained herein, the parties hereto agree that
compliance with the limitation set forth in this Section 1 on the aggregate gross sales price of Placement Shares that may be issued
and sold under this Agreement from time to time shall be the sole responsibility of the Company, and that the Agent shall have no obligation
in connection with such compliance. The issuance and sale of Placement Shares through the Agent will be effected pursuant to the Registration
Statement (as defined below) filed or to be filed by the Company with the Securities and Exchange Commission (the “Commission”)
and has been or will be declared effective by the Commission, although nothing in this Agreement shall be construed as requiring the Company
to issue any Placement Shares.
2. The
Company has prepared and will file, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules and
regulations thereunder (collectively, the “Securities Act”), with the Commission a registration statement on
Form S-3, including (a) a base prospectus, relating to certain securities, including the Common Stock, to be issued from time
to time by the Company and (b) a prospectus specifically relating to the Placement Shares to be issued from time to time pursuant
to this Agreement (the “ATM Prospectus”), and shall, if necessary, prepare a prospectus supplement specifically
relating to the Placement Shares (the “Prospectus Supplement”) to the ATM Prospectus included as part of such
registration statement, all of which incorporate by reference documents that the Company has filed or will file in accordance with the
provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (collectively, the “Exchange
Act”). The Company will furnish to the Agent, for use by the Agent, copies of the ATM Prospectus, included as part of such
registration statement at the time the registration statement becomes effective, as supplemented by the Prospectus Supplement, if any,
relating to the Placement Shares. The Company may file one or more additional registration statements from time to time that will contain
a base prospectus and related prospectus or prospectus supplement, if applicable (which shall be an ATM Prospectus), with respect to the
Placement Shares. Except where the context otherwise requires, such registration statement(s), including all documents filed as part thereof
or incorporated by reference therein, and including any information contained in a Prospectus (as defined below) subsequently filed with
the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such registration statement pursuant
to Rule 430B or Rule 462(b) under the Securities Act, is herein called the “Registration Statement.”
The ATM prospectus, including all documents incorporated therein by reference, included in the Registration Statement, in the form in
which such ATM Prospectus has most recently been filed by the Company with the Commission pursuant to Rule 424(b) under the
Securities Act, together with any “issuer free writing prospectus” (as used herein, as defined in Rule 433 under the
Securities Act (“Rule 433”)), relating to the Placement Shares that (i) is required to be filed with
the Commission by the Company or (ii) is exempt from filing pursuant to Rule 433(d)(5)(i), in each case, in the form filed or
required to be filed with the Commission or, if not required to be filed, in the form retained in the Company’s records pursuant
to Rule 433(g), is herein called the “Prospectus.” Any reference herein to the Registration Statement,
the ATM Prospectus, the Prospectus or any issuer free writing prospectus shall be deemed to refer to and include the documents, if any,
that are or are deemed to be incorporated by reference therein (the “Incorporated Documents”), including, unless
the context otherwise requires, the documents, if any, filed as exhibits to such Incorporated Documents. Any reference herein to the terms
“amend,” “amendment” or “supplement” with respect to the Registration Statement, the ATM Prospectus,
the Prospectus or any issuer free writing prospectus shall be deemed to refer to and include the filing of any document under the Exchange
Act on or after the most-recent effective date of the Registration Statement, or the respective dates of the ATM Prospectus, Prospectus
or such issuer free writing prospectus, as the case may be, and incorporated therein by reference. For purposes of this Agreement, all
references to the Registration Statement, the Prospectus or any amendment or supplement thereto shall be deemed to include the most recent
copy filed with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval System or, if applicable, the Interactive
Data Electronic Application system when used by the Commission (collectively, “EDGAR”).
3. Placements.
Each time that the Company wishes to issue and sell any Placement Shares through the Agent hereunder (each, a “Placement”),
it will notify the Agent by email notice (or other method mutually agreed to in writing by the parties) (each such notice, a “Placement
Notice”) containing the parameters in accordance with which it desires such Placement Shares to be sold, which at a minimum
shall include the maximum number or amount of Placement Shares to be sold, the time period during which sales are requested to be made,
any limitation on the number or amount of Placement Shares that may be sold in any one Trading Day (as defined in Section 4) and
any minimum price below which sales may not be made, a form of which containing such minimum sales parameters is attached hereto as Schedule
1. The Placement Notice must originate from one of the individuals authorized to act on behalf of the Company and set forth on
Schedule 2 (with a copy to each of the other individuals from the Company listed on such Schedule 2), and
shall be addressed to each of the recipients from the Agent set forth on Schedule 2, as such Schedule 2 may
be updated by either party from time to time by sending a written notice containing a revised Schedule 2 to the other party
in the manner provided in Section 13 (including by email correspondence to each of the individuals of the Company set forth on Schedule
2, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than
via auto-reply). The Placement Notice shall be effective upon receipt by the Agent unless and until (i) in accordance with the notice
requirements set forth in Section 5, the Agent declines to accept the terms contained therein for any reason, in its sole discretion,
within two Trading Days of the date the Agent receives the Placement Notice, (ii) in accordance with the notice requirements set
forth in Section 5, the Agent suspends sales under the Placement Notice for any reason in its sole discretion, (iii) the entire
amount of the Placement Shares has been sold pursuant to this Agreement, (iv) in accordance with the notice requirements set forth
in Section 5, the Company suspends sales under or terminates the Placement Notice for any reason in its sole discretion, (v) the
Company issues a subsequent Placement Notice and explicitly indicates that its parameters supersede those contained in the earlier dated
Placement Notice or (vi) this Agreement has been terminated pursuant to the provisions of Section 12. The amount of any discount,
commission or other compensation to be paid by the Company to the Agent in connection with the sale of the Placement Shares effected through
the Agent shall be calculated in accordance with the terms set forth in Schedule 3. It is expressly acknowledged and agreed
that neither the Company nor the Agent will have any obligation whatsoever with respect to a Placement or any Placement Shares unless
and until the Company delivers a Placement Notice to the Agent and the Agent does not decline such Placement Notice pursuant to the terms
set forth above, and then only upon the terms specified therein and herein. In the event of a conflict between the terms of this Agreement
and the terms of a Placement Notice, the terms of the Placement Notice will control with respect to the matters covered thereby.
4. Sale
of Placement Shares by the Agent. On the basis of the representations and warranties herein contained and subject to the terms and
conditions herein set forth, including Section 6(c), upon the Agent’s acceptance of the terms of a Placement Notice as provided
in Section 3, and unless the sale of the Placement Shares described therein has been declined, suspended or otherwise terminated
in accordance with the terms of this Agreement, the Agent, for the period specified in the Placement Notice, will use its commercially
reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations
and the rules of the Nasdaq Global Select Market (“Nasdaq”) to sell such Placement Shares up to the number
or amount specified in, and otherwise in accordance with the terms of, such Placement Notice. The Agent will provide written confirmation
to the Company (including by email correspondence to each of the individuals of the Company set forth on Schedule 2, if
receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply)
no later than the opening of the Trading Day (as defined below) immediately following the Trading Day on which it has made sales of Placement
Shares hereunder setting forth the number or amount of Placement Shares sold on such Trading Day, the volume-weighted average price of
the Placement Shares sold and the Net Proceeds (as defined below) payable to the Company. Unless otherwise specified by the Company in
a Placement Notice, the Agent may sell Placement Shares by any method permitted by law deemed to be an “at the market offering”
as defined in Rule 415(a)(4) of the Securities Act, including sales made directly on or through Nasdaq, on or through any other
existing trading market for the Common Stock or to or through a market maker. If expressly authorized by the Company (including in a Placement
Notice), the Agent may also sell Placement Shares in negotiated transactions. Notwithstanding the provisions of Section 7(vv), except
as may be otherwise agreed by the Company and the Agent, the Agent shall not purchase Placement Shares on a principal basis pursuant to
this Agreement unless the Company and the Agent enter into a separate written agreement setting forth the terms of such sale. The Company
acknowledges and agrees that (i) there can be no assurance that the Agent will be successful in selling Placement Shares, (ii) the
Agent will incur no liability or obligation to the Company or any other person or entity if it does not sell Placement Shares for any
reason other than a failure by the Agent to use its commercially reasonable efforts consistent with its normal trading and sales practices
and applicable state and federal laws, rules and regulations and the rules of Nasdaq to sell such Placement Shares as required
under this Agreement and (iii) the Agent shall be under no obligation to purchase Placement Shares on a principal basis pursuant
to this Agreement unless the Company and the Agent enter into a separate written agreement setting forth the terms of such sale. For the
purposes hereof, “Trading Day” means any day on which the Common Stock is purchased and sold on Nasdaq.
5. Suspension
of Sales.
(a) The
Company or the Agent may, upon notice to the other party in writing (including by email correspondence to each of the individuals of the
other party set forth on Schedule 2, if receipt of such correspondence is actually acknowledged by any of the individuals
to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by email correspondence to each of the individuals
of the other party set forth on Schedule 2), suspend any sale of Placement Shares; provided, however, that such suspension
shall not affect or impair either party’s obligations with respect to any Placement Shares sold hereunder prior to the receipt of
such notice. Each of the parties agrees that no such notice under this Section 5 shall be effective against the other party unless
notice is sent by one of the individuals named on Schedule 2 hereto to the other party in writing (including by email correspondence
to each of the individuals of the other party set forth on Schedule 2, if receipt of such correspondence is actually acknowledged
by any of the individuals to whom the notice is sent, other than via auto-reply).
(b) Notwithstanding
any other provision of this Agreement, during any period in which the Company is, or could be deemed to be, in possession of material
non-public information, the Company and the Agent agree that (i) no sale of Placement Shares will take place, (ii) the Company
shall not request the sale of any Placement Shares and shall suspend or cancel any effective Placement Notices instructing the Agent to
make any sales and (iii) the Agent shall not be obligated to sell or offer to sell any Placement Shares.
6. Settlement
and Delivery of the Placement Shares.
(a) Settlement
of Placement Shares. Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement Shares will
occur on the second Trading Day (or such earlier day as is industry practice or as is required for regular-way trading) following the
date on which such sales are made (each, a “Settlement Date”). The amount of proceeds to be delivered to the
Company on a Settlement Date against receipt of the Placement Shares sold (the “Net Proceeds”) will be equal
to the aggregate gross sales price received by the Agent at which such Placement Shares were sold, after deduction of (i) the Agent’s
commission, discount or other compensation for such sales payable by the Company pursuant to Section 3 hereof, (ii) any other
amounts due and payable by the Company to the Agent hereunder pursuant to Section 8(g) hereof and (iii) any transaction
fees imposed by any governmental or self-regulatory organization in respect of such sales.
(b) Delivery
of Placement Shares. On or before each Settlement Date, the Company will issue the Placement Shares being sold on such date and will,
or will cause its transfer agent to, electronically transfer such Placement Shares by crediting the Agent’s or its designee’s
account (provided the Agent shall have given the Company written notice of such designee prior to the Settlement Date) at The Depository
Trust Company through its Deposit and Withdrawal at Custodian System (“DWAC”) or by such other means of delivery
as may be mutually agreed upon by the parties hereto, which in all cases shall be duly authorized, freely tradeable, transferable, registered
shares of Common Stock in good deliverable form. On each Settlement Date, the Agent will deliver the related Net Proceeds in same day
funds to an account designated by the Company on or prior to the Settlement Date. The Agent shall be responsible for providing DWAC instructions
or other instructions for delivery by other means with regard to the transfer of the Placement Shares being sold. In addition to and in
no way limiting the rights and obligations set forth in Section 10(a) hereto, the Company agrees that if the Company or its
transfer agent (if applicable), defaults in its obligation to deliver duly authorized, freely tradeable, transferable, registered Placement
Shares in good deliverable form by 2:30 P.M., New York City time, on a Settlement Date (other than as a result of a failure by the Agent
to provide instructions for delivery), the Company will (i) take all necessary action to cause the full amount of any Net Proceeds
that were delivered to the Company’s account with respect to such settlement, together with any costs incurred by the Agent and/or
its clearing firm in connection with recovering such Net Proceeds, to be immediately returned to the Agent or its clearing firm no later
than 5:00 P.M., New York City time, on such Settlement Date, by wire transfer of immediately available funds to an account designated
by the Agent or its clearing firm, (ii) indemnify and hold the Agent and its clearing firm harmless against any loss, claim, damage,
or expense (including reasonable legal fees and expenses), as incurred, arising out of or in connection with such default by the Company
or its transfer agent (if applicable) and (iii) pay to the Agent any commission, discount or other compensation to which it would
otherwise have been entitled absent such default.
(c) Limitations
on Offering Size. Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares if, after giving
effect to the sale of such Placement Shares, the aggregate number or gross sales proceeds of Placement Shares sold pursuant to this Agreement
would exceed the lesser of: (i) the number or dollar amount of shares of Common Stock registered pursuant to, and available for offer
and sale under, the Registration Statement pursuant to which the offering of Placement Shares is being made, (ii) the number of authorized
but unissued shares of Common Stock of the Company (less shares of Common Stock issuable upon exercise, conversion or exchange of any
outstanding securities of the Company or otherwise reserved from the Company’s authorized capital stock), (iii) the number
or dollar amount of shares of Common Stock permitted to be offered and sold by the Company under Form S-3 (including General Instruction
I.B.6. thereof, if such instruction is applicable), (iv) the number or dollar amount of shares of Common Stock that the Company’s
board of directors or a duly authorized committee thereof is authorized to issue and sell from time to time, and notified to the Agent
in writing, or (v) the number or dollar amount of shares of Common Stock for which the Company has filed the ATM Prospectus. Under
no circumstances shall the Company cause or request the offer or sale of any Placement Shares pursuant to this Agreement at a price lower
than the minimum price authorized from time to time by the Company’s board of directors or a duly authorized committee thereof,
and notified to the Agent in writing. Notwithstanding anything to the contrary contained herein, the parties hereto acknowledge and agree
that compliance with the limitations set forth in this Section 6(c) on the number or dollar amount of Placement Shares that
may be issued and sold under this Agreement from time to time shall be the sole responsibility of the Company, and that the Agent shall
have no obligation in connection with such compliance.
7. Representations
and Warranties of the Company. The Company represents and warrants to, and agrees with, the Agent that as of the date of this Agreement,
and as of (i) each Representation Date (as defined in Section 8(m)), (ii) each date on which a Placement Notice is given,
(iii) the date and time of each sale of any Placement Shares pursuant to this Agreement and (iv) each Settlement Date (each
such time or date referred to in clauses (i) through (iv), an “Applicable Time”):
(a) The
Company and the transactions contemplated by this Agreement meet the requirements for and comply with the conditions for the use of Form S-3
(including General Instructions I.A and I.B.1.) under the Securities Act. The Registration Statement has been or will be filed with the
Commission and has been or will be declared effective by the Commission under the Securities Act prior to the issuance of any Placement
Notices by the Company. At the time the Registration Statement was or will be declared effective with the Commission and at the time the
Company’s most recent Annual Report on Form 10-K was filed with the Commission, the Company met the then-applicable requirements
for use of Form S-3 (including General Instructions I.A and I.B.1.) under the Securities Act. The Registration Statement meets, and
the offering and sale of Placement Shares as contemplated hereby comply with, the requirements of Rule 415(a)(1)(x) under the
Securities Act. The Agent is named as the agent engaged by the Company in the section entitled “Plan of Distribution”
in the ATM Prospectus. The Company has not received, and has no notice from the Commission of, any notice pursuant to Rule 401(g)(1) under
the Securities Act objecting to the use of the shelf registration statement form. No stop order of the Commission preventing or suspending
the use of the base prospectus, the ATM Prospectus or the Prospectus, or the effectiveness of the Registration Statement, has been issued,
and no proceedings for such purpose are pending before or, to the knowledge of the Company, threatened by the Commission. At the time
of the initial filing of the Registration Statement, the Company paid the required Commission filing fees relating to the securities covered
by the Registration Statement, including the Placement Shares that may be sold pursuant to this Agreement, in accordance with Rule 457(o) under
the Securities Act. Copies of the Registration Statement, the Prospectus, any such amendments or supplements to any of the foregoing and
all Incorporated Documents that were filed with the Commission on or prior to the date of this Agreement have been delivered, or are available
through EDGAR, to the Agent and its counsel.
(b) Each
of the Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective, at each deemed effective
date with respect to the Agent pursuant to Rule 430B(f)(2) under the Securities Act and as of each Applicable Time, complied,
complies and will comply in all material respects with the requirements of the Securities Act and did not, does not and will not contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading, except that the representations and warranties set forth in this sentence do not apply to Agent’s Information
(as defined below). The Prospectus and any amendment or supplement thereto, when so filed with the Commission under Rule 424(b) under
the Securities Act, complied, complies and as of each Applicable Time will comply in all material respects with the requirements of the
Securities Act, and each ATM Prospectus, Prospectus or issuer free writing prospectus (or any amendments or supplements to any of the
foregoing) furnished to the Agent for use in connection with the offering of the Placement Shares was identical to the electronically
transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T. Neither the
Prospectus nor any amendment or supplement thereto, as of its date and as of each Applicable Time, included, includes or will include
an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading, except that the representations and warranties
set forth in this sentence do not apply to Agent’s Information. Each Incorporated Document heretofore filed, when it was filed (or,
if any amendment with respect to any such document was filed, when such amendment was filed), conformed in all material respects with
the requirements of the Exchange Act and were filed on a timely basis with the Commission, and any further Incorporated Documents so filed
and incorporated after the date of this Agreement will be filed on a timely basis and, when so filed, will conform in all material respects
with the requirements of the Exchange Act; no such Incorporated Document when it was filed (or, if an amendment with respect to any such
document was filed, when such amendment was filed), contained an untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they
were made, not misleading; and no such Incorporated Document, when it is filed, will contain an untrue statement of a material fact or
will omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading.
(c) (i) At
the time of filing the Registration Statement and (ii) at the time of the execution of this Agreement (with such date being used
as the determination date for purposes of this clause (ii)), the Company was not and is not an “ineligible issuer” (as defined
in Rule 405), without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that
the Company be considered an ineligible issuer.
(d) The
Company is, and since the initial confidential submission of its initial registration statement has been, an “emerging growth company,”
as defined in Section 3(a) of the Securities Act (an “Emerging Growth Company”).
(e) Each
issuer free writing prospectus, as of its issue date and as of each Applicable Time, did not, does not and will not include any information
that conflicted, conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including
any Incorporated Document deemed to be a part thereof that has not been superseded or modified. Each issuer free writing prospectus that
the Company has filed, or is required to file, pursuant to Rule 433 or that was prepared by or on behalf of or used by the Company
complies or will comply in all material respects with the requirements of the Securities Act.
(f) The
Company has not distributed and, prior to the later to occur of each Settlement Date and completion of the Agent’s distribution
of the Placement Shares under this Agreement, will not distribute any offering material in connection with the offering and sale of the
Placement Shares other than the Registration Statement, the Prospectus or any Permitted Free Writing Prospectus (as defined below).
(g) If
applicable, the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement
and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s
rules and guidelines applicable thereto.
(h) The
Company is subject to and in compliance in all material respects with the reporting requirements of Section 13 or Section 15(d) of
the Exchange Act. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is listed on Nasdaq, and
the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock
under the Exchange Act or delisting the Common Stock from Nasdaq, nor has the Company received any notification that the Commission or
Nasdaq is contemplating terminating such registration or listing. The Company is in compliance with the current listing standards of Nasdaq.
The Company has filed a Notification of Listing of Additional Shares with Nasdaq with respect to the Placement Shares.
(i) No
person (as such term is defined in Rule 1-02 of Regulation S-X promulgated under the Securities Act) has the right to act as an underwriter
or as a financial advisor to the Company in connection with the offer and sale of the Placement Shares hereunder, whether as a result
of the filing or effectiveness of the Registration Statement or the sale of the Placement Shares as contemplated hereby or otherwise.
Except for the Agent, there is no broker, finder or other party that is entitled to receive from the Company or any of its Subsidiaries
(as defined below) any brokerage or finder’s fee or other fee or commission as a result of any transactions contemplated by this
Agreement.
(j) The
Company has been duly incorporated, is validly existing as a corporation and in good standing under the laws of the jurisdiction of its
incorporation, has the corporate power and authority to own or lease its property and to conduct its business as described in the Registration
Statement and Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct
of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified
or be in good standing would not reasonably be expected individually or in the aggregate, to have a material adverse effect on the condition
(financial or otherwise), earnings, results of operations, business, properties, operations, assets, liabilities or prospects of the Company
and its subsidiaries, taken as a whole, whether or not arising from transactions in the ordinary course of business (a “Material
Adverse Effect”).
(k) Each
of the Company’s “significant subsidiaries” (for purposes of this Agreement, as defined in Rule 405 under the Securities
Act) (each, a “Subsidiary” and collectively, the “Subsidiaries”), if any, has been
duly organized and is validly existing in good standing (where such concept exists) under the laws of the jurisdiction of its organization
and has full power and authority to acquire, own, lease and operate its properties, and to conduct its business as described in the Registration
Statement and the Prospectus. Each Subsidiary is duly qualified to transact business and is in good standing (where such concept exists)
under the laws of each jurisdiction that requires such qualification, whether by reason of the ownership or leasing of property or the
conduct of business, except to the extent that the failure to be so qualified or in good standing could not reasonably be expected, individually
or in the aggregate, to have a Material Adverse Effect. All of the issued and outstanding share capital or other equity or ownership interests
of each Subsidiary has been duly authorized and validly issued, is fully paid and nonassessable, has been issued in compliance with federal
state and securities laws and is owned by the Company, directly or through other wholly-owned Subsidiaries, free and clear of any security
interest, mortgage, pledge, lien, encumbrance or adverse claim. The Company does not own or control, directly or indirectly, any corporation,
association or other entity, other than the Subsidiaries listed on Exhibit 21.1 to the Company’s most recent Annual Report
on Form 10-K filed with the Commission. No Subsidiary is prohibited or restricted, directly or indirectly, from paying dividends
to the Company, from making any other distribution with respect to such Subsidiary’s equity securities, from repaying to the Company
or any other Subsidiary any amounts that may from time to time become due under any loans or advances to such Subsidiary from the Company
or from transferring any property or assets to the Company or to any other Subsidiary.
(l) This
Agreement has been duly authorized, executed and delivered by the Company. This Agreement conforms in all material respects to the descriptions
thereof in the Registration Statement and the Prospectus.
(m) The
authorized capital stock of the Company conforms as to legal matters to the description thereof contained in the section entitled “Description
of Capital Stock” in each of the Registration Statement and the Prospectus.
(n) The
shares of Common Stock outstanding prior to the issuance of the Placement Shares have been duly authorized and are validly issued, fully
paid and non-assessable.
(o) The
Placement Shares have been duly authorized and, when issued, delivered and paid for in accordance with the terms of this Agreement, will
be validly issued, fully paid and non-assessable, and the issuance of such Placement Shares will not be subject to any preemptive or similar
rights that have not been validly waived.
(p) The
execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement will not contravene
(i) any provision of applicable law, (ii) the certificate of incorporation or by-laws of the Company or any of its Subsidiaries,
(iii) any agreement or other instrument binding upon the Company that is material to the Company or any of its Subsidiaries, or (iv) any
judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any of its Subsidiaries, except
in the case of clauses (i), (iii) and (iv) as would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect, and no consent, approval, authorization or order of, or qualification with, any governmental body or agency is
required for the performance by the Company of its obligations under this Agreement, except such as have been obtained or waived or as
may be required by the securities or blue sky laws of the various states in connection with the offer and sale of the Shares.
(q) There
has not occurred any material adverse change, or any development that would reasonably be expected to result in a material adverse change,
in the condition, financial or otherwise, or in the earnings, business, management or operations of the Company and its Subsidiaries from
that set forth in the Registration Statement or the Prospectus.
(r) There
are no legal or governmental proceedings pending or, to the Company’s knowledge, threatened to which the Company or any of its Subsidiaries
is a party or to which any of the properties of the Company or any of its Subsidiaries is subject (i) other than (A) proceedings
accurately described in all material respects in the Registration Statement or the Prospectus and (B) proceedings that would not
reasonably, individually or in the aggregate, be expected to have a Material Adverse Effect or on the power or ability of the Company
to perform its obligations under this Agreement or to consummate the transactions contemplated by the Registration Statement or the Prospectus
or (ii) that are required to be described in the Registration Statement or the Prospectus and are not so described in all material
respects; and there are no statutes, regulations, contracts or other documents to which the Company or its property are subject or bound
that are required to be described in the Registration Statement or the Prospectus or to be filed or incorporated by reference as exhibits
to the Registration Statement that are not described in all material respects or filed or incorporated by reference as required.
(s) The
Company is not, and after giving effect to the offering and sale of the Placement Shares and the application of the proceeds thereof as
described in the Prospectus will not be, required to register as an “investment company” as such term is defined in the Investment
Company Act of 1940, as amended.
(t) The
Company and each of its Subsidiaries (i) is in compliance with any and all applicable foreign, federal, state and local laws and
regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants
or contaminants (“Environmental Laws”), (ii) has received all permits, licenses or other approvals required
of it under applicable Environmental Laws to conduct its business and (iii) is in compliance with all terms and conditions of any
such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses
or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in the
aggregate, reasonably be expected to have a Material Adverse Effect.
(u) There
are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or operating expenditures required
for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints
on operating activities and any potential liabilities to third parties) that would, singly or in the aggregate, reasonably be expected
to have a Material Adverse Effect.
(v) There
are no contracts, agreements or understandings between the Company and any person granting such person the right to require the Company
to file a registration statement under the Securities Act with respect to any securities of the Company or to require the Company to include
such securities with the Placement Shares registered pursuant to the Registration Statement, except those contracts, agreements and understandings
described in the Registration Statement and the Prospectus (i) as have been validly waived in connection with the issuance and sale
of the Placement Shares or (ii) pursuant to which such right has lapsed in accordance with its terms.
(w) (i) None
of the Company or any of its Subsidiaries or its controlled affiliates, any director or officer, thereof, or, to the Company’s knowledge,
any employee, agent or representative of the Company or any of its subsidiaries or of any of its controlled affiliates, has taken or will
take any action in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt of
money, property, gifts or anything else of value, directly or indirectly, to any government official (including any officer or employee
of a government or government-owned or controlled entity or of a public international organization, or any person acting in an official
capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office) in order
to improperly influence official action, or to any person in violation of any applicable anti-corruption laws; (ii) the Company and
each of its Subsidiaries and its controlled affiliates have conducted their businesses in compliance with applicable anti-corruption laws
and have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance
with such laws and with the representations and warranties contained herein; and (iii) neither the Company nor any of its Subsidiaries
will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of
the payment or giving of money, or anything else of value, to any person in violation of any applicable anti-corruption laws.
(x) The
operations of the Company and each of its Subsidiaries are and have been conducted at all times in material compliance with all applicable
financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and
Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the
applicable anti-money laundering statutes of jurisdictions where the Company and each of its Subsidiaries conducts business, the rules and
regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental
agency (collectively, the “Anti-Money Laundering Laws”), and no action, suit or proceeding by or before any
court or governmental agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries with respect to the
Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.
(y) (i) None
of the Company, any of its Subsidiaries, or any director or officer thereof, or, to the Company’s knowledge, any employee, agent,
affiliate or representative of the Company or any of its Subsidiaries, is an individual or entity (“Person”)
that is, or is owned or controlled by one or more Persons that are:
(A) the
subject of any sanctions administered or enforced by the U.S. Department of Treasury’s Office of Foreign Assets Control, the United
Nations Security Council, the European Union, His Majesty’s Treasury, or other relevant sanctions authority (collectively, “Sanctions”),
or
(B) located,
organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, Cuba, Crimea, the so-called
Donetsk People’s republic and so-called Luhansk People’s Republic regions of Ukraine, Iran, North Korea and Syria).
(ii) The
Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds
to any subsidiary, joint venture partner or other Person:
(A) to
fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or
facilitation, is the subject of Sanctions; or
(B) in
any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether
as underwriter, advisor, investor or otherwise).
(iii) For
the past five years, the Company and its Subsidiaries have not knowingly engaged in, is not now knowingly engaged in, and will not engage
in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or
was the subject of Sanctions.
(z) Subsequent
to the respective dates as of which information is given in each of the Registration Statement and the Prospectus, (i) the Company
and its Subsidiaries have not incurred any material liability or obligation, direct or contingent, nor entered into any material transaction;
(ii) the Company has not purchased any of its outstanding capital stock, other than in connection with the termination of service
of employees, directors or other service providers pursuant to equity compensation plans described in the Registration Statement and the
Prospectus or existing agreements or in connection with the exercise of the Company’s right of first refusal upon a proposed transfer,
nor declared, paid or otherwise made any dividend or distribution of any kind on its capital stock other than ordinary and customary dividends;
and (iii) there has not been any material change in the capital stock (other than the exercise of equity awards or grants of equity
awards or repurchase or forfeiture of equity awards or restricted stock outstanding as of such respective dates as of which information
is given in each of the Registration Statement and the Prospectus, in each case granted pursuant to the equity compensation plans described
in the Registration Statement and the Prospectus or subject to an existing agreement), short-term debt or long-term debt of the Company
and its Subsidiaries, except in each case as described in each of the Registration Statement and the Prospectus, respectively.
(aa) The Company
and its Subsidiaries does not own any real property. The Company and its Subsidiaries have good and marketable title to all personal property
owned by it that is material to the business of the Company and its Subsidiaries, in each case free and clear of all liens, encumbrances
and defects except such as are described in the Registration Statement or the Prospectus or such as do not materially diminish the value
of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and its Subsidiaries;
and any real property and buildings held under lease by the Company and its Subsidiaries is held by them under valid, subsisting and enforceable
leases with such exceptions as are not material and do not materially interfere with the use made and proposed to be made of such property
and buildings by the Company and its Subsidiaries, in each case except as described in the Registration Statement or the Prospectus.
(bb) The Company
and its Subsidiaries own, have obtained licenses or can acquire on reasonable terms all material patent rights, inventions, trademarks,
trade names, service marks, logos, trade dress, designs, data, database rights, Internet domain names, copyrights, works of authorship,
trade secrets, know-how and proprietary information (including unpatented and unpatentable proprietary or confidential information, systems
or procedures) and other intellectual property rights (collectively, “Intellectual Property Rights”) necessary
to the current conduct of the business as described in the Registration Statement and the Prospectus, except where any failure to own,
possess or acquire such Intellectual Property Rights would not reasonably be expected to have a Material Adverse Effect. Such Intellectual
Property Rights owned by or licensed to the Company or its Subsidiaries have not been adjudged by a court of competent jurisdiction to
be invalid or unenforceable, in whole or in part. To the Company’s knowledge: (i) there are no third parties that have rights
to any Intellectual Property Rights of the Company or its Subsidiaries except for (a) customary retained and reversionary rights
of third-party licensors with respect to Intellectual Property Rights licensed to the Company or its Subsidiaries, (b) non-exclusively
licensed Intellectual Property Rights, where the licensor may provide licenses to a third party and (c) third parties that have been
explicitly granted licenses by the Company or its Subsidiaries; and (ii) there is no infringement by third parties of any Intellectual
Property Rights of the Company or its Subsidiaries. Except as disclosed in the Registration Statement and the Prospectus, there is no
pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by any third party: (A) challenging the
Company’s or any of its Subsidiaries’ rights in or to any of their Intellectual Property Rights; (B) challenging the
validity, enforceability or scope of any Intellectual Property Rights of the Company or its Subsidiaries; or (C) asserting that the
Company or any of its Subsidiaries infringes, misappropriates, or otherwise violates, or would, upon the commercialization of any product
or service described in the Registration Statement or the Prospectus as under development, infringe, misappropriate, or violate, any patent,
trademark, trade name, service name, copyright, trade secret or other proprietary rights of others. The Company and its Subsidiaries have
complied in all material respects with the terms of each agreement pursuant to which Intellectual Property Rights have been licensed to
the Company or its Subsidiaries, and all such agreements are in full force and effect. The Company and its Subsidiaries has taken all
reasonable steps necessary to secure its interests in the Company-owned Intellectual Property Rights from its employees and contractors
and to protect the confidentiality of all of its confidential information and trade secrets, including the execution of appropriate nondisclosure,
confidentiality agreements, invention assignment agreements and invention assignments with its employees, and to the Company’s knowledge,
no employee of the Company or its Subsidiaries is in or has been in violation of any term of any employment contract, patent disclosure
agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement, or any restrictive
covenant to or with a former employer where the basis of such violation relates to such employee’s employment with the Company or
its Subsidiaries. The product candidates described in the Registration Statement and the Prospectus as under development by the Company
fall within the scope of one or more claim of one or more patents or patent applications owned by, or exclusively licensed to, the Company
or its Subsidiaries. To the Company’s knowledge, the duties of candor and good faith required by the United States Patent and Trademark
Office, including citation of material prior art that the Company is aware of, during the prosecution of Company-owned United States patents
and patent applications included in the Intellectual Property Rights have been complied with.
(cc) To the Company’s
knowledge, none of the Company-owned Intellectual Property Rights or technology (including information technology and outsourced arrangements)
employed by the Company or its Subsidiaries in the conduct of the business in the manner described in the Registration Statement or the
Prospectus has been obtained or is being used by the Company or its Subsidiaries in violation of any contractual obligation binding on
the Company or its Subsidiaries or any of their officers, directors or employees or otherwise in violation of the rights of any persons.
(dd) Except as
would not reasonably be expected to result in a Material Adverse Effect, (A) each Plan (as defined below) has been maintained in
compliance with its terms and in all material respects with the requirements of any applicable statutes, orders, rules and regulations,
including but not limited to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”) and the
Internal Revenue Code of 1986, as amended (the “Code”); (B) no non-exempt prohibited transaction, within
the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Plan; (C) for each Plan,
no failure to satisfy the minimum funding standards (within the meaning of Section 412 of the Code or Section 302 of ERISA),
whether or not waived, has occurred or is reasonably expected to occur; (D) no “reportable event” (within the meaning
of Section 4043(c) of ERISA, other than those events as to which notice is waived) has occurred or is reasonably expected to
occur; and (E) neither the Company nor any member of its “Controlled Group” (defined as any organization that is a member
of a controlled group of corporations within the meaning of Section 414 of the Code) has incurred, nor is reasonably expected to
incur, any liability under Title IV of ERISA (other than contributions to any Plan or any Multiemployer Plan or premiums to the PBGC,
in the ordinary course and without default) in respect of a Plan or a Multiemployer Plan. For purposes of this paragraph, (x) the
term “Plan” means an employee benefit plan, within the meaning of Section 3(3) of ERISA, subject to
Title IV of ERISA, but excluding any Multiemployer Plan, for which the Company or any member of its “Controlled Group” has
any liability and (y) the term “Multiemployer Plan” means a multiemployer plan within the meaning of Section 4001(a)(3) of
ERISA.
(ee) No material
labor dispute with the employees of the Company or any of its Subsidiaries exists, except as described in the Registration Statement or
the Prospectus, or, to the knowledge of the Company, is imminent; and the Company is not aware of any existing, threatened or imminent
labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that would reasonably be expected to
have a Material Adverse Effect.
(ff) The Company
and each of its Subsidiaries is insured by insurers of recognized financial responsibility against such losses and risks and in such amounts
as are, in the reasonable judgment of the Company, prudent and customary in the businesses in which it is engaged; neither the Company
nor any of its Subsidiaries has not been refused any insurance coverage sought or applied for; and neither the Company nor any of its
Subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires
or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a Material
Adverse Effect, except as described in the Registration Statement and the Prospectus.
(gg) The Company
and each of its Subsidiaries possesses all certificates, authorizations and permits issued by the appropriate federal, state or foreign
regulatory authorities necessary to conduct its business, except where failure to obtain such certificates, authorizations and permits
would not, singly or in the aggregate, reasonably be expected to have a Material Adverse Effect, and neither the Company nor any of its
Subsidiaries has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization
or permit that, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected
to have a Material Adverse Effect, except as described in the Registration Statement and the Prospectus.
(hh) The Company
and its Subsidiaries, taken as a whole, maintain a system of internal accounting controls sufficient to provide reasonable assurance that
(i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are
recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles in the
United States (“U.S. GAAP”) and to maintain asset accountability; (iii) access to assets is permitted only
in accordance with management’s general or specific authorization; (iv) the recorded accountability for assets is compared
with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v) the interactive
data in eXtensible Business Reporting Language included in the Registration Statement fairly presents the information called for in all
material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto. Except
as described in the Registration Statement and the Prospectus, since the end of the Company’s most recent audited fiscal year, there
has been (i) no material weakness in the Company’s internal control over financial reporting (whether or not remediated) and
(ii) no change in the Company’s internal control over financial reporting that has materially and adversely affected, or is
reasonably likely to materially and adversely affect, the Company’s internal control over financial reporting.
(ii) The
financial statements (including the related notes thereto) of the Company included or incorporated by reference in each of the Registration
Statement and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and present fairly
in all material respects the consolidated financial position of the Company and its Subsidiaries as of the dates indicated and the results
of its operations and cash flows for the periods specified. Such financial statements have been prepared in conformity with U.S. GAAP
applied on a consistent basis throughout the periods involved. The other financial information of the Company included in the Registration
Statement and the Prospectus has been derived from the accounting or other records of the Company and presents fairly in all material
respects the information shown thereby.
(jj) Ernst &
Young LLP, independent public accountants, who have expressed their opinion with respect to certain financial statements (which term as
used in this Agreement includes the related notes thereto) of the Company and its Subsidiaries included or incorporated by reference in
the Registration Statement, are independent with respect to the Company within the applicable rules and regulations of the Commission
and as required by the Securities Act.
(kk) The Company
maintains disclosure controls and procedures that comply with the requirements of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”); such disclosure controls and procedures have been designed to ensure that material information
relating to the Company is made known to the Company’s principal executive officer and principal financial officer by others within
the Company; such disclosure controls and procedures are effective at the reasonable assurance level; and the Company has carried out
evaluations of the effectiveness of its disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act.
(ll) Except as
described in the Registration Statement and the Prospectus, the Company has not sold, issued or distributed any shares of Common Stock
during the six-month period preceding the date hereof, including any sales pursuant to Rule 144A under, or Regulation D or S of,
the Securities Act, other than shares issued pursuant to employee benefit plans, qualified stock option plans or other employee compensation
plans or pursuant to outstanding options, rights or warrants.
(mm) The Company
is in compliance, to the extent required, with all provisions of the Sarbanes-Oxley Act of 2002, as amended (the “Sarbanes-Oxley
Act”), and all rules and regulations promulgated thereunder applicable to the Company as of the date hereof.
(nn) The Company
and each of its Subsidiaries has filed all federal, state, local and foreign tax returns required to be filed through the date of this
Agreement or has requested extensions thereof, except where the failure to file would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect, and has paid all taxes required to be paid thereon, except for cases in which the failure
to file or pay would not reasonably be expected to have a Material Adverse Effect, or, except as currently being contested in good faith
and for which reserves required by U.S. GAAP have been created in the financial statements of the Company, and no tax deficiency has been
determined adversely to the Company or any of its Subsidiaries that has had (nor does the Company have any notice or knowledge of any
tax deficiency that would reasonably be expected to be determined adversely to the Company or its Subsidiaries and that would reasonably
be expected to have) a Material Adverse Effect.
(oo) The
Company and each of its Subsidiaries have complied, and is presently in compliance, in all material respects with its privacy and security
policies, and with all obligations, laws and regulations regarding the collection, use, transfer, storage, protection, disposal or disclosure
of personally identifiable information or any other information collected from or provided by third parties. The Company and each of its
Subsidiaries have taken commercially reasonable steps to protect the information technology systems and data used in connection with the
operation of the Company and its Subsidiaries. The Company and each of its Subsidiaries have used reasonable efforts to establish, and
has established, commercially reasonable disaster recovery and security plans, procedures and facilities for the business, including,
without limitation, for the information technology systems and data held or used by or for the Company or its Subsidiaries. To its knowledge,
there has been no material security breach or attack or other compromise of or relating to any such information technology system or data.
(pp) The statistical,
industry and market-related data included in the Registration Statement and the Prospectus are based on or derived from sources that the
Company believes, after reasonable inquiry, to be reliable and accurate. To the Company’s knowledge, it does not require the consent
of any third party for the use of any such data except as already obtained.
(qq) Neither the
Company nor any of its Subsidiaries has taken, directly or indirectly, any action designed to or that would reasonably be expected to
cause or result in any stabilization or manipulation of the price of the Placement Shares to facilitate the sale or resale thereof.
(rr) The preclinical
tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results
of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are being conducted in all material
respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and
scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and
fairly presents the data derived from such studies, and the Company has no knowledge of any other studies the results of which are inconsistent
with, or otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company
has made all such filings and obtained all such approvals or authorizations as may be required by the Food and Drug Administration of
the U.S. Department of Health and Human Services or from any other U.S. or foreign government or drug regulatory agency, or health care
facility Institutional Review Board (collectively, the “Regulatory Agencies”), except where the failure to make
such filing or obtain such approval would not reasonably be expected to result in a Material Adverse Effect; except as described in the
Registration Statement and the Prospectus, the Company has not received any notice of, or correspondence from, any Regulatory Agency requiring
the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement and
the Prospectus; and the Company and each of its Subsidiaries has operated and currently is in compliance in all material respects with
all applicable rules and regulations of the Regulatory Agencies.
(ss) The Company
and each of its Subsidiaries is, and at all times has been, in compliance with all applicable Health Care Laws except where failure to
be in compliance would not be reasonably expected to have a Material Adverse Effect. For purposes of this Agreement, “Health
Care Laws” means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §§ 301 et seq.), the Public Health
Service Act (42 U.S.C. §§ 201 et seq.) and the regulations promulgated thereunder; (ii) all applicable federal, state,
local and foreign health care related fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. §
1320a-7b(b)), the U.S. False Statements Law (42 U.S.C. § 1320a-7b(a)), the Civil Monetary Penalties Law (42 U.S.C. §1320a-7a),
the U.S. Civil False Claims Act (31 U.S.C. § 3729 et seq.), all applicable federal, state, local and foreign criminal laws relating
to health care fraud and abuse, including but not limited to 18 U.S.C. §§ 286 and 287, and the health care fraud criminal provisions
under the U.S. Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) (42 U.S.C. §§
1320d et seq.), the Physician Payments Sunshine Act (42 U.S.C. § 1320a-7h), the exclusion law (42 U.S.C. §1320a-7), the statutes,
regulations and directives of applicable federal healthcare programs (as defined in 42 U.S.C. § 1320a-7b(f)), and the regulations
promulgated pursuant to such statutes, including but not limited to Medicare (Title XVIII of the Social Security Act) and Medicaid (Title
XIX of the Social Security Act); (iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act
(42 U.S.C. §§ 17921 et seq.), and the regulations promulgated thereunder, including without limitation, the Standards for Privacy
of Individually Identifiable Health Information, the Security Standards, and the Standards for Electronic Transactions and Code Sets,
and any state or non-U.S. counterpart thereof or other law or regulation the purpose of which is to protect the privacy of individuals
or prescribers; (iv) the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act
of 2010, the regulations promulgated thereunder; and (v) any and all other applicable health care laws and regulation applicable
to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, advertising, labeling, promotion,
sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company or its Subsidiaries.
Nether the Company nor any of its Subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging
that it is in violation of any Health Care Laws, and, to the Company’s knowledge, no such claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action is threatened. Neither the Company, any of its Subsidiaries, nor its officers,
directors, or, to the Company’s knowledge, its employees, contractors or agents, is a party to any corporate integrity agreements,
monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority.
Additionally, neither the Company, any of its Subsidiaries, nor any of its officers, directors, or to the Company’s knowledge, its
employees, contractors or agents has been excluded, suspended or debarred from participation in any federal health care program (as defined
in 42 U.S.C. § 1320a-7b(f)) or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry,
investigation, proceeding, or other similar action that could reasonably be expected to result in such debarment, suspension, or exclusion.
The Company and each of its Subsidiaries has filed, obtained, maintained or submitted all material reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments as required by the Health Care Laws, and all such reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments were timely, complete, accurate and not misleading
on the date filed (or were corrected or supplemented by a subsequent submission), except as would not reasonably be expected to have a
Material Adverse Effect.
(tt) The interactive
data in eXtensible Business Reporting Language included in the Registration Statement fairly presents the information called for in all
material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto.
(uu) There are
no transfer taxes or other similar fees or charges under federal law, the laws of any state, any foreign law, or any political subdivision
thereof, required to be paid in connection with the execution and delivery of this Agreement or the issuance by the Company or sale by
the Company of the Placement Shares.
(vv) The Company
acknowledges and agrees that the Agent has informed the Company that the Agent may, to the extent permitted under the Securities Act and
the Exchange Act, purchase and sell shares of Common Stock for its own account while this Agreement is in effect; provided, that
(i) no such purchase or sales shall take place while a Placement Notice is in effect (except to the extent the Agent may engage in
sales of Placement Shares purchased or deemed purchased from the Company as a “riskless principal” or in a similar capacity)
and (ii) the Company shall not be deemed to have authorized or consented to any such purchases or sales by the Agent, except as may
be otherwise agreed by the Company and the Agent.
(ww) The Company
is not a party to any agreement with an agent or underwriter for any other “at the market” or continuous equity transaction.
(xx) As
of the close of trading on Nasdaq on August 3, 2023, the aggregate market value of the outstanding voting and non-voting common equity
(as defined in Rule 405) of the Company held by persons other than affiliates of the Company (pursuant to Rule 144 of the Securities
Act, those that directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control
with, the Company) (the “Non-Affiliate Shares”), was approximately $50,287,721 (calculated by multiplying (x) the
price at which the common equity of the Company was last sold on Nasdaq on July 18, 2023 by (y) the number of Non-Affiliate
Shares outstanding on August 3, 2023). The Company is not a shell company (as defined in Rule 405) and has not been a shell
company for at least 12 calendar months previously.
Any certificate signed by any officer of the Company
and delivered to the Agent or its counsel in connection with the offering of the Placement Shares shall be deemed a representation and
warranty by the Company, as to matters covered thereby, to the Agent.
8. Covenants
of the Company. The Company covenants and agrees with the Agent that:
(a) Registration
Statement Amendments. After the date of this Agreement and during any period in which the Prospectus relating to any Placement Shares
is required to be delivered by the Agent under the Securities Act (including in circumstances where such requirement may be satisfied
pursuant to Rule 172 under the Securities Act or a similar rule); (i) the Company will notify the Agent promptly of the time
when any subsequent amendment to the Registration Statement, other than Incorporated Documents, has been filed with the Commission and/or
has become effective or any subsequent supplement to the Prospectus, other than Incorporated Documents, has been filed and of any request
by the Commission for any amendment or supplement to the Registration Statement or Prospectus related to the Placement Shares or for additional
information related to the Placement Shares; (ii) the Company will prepare and file with the Commission, promptly upon the Agent’s
request, any amendments or supplements to the Registration Statement or Prospectus that, in the Agent’s reasonable opinion, may
be necessary or advisable in connection with the distribution of the Placement Shares by the Agent (provided, however, that the
failure of the Agent to make such request shall not relieve the Company of any obligation or liability hereunder, or affect the Agent’s
right to rely on the representations and warranties made by the Company in this Agreement and provided, further, that the
only remedy the Agent shall have with respect to the failure by the Company to make such filing (but without limiting the Agent’s
rights under Section 10 hereof) will be to cease making sales under this Agreement until such amendment or supplement is filed);
(iii) the Company will not file any amendment or supplement to the Registration Statement or Prospectus, other than Incorporated
Documents, relating to the Placement Shares or a security convertible into or exchangeable or exercisable for the Placement Shares unless
a copy thereof has been submitted to the Agent within a reasonable period of time before the filing and the Agent has not reasonably objected
thereto (provided, however, that the failure of the Agent to make such objection shall not relieve the Company of any obligation
or liability hereunder, or affect the Agent’s right to rely on the representations and warranties made by the Company in this Agreement
and the Company shall have no obligation to provide the Agent any advance copy of such filing or to provide the Agent an opportunity to
object to such filing if the filing does not name the Agent or does not relate to the Placement Shares or the transactions contemplated
by this Agreement; and provided, further, that the only remedy the Agent shall have with respect to the Company’s
making such filing notwithstanding the Agent’s objection (but without limiting the Agent’s rights under Section 10 hereof)
will be to cease making sales under this Agreement) and the Company will furnish to the Agent at the time of filing thereof a copy of
any Incorporated Document, except for those documents available via EDGAR; and (iv) the Company will cause each amendment or supplement
to the Prospectus, other than Incorporated Documents, to be filed with the Commission as required pursuant to the applicable paragraph
of Rule 424(b) of the Securities Act and, in the case of any Incorporated Document, to be filed with the Commission as required
pursuant to the Exchange Act, within the time period prescribed (the determination to file or not file any amendment or supplement with
the Commission under this Section 8(a), based on the Company’s reasonable opinion or reasonable objections, shall be made exclusively
by the Company).
(b) Notice
of Commission Stop Orders. The Company will advise the Agent, promptly after it receives notice or obtains knowledge thereof, of the
issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement, of the
suspension of the qualification of the Placement Shares for offering or sale in any jurisdiction or of the initiation or threatening of
any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts to prevent the issuance of any stop
order or to obtain its withdrawal if such a stop order should be issued. The Company will advise the Agent promptly after it receives
any request by the Commission for any amendments to the Registration Statement related to the Placement Shares or any amendment or supplements
to the Prospectus or for additional information related to the offering of the Placement Shares or for additional information related
to the Registration Statement with respect to the Placement Shares or the Prospectus.
(c) Delivery
of Prospectus; Subsequent Changes. During any period in which the Prospectus relating to the Placement Shares is required to be delivered
by the Agent under the Securities Act with respect to the offer and sale of the Placement Shares (including in circumstances where such
requirement may be satisfied pursuant to Rule 172 under the Securities Act or a similar rule), the Company will comply with all requirements
imposed upon it by the Securities Act, as from time to time in force, and will file on or before their respective due dates (taking into
account any extensions available under the Exchange Act) all reports and any definitive proxy or information statements required to be
filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange
Act. If during such period any event occurs as a result of which the Prospectus as then amended or supplemented would include an untrue
statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances
then existing, not misleading, or if during such period it is necessary to amend or supplement the Registration Statement or Prospectus
to comply with the Securities Act, the Company will promptly notify the Agent to suspend the offering of Placement Shares during such
period and the Company will promptly amend or supplement the Registration Statement or Prospectus (at the expense of the Company) so as
to correct such statement or omission or effect such compliance; provided, however, that the Company may delay the filing of any
amendment or supplement if, in the judgment of the Company, it would adversely affect the Company not to do so. If the Company has omitted
any information with respect to the Placement Shares from the Registration Statement pursuant to Rule 430B under the Securities Act,
it will use its best efforts to comply with the provisions thereof and make all requisite filings with the Commission pursuant to said
Rule 430B and to notify the Agent promptly of all such filings if not available on EDGAR.
(d) Listing
of Placement Shares. During any period in which the Prospectus relating to the Placement Shares is required to be delivered by the
Agent under the Securities Act with respect to the offer and sale of the Placement Shares (including in circumstances where such requirement
may be satisfied pursuant to Rule 172 under the Securities Act or a similar rule), the Company will use its commercially reasonable
efforts to cause the Placement Shares to be listed on Nasdaq. The Company will timely file with Nasdaq all material documents and notices
required by Nasdaq of companies that have or will issue securities that are traded on Nasdaq.
(e) Delivery
of Registration Statement and Prospectus. The Company will furnish to the Agent and its counsel (at the expense of the Company) copies
of the Registration Statement, the Prospectus (including all Incorporated Documents) and all amendments and supplements to the Registration
Statement or Prospectus that are filed with the Commission during any period in which the Prospectus relating to the Placement Shares
is required to be delivered under the Securities Act (including all Incorporated Documents filed with the Commission during such period),
in each case as soon as reasonably practicable and in such quantities as the Agent may from time to time reasonably request and, at the
Agent’s request, will also furnish copies of the Prospectus to each exchange or market on which sales of the Placement Shares may
be made; provided, however, that the Company shall not be required to furnish any document (other than the Prospectus) to the Agent
to the extent such document is available on EDGAR.
(f) Earnings
Statement. The Company will make generally available to its security holders and to the Agent as soon as practicable, but in any event
not later than 15 months after the end of the Company’s current fiscal quarter, an earnings statement covering a 12-month period
that satisfies the provisions of Section 11(a) of and Rule 158 under the Securities Act.
(g) Expenses.
The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated in accordance with
the provisions of Section 12 hereunder, will pay all expenses incident to the performance of its obligations hereunder, including
expenses relating to (i) the preparation, printing and filing of the Registration Statement and each amendment and supplement thereto,
of the Prospectus and of each amendment and supplement thereto and of this Agreement and such other documents as may be required in connection
with the offering, purchase, sale, issuance or delivery of the Placement Shares, (ii) the preparation, issuance, sale and delivery
of the Placement Shares and any taxes due or payable in connection therewith, (iii) the qualification of the Placement Shares under
securities laws in accordance with the provisions of Section 8(w) of this Agreement, including filing fees (provided, however,
that any fees or disbursements of counsel for the Agent in connection therewith shall be paid by the Agent except as set forth in clauses
(vii) and (viii) below), (iv) the printing and delivery to the Agent and its counsel of copies of the Prospectus and any
amendments or supplements thereto, and of this Agreement, (v) the fees and expenses incurred in connection with the listing or qualification
of the Placement Shares for trading on Nasdaq, (vi) the filing fees and expenses, if any, owed to the Commission or FINRA and the
fees and expenses of any transfer agent or registrar for the Placement Shares, (vii) the fees and associated expenses of the Agent’s
outside legal counsel for filings with the FINRA Corporate Financing Department in an amount not to exceed $15,000 (excluding FINRA filing
fees referred to in clause (vi) above and in addition to the fees and disbursements referred to in clause (viii) below), and
(viii) the reasonable fees and disbursements of the Agent’s outside legal counsel (A) in an amount not to exceed $75,000
arising out of executing this Agreement and the Company’s delivery of the initial certificate pursuant to Section 8(m) and
(B) in an amount not to exceed $15,000 in connection with each Representation Date (as defined below) on which the Company is required
to provide a certificate pursuant to Section 8(m) (in addition to the fees and associated expenses referred to in clause (vii) above)
except that to the extent any such Representation Date includes a review of the Company’s Annual Report on Form 10-K, such
amount shall not exceed $25,000.
(h) Use
of Proceeds. The Company will use the Net Proceeds as described in the Prospectus in the section entitled “Use of Proceeds.”
(i) Notice
of Other Sales. Without the prior written consent of the Agent, the Company will not, directly or indirectly, offer to sell, sell,
contract to sell, grant any option to sell or otherwise dispose of any shares of Common Stock (other than the Placement Shares offered
pursuant to this Agreement) or securities convertible into or exchangeable or exercisable for shares of Common Stock, warrants or any
rights to purchase or acquire shares of Common Stock during the period beginning on the third Trading Day immediately prior to the date
on which any Placement Notice is delivered to Agent hereunder and ending on the second Trading Day immediately following the final Settlement
Date with respect to Placement Shares sold pursuant to such Placement Notice (or, if the Placement Notice has been terminated or suspended
prior to the sale of all Placement Shares covered by a Placement Notice, the date of such suspension or termination); and will not directly
or indirectly in any other “at the market offering” or continuous equity transaction offer to sell, sell, contract to sell,
grant any option to sell or otherwise dispose of any shares of Common Stock (other than the Placement Shares offered pursuant to this
Agreement) or securities convertible into or exchangeable or exercisable for shares of Common Stock, warrants or any rights to purchase
or acquire, shares of Common Stock prior to the later of the termination of this Agreement and the thirtieth day immediately following
the final Settlement Date with respect to Placement Shares sold pursuant to such Placement Notice; provided, however, that such
restrictions will not be required in connection with the Company’s issuance or sale of (i) shares of Common Stock, options
to purchase shares of Common Stock, other securities under the Company’s existing equity incentive plans, or shares of Common Stock
issuable upon the exercise of options or vesting of other securities, pursuant to any employee or director stock option or benefits plan,
inducement grant award, stock ownership plan or dividend reinvestment plan (but not shares of Common Stock subject to a waiver to exceed
plan limits in its dividend reinvestment plan) of the Company whether now in effect or hereafter implemented, (ii) shares of Common
Stock issuable upon conversion of securities or the exercise of warrants, options or other rights in effect or outstanding, and disclosed
in filings by the Company available on EDGAR or otherwise in writing to the Agent and (iii) shares of Common Stock or securities
convertible into or exchangeable for shares of Common Stock as consideration for mergers, acquisitions, other business combinations or
strategic alliances occurring after the date of this Agreement which are not issued for capital raising purposes.
(j) Change
of Circumstances. The Company will, at any time during a fiscal quarter in which the Company intends to tender a Placement Notice
or sell Placement Shares, advise the Agent promptly after it shall have received notice or obtained knowledge of any information or fact
that would alter or affect in any material respect any opinion, certificate, letter or other document provided or required to be provided
to the Agent pursuant to this Agreement.
(k) Due
Diligence Cooperation. During the term of this Agreement, the Company will cooperate with any reasonable due diligence review conducted
by the Agent, its affiliates agents and counsel from time to time in connection with the transactions contemplated hereby, including providing
information and making available documents and senior corporate officers, during regular business hours and at the Company’s principal
offices, as the Agent may reasonably request.
(l) Required
Filings Relating to Placement of Placement Shares. The Company agrees that on or prior to such dates as the Securities Act shall require,
the Company will (i) file a prospectus supplement with the Commission under the applicable paragraph of Rule 424(b) under
the Securities Act, which prospectus supplement will set forth, within the relevant period, the number or amount of Placement Shares sold
through the Agent, the Net Proceeds to the Company and the compensation payable by the Company to the Agent with respect to such Placement
Shares, and (ii) deliver such number of copies of each such prospectus supplement to each exchange or market on which such sales
were effected as may be required by the rules or regulations of such exchange or market; provided, that, unless a prospectus
supplement containing such information is required to be filed under the Securities Act, the requirement of this Section 8(l) may
be satisfied by Company’s inclusion in the Company’s Form 10-K or Form 10-Q, as applicable, of the number or amount
of Placement Shares sold through the Agent, the Net Proceeds to the Company and the compensation payable by the Company to the Agent with
respect to such Placement Shares during the relevant period.
(m) Representation
Dates; Certificate. On or prior to the date on which the Company first delivers a Placement Notice pursuant to this Agreement (the
“First Placement Notice Date”) and each time the Company:
(i) amends
or supplements the Registration Statement or the Prospectus relating to the Placement Shares (other than a prospectus supplement filed
in accordance with Section 8(l) of this Agreement) by means of a post-effective amendment, sticker or supplement but not by
means of incorporation of document(s) by reference into the Registration Statement or the Prospectus relating to the Placement Shares;
(ii) files
an annual report on Form 10-K under the Exchange Act (including any Form 10-K/A containing amended financial information or
a material amendment to the previously filed Form 10-K);
(iii) files
a quarterly report on Form 10-Q under the Exchange Act; or
(iv) files
a current report on Form 8-K containing amended financial information (other than an earnings release that is “furnished”
pursuant to Item 2.02 or Item 7.01 of Form 8-K) under the Exchange Act (each date of filing of one or more of the documents referred
to in clauses (i) through (iv) shall be a “Representation Date”),
the Company shall furnish the Agent (but in the case of clause (iv) above
only if (1) a Placement Notice is pending or in effect and (2) the Agent requests such certificate within three Business Days
after the filing of such Form 8-K with the Commission) with a certificate, in the form attached hereto as Exhibit 8(m) (modified,
as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented), within two Trading Days of
any Representation Date. The requirement to provide a certificate under this Section 8(m) shall be waived for any Representation
Date occurring at a time at which no Placement Notice is pending or in effect, which waiver shall continue until the earlier to occur
of (1) the date the Company delivers a Placement Notice hereunder (which for such calendar quarter shall be considered a Representation
Date) and (2) the next occurring Representation Date. Notwithstanding the foregoing, if the Company subsequently decides to sell
Placement Shares following a Representation Date on which the Company relied on the waiver referred to in the previous sentence and did
not provide the Agent with a certificate under this Section 8(m), then before the Company delivers a Placement Notice or the Agent
sells any Placement Shares pursuant thereto, the Company shall provide the Agent with a certificate, in the form attached hereto as Exhibit 8(m),
dated the date of such Placement Notice. Within two Trading Days of each Representation Date, the Company shall have furnished to the
Agent such further information, certificates and documents as the Agent may reasonably request.
(n) Legal
Opinions. On or prior to the First Placement Notice Date and on any date on which the Company is obligated to deliver a certificate
pursuant to Section 8(m) for which no waiver is applicable, the Company shall cause to be furnished to the Agent the written
opinion and negative assurance letter of Sidley Austin LLP, counsel to the Company, or such other counsel satisfactory to the Agent (“Company
Counsel”), in form and substance satisfactory to the Agent and its counsel, dated the date that the opinion and negative
assurance letter are required to be delivered, modified, as necessary, to relate to the Registration Statement and the Prospectus as then
amended or supplemented; provided, however, that in lieu of such opinion and negative assurance letter for subsequent Representation
Dates, Company Counsel may furnish the Agent with a letter to the effect that the Agent may rely on a prior opinion or negative assurance
letter delivered by such counsel under this Section 8(n) to the same extent as if it were dated the date of such letter (except
that statements in such prior opinion or negative assurance letter shall be deemed to relate to the Registration Statement and the Prospectus
as amended or supplemented at such Representation Date).
(o) Intellectual
Property Opinion. On or prior to the First Placement Notice Date and on any date which the Company is obligated to deliver a certificate
pursuant to Section 8(m) for which no waiver is applicable, the Company shall cause to be furnished to the Agent the written
opinion of Smith, Gambrell & Russell, LLP, counsel for the Company with respect to intellectual property matters, or such other
intellectual property counsel satisfactory to the Agent (“Intellectual Property Counsel”), in form and substance
satisfactory to the Agent and its counsel, dated the date that the opinion letter is required to be delivered, modified, as necessary,
to relate to the Registration Statement and the Prospectus as then amended or supplemented; provided, however, that in lieu of
such written opinion for subsequent Representation Dates, Intellectual Property Counsel may furnish the Agent with a letter to the
effect that the Agent may rely on a prior opinion letter delivered by such counsel under this Section 8(o) to the same extent
as if it were dated the date of such opinion letter (except that statements in such prior opinion letter shall be deemed to relate to
the Registration Statement and the Prospectus as amended or supplemented at such Representation Date).
(p) Comfort
Letter. On or prior to the First Placement Notice Date and on any date which the Company is obligated to deliver a certificate pursuant
to Section 8(m) for which no waiver is applicable, the Company shall cause its independent registered public accounting firm
(and any other independent accountants whose report is included in the Registration Statement or the Prospectus) to furnish the Agent
letters (the “Comfort Letters”), dated the date the Comfort Letter is delivered, which shall meet the requirements
set forth in this Section 8(p); provided, that if requested by the Agent, the Company shall cause a Comfort Letter to be furnished
to the Agent within 10 Trading Days of the occurrence of any material transaction or event that necessitates the filing of additional,
pro forma, amended or revised financial statements (including any restatement of previously issued financial statements). Each Comfort
Letter shall be in form and substance satisfactory to the Agent and each Comfort Letter from the Company’s independent registered
public accounting firm shall (i) confirm that they are an independent registered public accounting firm within the meaning of the
Securities Act and the PCAOB, (ii) state, as of such date, the conclusions and findings of such firm with respect to the financial
information and other matters ordinarily covered by accountants’ “comfort letters” to underwriters in connection with
registered public offerings (the first such letter, the “Initial Comfort Letter”) and (iii) update the
Initial Comfort Letter with any information that would have been included in the Initial Comfort Letter had it been given on such date
and modified as necessary to relate to the Registration Statement and the Prospectus, as amended and supplemented to the date of such
letter.
(q) Market
Activities. The Company will not, directly or indirectly, and will cause its officers, directors and Subsidiaries not to (i) take
any action designed to cause or result in, or that constitutes or might reasonably be expected to constitute, the stabilization or manipulation
of the price of any security of the Company to facilitate the sale or resale of shares of Common Stock or (ii) sell, bid for, or
purchase shares of Common Stock in violation of Regulation M, or pay anyone any compensation for soliciting purchases of the Placement
Shares other than the Agent; provided, however, that the Company may bid for and purchase shares of Common Stock in accordance
with Rule 10b-18 under the Exchange Act.
(r) Insurance.
The Company and its Subsidiaries shall maintain, or cause to be maintained, insurance in such amounts and covering such risks as is reasonable
and customary for the business for which it is engaged.
(s) Compliance
with Laws. The Company and each of its Subsidiaries shall maintain, or cause to be maintained, all material environmental certificates,
authorizations or permits required by federal, state and local law in order to conduct their businesses as described in the Prospectus
(collectively, “Permits”), and the Company and each of its Subsidiaries shall conduct their businesses, or cause
their businesses to be conducted, in substantial compliance with such Permits and with applicable Environmental Laws, except where the
failure to maintain or be in compliance with such Permits could not reasonably be expected to result in a Material Adverse Effect.
(t) Investment
Company Act. The Company will conduct its affairs in such a manner so as to reasonably ensure that neither it nor any of its Subsidiaries
will be or become, at any time prior to the termination of this Agreement, an “investment company,” as such term is defined
in the Investment Company Act.
(u) Securities
Act and Exchange Act. The Company will use its reasonable best efforts to comply with all requirements imposed upon it by the Securities
Act and the Exchange Act as from time to time in force, so far as necessary to permit the sales of, or dealings in, the Placement Shares
as contemplated by the provisions hereof and the Prospectus.
(v) No
Offer to Sell. Other than a free writing prospectus (as defined in Rule 405 under the Securities Act) approved in advance by
the Company and the Agent, neither the Agent nor the Company (including its agents and representatives, other than the Agent in its capacity
as agent) will make, use, prepare, authorize, approve or refer to any written communication (as defined in Rule 405 under the Securities
Act), required to be filed with the Commission, that constitutes an offer to sell or solicitation of an offer to buy Placement Shares
hereunder.
(w) Blue
Sky and Other Qualifications. The Company will use its commercially reasonable efforts, in cooperation with the Agent, to qualify
the Placement Shares for offering and sale, or to obtain an exemption for the Placement Shares to be offered and sold, under the applicable
securities laws of such states and other jurisdictions (domestic or foreign) as the Agent may designate and to maintain such qualifications
and exemptions in effect for so long as required for the distribution of the Placement Shares (but in no event for less than one year
from the date of this Agreement); provided, however, that the Company shall not be obligated to file any general consent to service
of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or
to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject. In each jurisdiction
in which the Placement Shares have been so qualified or exempt, the Company will file such statements and reports as may be required by
the laws of such jurisdiction to continue such qualification or exemption, as the case may be, in effect for so long as required for the
distribution of the Placement Shares (but in no event for less than one year from the date of this Agreement).
(x) Sarbanes-Oxley
Act. As applicable, the Company will comply with any provision of the Sarbanes-Oxley Act and the rules and regulations promulgated
in connection therewith with which the Company is required to comply, including Section 402 related to loans.
(y) Emerging
Growth Company. The Company will promptly notify the Agent if the company ceases to be an Emerging Growth Company at any time prior
to the completion of the Agent’s distribution of the Placement Shares pursuant to this Agreement.
(z) Renewal
of Registration Statement. If, immediately prior to the third anniversary of the initial effective date of the Registration Statement
(the “Renewal Date”), any of the Placement Shares remain unsold and this Agreement has not been terminated,
the Company will, prior to the Renewal Date, file a new shelf registration statement or, if applicable, an automatic shelf registration
statement relating to the Common Stock that may be offered and sold pursuant to this Agreement (which shall include a prospectus reflecting
the number or amount of Placement Shares that may be offered and sold pursuant to this Agreement), in a form satisfactory to the Agent
and its counsel, and, if such registration statement is not an automatic shelf registration statement, will use its best efforts to cause
such registration statement to be declared effective within 180 days after the Renewal Date. The Company will take all other reasonable
actions necessary or appropriate to permit the public offer and sale of the Placement Shares to continue as contemplated in the expired
registration statement and this Agreement. From and after the effective date thereof, references herein to the “Registration
Statement” shall include such new shelf registration statement or such new automatic shelf registration statement, as the
case may be.
(aa) General
Instruction I.B.6. of Form S-3. If, from and after the date of this Agreement, the Company is no longer eligible to use Form S-3
(including pursuant to General Instruction I.B.6.) at the time it files with the Commission an annual report on Form 10-K or any
post-effective amendment to the Registration Statement, then it shall promptly notify the Agent and, within two Business Days after the
date of filing of such annual report on Form 10-K or amendment to the Registration Statement, the Company shall file a new prospectus
supplement with the Commission reflecting the number of shares of Common Stock available to be offered and sold by the Company under this
Agreement pursuant to General Instruction I.B.6. of Form S-3; provided, however, that the Company may delay the filing of
any such prospectus supplement for up to 30 days if, in the reasonable judgment of the Company, it is in the best interest of the Company
to do so, provided that no Placement Notice is in effect or pending during such time. Until such time as the Company shall have
corrected such misstatement or omission or effected such compliance, the Company shall not notify the Agent to resume the offering of
Placement Shares.
(bb) Tax Indemnity.
The Company will indemnify and hold harmless the Agent against any documentary, stamp or similar issue tax, including any interest and
penalties, on the issue and sale of the Placement Shares.
(cc) Transfer
Agent. The Company has engaged and will maintain, at its sole expense, a transfer agent and registrar for the Common Stock.
9. Conditions
to the Agent’s Obligations. The obligations of the Agent hereunder with respect to a Placement will be subject to the continuing
accuracy and completeness of the representations and warranties made by the Company herein, to the due performance by the Company of its
obligations hereunder, to the completion by the Agent of a due diligence review satisfactory to the Agent in its reasonable judgment,
and to the continuing satisfaction (or waiver by the Agent in its sole discretion) of the following additional conditions:
(a) Registration
Statement Effective. The Registration Statement shall be effective and shall be available for all offers and sales of Placement Shares
(i) that have been issued pursuant to all prior Placement Notices and (ii) that will be issued pursuant to any Placement Notice.
(b) [Reserved]
(c) No
Material Notices. None of the following events shall have occurred and be continuing: (i) receipt by the Company or any of its
Subsidiaries of any request for additional information from the Commission or any other federal or state governmental authority during
the period of effectiveness of the Registration Statement, the response to which would require any post-effective amendments or supplements
to the Registration Statement or the Prospectus; (ii) the issuance by the Commission or any other federal or state governmental authority
of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt
by the Company or any of its Subsidiaries of any notification with respect to the suspension of the qualification or exemption from qualification
of any of the Placement Shares for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; or (iv) the
occurrence of any event that makes any material statement made in the Registration Statement or the Prospectus or any material Incorporated
Document untrue in any material respect or that requires the making of any changes in the Registration Statement, the Prospectus or Incorporated
Documents so that, in the case of the Registration Statement, it will not contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary to make the statements therein not misleading and, in the case of the Prospectus,
so that it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.
(d) No
Misstatement or Material Omission. The Agent shall not have advised the Company that the Registration Statement or Prospectus, or
any amendment or supplement thereto, contains an untrue statement of fact that in the Agent’s opinion is material, or omits to state
a fact that in the Agent’s opinion is material and is required to be stated therein or is necessary to make the statements therein
not misleading.
(e) Material
Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall
not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse
Effect or any development that could reasonably be expected to result in a Material Adverse Effect, or any downgrading in or withdrawal
of the rating assigned to any of the Company’s securities (other than asset backed securities), if any, by any rating organization
or a public announcement by any rating organization that it has under surveillance or review its rating of any of the Company’s
securities (other than asset backed securities), if any, the effect of which, in the judgment of the Agent (without relieving the Company
of any obligation or liability it may otherwise have), is so material as to make it impracticable or inadvisable to proceed with the offering
of the Placement Shares on the terms and in the manner contemplated in the Prospectus.
(f) Company
Counsel Legal Opinions. The Agent shall have received the opinions and negative assurance letters, as applicable, of Company Counsel
and Intellectual Property Counsel required to be delivered pursuant to Section 8(n) and Section 8(o), as applicable, on
or before the date on which such delivery of such opinions and negative assurance letters are required pursuant to Section 8(n) and
Section 8(o), as applicable.
(g) Agent’s
Counsel Legal Opinion. The Agent shall have received from Cooley LLP, counsel for the Agent, such opinion or opinions, on or before
the date on which the delivery of the Company Counsel legal opinion is required pursuant to Section 8(n), with respect to such matters
as the Agent may reasonably require, and the Company shall have furnished to such counsel such documents as they may request to enable
them to pass upon such matters.
(h) Comfort
Letter. The Agent shall have received the Comfort Letter required to be delivered pursuant to Section 8(p) on or before
the date on which such delivery of such Comfort Letter is required pursuant to Section 8(p).
(i) Representation
Certificate. The Agent shall have received the certificate required to be delivered pursuant to Section 8(m) on or before
the date on which delivery of such certificate is required pursuant to Section 8(m).
(j) Secretary’s
Certificate. On or prior to the First Placement Notice Date, the Agent shall have received a certificate, signed on behalf of the
Company by the Secretary of the Company and attested to by an executive officer of the Company, dated as of such date and in form and
substance satisfactory to the Agent and its counsel, certifying as to (i) the amended and restated certificate of incorporation of
the Company, (ii) the amended and restated bylaws of the Company, (iii) the resolutions of the board of directors of the Company
or duly authorized committee thereof authorizing the execution, delivery and performance of this Agreement and the issuance and sale of
the Placement Shares and (iv) the incumbency of the officers of the Company duly authorized to execute this Agreement and the other
documents contemplated by this Agreement (including each of the officers set forth on Schedule 2).
(k) No
Suspension. The Common Stock shall be duly listed, and admitted and authorized for trading, subject to official notice of issuance,
on Nasdaq. Trading in the Common Stock shall not have been suspended on, and the Common Stock shall not have been delisted from, Nasdaq.
(l) Other
Materials. On each date on which the Company is required to deliver a certificate pursuant to Section 8(m), the Company shall
have furnished to the Agent such appropriate further information, opinions, certificates, letters and other documents as the Agent may
have reasonably requested. All such information, opinions, certificates, letters and other documents shall have been in compliance with
the provisions hereof. The Company shall have furnished the Agent with conformed copies of such opinions, certificates, letters and other
documents as the Agent may have reasonably requested.
(m) Securities
Act Filings Made. All filings with the Commission required by Rule 424(b) or Rule 433 under the Securities Act to have
been filed prior to the issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for
such filing by Rule 424(b) (without reliance on Rule 424(b)(8) of the Securities Act) or Rule 433, as applicable.
(n) Approval
for Listing. Either (i) the Placement Shares shall have been approved for listing on Nasdaq, subject only to notice of issuance,
or (ii) the Company shall have filed an application for listing of the Placement Shares on Nasdaq at, or prior to, the First Placement
Notice Date and Nasdaq shall have reviewed such application and not provided any objections thereto.
(o) FINRA.
FINRA shall have raised no objection to the terms of the offering contemplated hereby and the amount of compensation allowable or payable
to the Agent as described in the Prospectus.
(p) No
Termination Event. There shall not have occurred any event that would permit the Agent to terminate this Agreement pursuant to Section 12(a).
10. Indemnification
and Contribution.
(a) Company
Indemnification. The Company agrees to indemnify and hold harmless the Agent, its affiliates and their respective partners, members,
directors, officers, employees and agents, and each person, if any, who (i) controls the Agent within the meaning of Section 15
of the Securities Act or Section 20 of the Exchange Act or (ii) is controlled by or is under common control with the Agent,
in each case from and against any and all losses, claims, liabilities, expenses and damages (including any and all investigative, legal
and other expenses reasonably incurred in connection with, and any and all amounts paid in settlement (in accordance with this Section 10))
of any action, suit, investigation or proceeding between any of the indemnified parties and any indemnifying parties or between any indemnified
party and any third party (including any governmental or self-regulatory authority, or otherwise, or any claim asserted or threatened),
as and when incurred, to which the Agent, or any such other person may become subject under the Securities Act, the Exchange Act or other
federal or state statutory law or regulation, at common law or otherwise, insofar as such losses, claims, liabilities, expenses or damages
arise out of or are based, directly or indirectly, on (x) any untrue statement or alleged untrue statement of a material fact contained
in the Registration Statement or the Prospectus (or any amendment or supplement to the Registration Statement or the Prospectus) or in
any free writing prospectus or in any application or other document executed by or on behalf of the Company or based on written information
furnished by or on behalf of the Company filed in any jurisdiction in order to qualify the Common Stock under the securities laws thereof
or filed with the Commission, (y) the omission or alleged omission to state in any such document a material fact required to be stated
therein or necessary to make the statements therein (solely with respect to the Prospectus, in light of the circumstances under which
they were made) not misleading or (z) any breach by any of the indemnifying parties of any of their respective representations, warranties
or agreements contained in this Agreement; provided, however, that this indemnity agreement shall not apply to the extent that
such loss, claim, liability, expense or damage arises from the sale of the Placement Shares pursuant to this Agreement and is caused,
directly or indirectly, by an untrue statement or omission, or alleged untrue statement or omission, made in reliance upon and in conformity
with the Agent’s Information. This indemnity agreement will be in addition to any liability that the Company might otherwise have.
(b) Agent
Indemnification. The Agent agrees to indemnify and hold harmless the Company and its directors and each officer of the Company who
signed the Registration Statement, and each person, if any, who (i) controls the Company within the meaning of Section 15 of
the Securities Act or Section 20 of the Exchange Act or (ii) is controlled by or is under common control with the Company against
any and all loss, liability, claim, damage and expense described in the indemnity contained in Section 10(a), as incurred, but only
with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any
amendments thereto) or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Agent’s
Information.
(c) Procedure.
Any party that proposes to assert the right to be indemnified under this Section 10 will, promptly after receipt of notice of commencement
of any action against such party in respect of which a claim is to be made against an indemnifying party or parties under this Section 10,
notify each such indemnifying party of the commencement of such action, enclosing a copy of all papers served, but the omission so to
notify such indemnifying party will not relieve the indemnifying party from (i) any liability that it might have to any indemnified
party otherwise than under this Section 10 and (ii) any liability that it may have to any indemnified party under the foregoing
provision of this Section 10 unless, and only to the extent that, such omission results in the forfeiture of substantive rights or
defenses by the indemnifying party. If any such action is brought against any indemnified party and it notifies the indemnifying party
of its commencement, the indemnifying party will be entitled to participate in and, to the extent that it elects by delivering written
notice to the indemnified party promptly after receiving notice of the commencement of the action from the indemnified party, jointly
with any other indemnifying party similarly notified, to assume the defense of the action, with counsel reasonably satisfactory to the
indemnified party, and after notice from the indemnifying party to the indemnified party of its election to assume the defense, the indemnifying
party will not be liable to the indemnified party for any other legal expenses except as provided below and except for the reasonable
costs of investigation subsequently incurred by the indemnified party in connection with the defense. The indemnified party will have
the right to employ its own counsel in any such action, but the fees, expenses and other charges of such counsel will be at the expense
of such indemnified party unless (1) the employment of counsel by the indemnified party has been authorized in writing by the indemnifying
party, (2) the indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available
to it or other indemnified parties that are different from or in addition to those available to the indemnifying party, (3) a conflict
or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party and the indemnifying
party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the indemnified
party) or (4) the indemnifying party has not in fact employed counsel reasonably satisfactory to the indemnified party to assume
the defense of such action within a reasonable time after receiving notice of the commencement of the action, in each of which cases the
reasonable fees, disbursements and other charges of counsel will be at the expense of the indemnifying party or parties. It is understood
that the indemnifying party or parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be
liable for the reasonable fees, disbursements and other charges of more than one separate firm (plus local counsel) admitted to practice
in such jurisdiction at any one time for all such indemnified party or parties. All such fees, disbursements and other charges will be
reimbursed by the indemnifying party promptly after the indemnifying party receives a written invoice relating to such fees, disbursements
and other charges in reasonable detail. An indemnifying party will not, in any event, be liable for any settlement of any action or claim
effected without its written consent. No indemnifying party shall, without the prior written consent of each indemnified party, settle
or compromise or consent to the entry of any judgment in any pending or threatened claim, action or proceeding relating to the matters
contemplated by this Section 10 (whether or not any indemnified party is a party thereto), unless such settlement, compromise or
consent (1) includes an unconditional release of each indemnified party, in form and substance reasonably satisfactory to such indemnified
party, from all liability arising out of such claim, action or proceeding and (2) does not include a statement as to or an admission
of fault, culpability or a failure to act by or on behalf of any indemnified party.
(d) Settlement
Without Consent if Failure to Reimburse. If an indemnified party shall have requested an indemnifying party to reimburse the indemnified
party for reasonable fees and expenses of counsel for which it is entitled to be reimbursed under this Section 10, such indemnifying
party agrees that it shall be liable for any settlement of the nature contemplated by Section 10(a) effected without its written
consent if (i) such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request,
(ii) such indemnifying party shall have received notice of the terms of such settlement at least 30 days prior to such settlement
being entered into and (iii) such indemnifying party shall not have reimbursed such indemnified party in accordance with such request
prior to the date of such settlement.
(e) Contribution.
In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing paragraphs
of this Section 10 is applicable in accordance with its terms but for any reason is held to be unavailable or insufficient from the
Company or the Agent, the Company and the Agent will contribute to the total losses, claims, liabilities, expenses and damages (including
any investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of, any action,
suit, investigation or proceeding or any claim asserted, but after deducting any contribution received by the Company from persons other
than the Agent, such as persons who control the Company within the meaning of the Securities Act, officers of the Company who signed the
Registration Statement and directors of the Company, who also may be liable for contribution) to which the Company and the Agent may be
subject in such proportion as shall be appropriate to reflect the relative benefits received by the Company on the one hand and the Agent
on the other hand. The relative benefits received by the Company on the one hand and the Agent on the other hand shall be deemed to be
in the same proportion as the total Net Proceeds from the sale of the Placement Shares (before deducting expenses) received by the Company
bear to the total compensation received by the Agent from the sale of Placement Shares on behalf of the Company. If, but only if, the
allocation provided by the foregoing sentence is not permitted by applicable law, the allocation of contribution shall be made in such
proportion as is appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault
of the Company, on the one hand, and the Agent, on the other hand, with respect to the statements or omission that resulted in such loss,
claim, liability, expense or damage, or action, suit, investigation or proceeding in respect thereof, as well as any other relevant equitable
considerations with respect to such offering. Such relative fault shall be determined by reference to, among other things, whether the
untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information
supplied by the Company or the Agent, the intent of the parties and their relative knowledge, access to information and opportunity to
correct or prevent such statement or omission. The Company and the Agent agree that it would not be just and equitable if contributions
pursuant to this Section 10(e) were to be determined by pro rata allocation or by any other method of allocation that does not
take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the
loss, claim, liability, expense or damage, or action, suit, investigation or proceeding in respect thereof, referred to above in this
Section 10(e) shall be deemed to include, for the purpose of this Section 10(e), any legal or other expenses reasonably
incurred by such indemnified party in connection with investigating or defending any such action, suit, investigation, proceeding or claim
to the extent consistent with this Section 10. Notwithstanding the foregoing provisions of this Section 10(e), the Agent shall
not be required to contribute any amount in excess of the commissions received by it under this Agreement and no person found guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from
any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section 10(e), any person who controls a
party to this Agreement within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, any affiliates
of the Agent, any partners, members, directors, officers, employees and agents of the Agent and each person that is controlled by or under
common control with the Agent will have the same rights to contribution as that party, and each director of the Company and each officer
of the Company who signed the Registration Statement will have the same rights to contribution as the Company, subject in each case to
the provisions hereof. Any party entitled to contribution, promptly after receipt of notice of commencement of any action against such
party in respect of which a claim for contribution may be made under this Section 10(e), will notify any such party or parties from
whom contribution may be sought, but the omission to so notify will not relieve that party or parties from whom contribution may be sought
from any other obligation it or they may have under this Section 10(e) except to the extent that the failure to so notify such
other party materially prejudiced the substantive rights or defenses of the party from whom contribution is sought. Except for a settlement
entered into pursuant to the last sentence of Section 10(c) hereof or pursuant to Section 10(d) hereof, no party will
be liable for contribution with respect to any action or claim settled without its written consent if such consent is required pursuant
to Section 10(c) hereof.
11. Representations
and Agreements to Survive Delivery. The indemnity and contribution agreements contained in Section 10 of this Agreement and all
representations and warranties of the Company herein or in certificates delivered pursuant hereto shall survive, as of their respective
dates, regardless of (i) any investigation made by or on behalf of the Agent, any controlling persons, or the Company (or any of
their respective officers, directors, employees or controlling persons), (ii) delivery and acceptance of the Placement Shares and
payment therefor or (iii) any termination of this Agreement.
12. Termination.
(a) The
Agent shall have the right, by giving notice as hereinafter specified, at any time to terminate this Agreement if (i) any Material
Adverse Effect, or any development that could reasonably be expected to result in a Material Adverse Effect, has occurred that, in the
judgment of the Agent, may materially impair the ability of the Agent to sell the Placement Shares hereunder, (ii) the Company shall
have failed, refused or been unable to perform any agreement on its part to be performed hereunder; provided, however, in the case
of any failure of the Company to deliver (or cause another person to deliver) any certification, opinion or letter required under Section 8(m),
Section 8(n), Section 8(o) or Section 8(p), the Agent’s right to terminate shall not arise unless such failure
to deliver (or cause to be delivered) continues for more than 15 calendar days from the date such delivery was required, (iii) any
other condition of the Agent’s obligations hereunder is not fulfilled, (iv) any suspension or limitation of trading in the
Placement Shares or in securities generally on Nasdaq shall have occurred, (v) a general banking moratorium shall have been declared
by any of United States federal or New York authorities, or (vi) there shall have occurred any outbreak or escalation of national
or international hostilities or any crisis or calamity, or any adverse change in the United States or international financial markets,
or any substantial change or development involving a prospective substantial change in United States or international political, financial
or economic conditions that, in the judgment of the Agent, may materially impair the ability of the Agent to sell the Placement Shares
hereunder or to enforce contracts for the sale of securities. Any such termination shall be without liability of any party to any other
party except that the provisions of Section 8(g), Section 10, Section 11, Section 12(f), Section 17 and Section 18
hereof shall remain in full force and effect notwithstanding such termination. If the Agent elects to terminate this Agreement as provided
in this Section 12(a), the Agent shall provide the required notice as specified in Section 13.
(b) The
Company shall have the right, by giving 5 days’ prior notice as hereinafter specified, to terminate this Agreement in its sole discretion
at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other party except that
the provisions of Section 8(g), Section 10, Section 11, Section 12(f), Section 17 and Section 18 hereof
shall remain in full force and effect notwithstanding such termination.
(c) The
Agent shall have the right, by giving 5 days’ prior notice as hereinafter specified, to terminate this Agreement in its sole discretion
at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other party except that
the provisions of Section 8(g), Section 10, Section 11, Section 12(f), Section 17 and Section 18 hereof
shall remain in full force and effect notwithstanding such termination.
(d) Unless
earlier terminated pursuant to this Section 12, this Agreement shall automatically terminate upon the issuance and sale of all of
the Placement Shares through the Agent on the terms and subject to the conditions set forth herein; provided that the provisions
of Section 8(g), Section 10, Section 11, Section 12(f), Section 17 and Section 18 hereof shall remain in
full force and effect notwithstanding such termination.
(e) This
Agreement shall remain in full force and effect unless terminated pursuant to Sections 12(a), (b), (c), or (d) above or otherwise
by mutual agreement of the parties; provided, however, that any such termination by mutual agreement shall in all cases be deemed
to provide that Section 8(g), Section 10, Section 11, Section 12(f), Section 17 and Section 18 shall remain
in full force and effect.
(f) Any
termination of this Agreement shall be effective on the date specified in such notice of termination; provided, however, that such
termination shall not be effective until the close of business on the date of receipt of such notice by the Agent or the Company, as the
case may be. If such termination shall occur prior to the Settlement Date for any sale of Placement Shares, such Placement Shares shall
settle in accordance with the provisions of this Agreement. Upon termination of this Agreement, the Company shall not be required to pay
to the Agent any discount or commission with respect to any Placement Shares not otherwise sold by the Agent under this Agreement; provided,
however, that the Company shall remain obligated to reimburse the Agent’s expenses pursuant to Section 8(g).
13. Notices.
All notices or other communications required or permitted to be given by any party to any other party pursuant to the terms of this Agreement
shall be in writing, unless otherwise specified in this Agreement, and if sent to the Agent, shall be delivered to:
Leerink Partners LLC
1301 Avenue of the Americas, 12th Floor
New York, New York 10019
Attention: Peter M. Fry
E-mail: peter.fry@leerink.com
with a copy (which shall not constitute notice) to:
Leerink Partners LLC
1301 Avenue of the Americas, 12th Floor
New York, New York 10019
Attention: Stuart R. Nayman, Esq.
E-mail: stuart.nayman@leerink.com
and:
Cooley LLP
55 Hudson Yards
New York, New York 10001-2157
Attention: Daniel I. Goldberg, Esq.
E-mail: dgoldberg@cooley.com
and if to the Company, shall be delivered to:
NextCure, Inc.
9000 Virginia Manor Road, Suite 200
Beltsville, Maryland 20705
Attention: Chief Executive Officer
with copies (which shall not constitute notice) to:
Sidley Austin LLP
2850 Quarry Lake Drive, Suite 301
Baltimore, MD 21209
Attention: Asher Rubin
E-mail: arubin@sidley.com
Each party to this Agreement may change such address for notices by
sending to the parties to this Agreement written notice of a new address for such purpose. Each such notice or other communication shall
be deemed given (i) when delivered personally on or before 4:30 P.M., New York City time, on a Business Day, or, if such day is not
a Business Day, on the next succeeding Business Day, (ii) by Electronic Notice as set forth in the next paragraph, (iii) on
the next Business Day after timely delivery to a nationally-recognized overnight courier or (iv) on the Business Day actually received
if deposited in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid). For purposes of this Agreement,
“Business Day” shall mean any day on which the Nasdaq and commercial banks in the City of New York are open
for business.
An electronic communication (“Electronic Notice”)
shall be deemed written notice for purposes of this Section 13 if sent to the electronic mail address specified by the receiving
party in Section 13. Electronic Notice shall be deemed received at the time the party sending Electronic Notice receives actual acknowledgment
of receipt from the person to whom the notice is sent, other than via auto-reply. Any party receiving Electronic Notice may request and
shall be entitled to receive the notice on paper, in a nonelectronic form (“Nonelectronic Notice”), which shall
be sent to the requesting party within 10 days of receipt of the written request for Nonelectronic Notice.
14. Successors
and Assigns. This Agreement shall inure to the benefit of and be binding upon the Company and the Agent and their respective successors
and the affiliates, controlling persons, officers, directors and other persons referred to in Section 10 hereof. References to any
of the parties contained in this Agreement shall be deemed to include the successors and permitted assigns of each such party. Nothing
in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto, the persons referred to in
the preceding sentence and their respective successors and permitted assigns any rights, remedies, obligations or liabilities under or
by reason of this Agreement, except as expressly provided in this Agreement. Neither party may assign its rights or obligations under
this Agreement without the prior written consent of the other party; provided, however, that the Agent may assign its rights and
obligations hereunder to an affiliate of the Agent without obtaining the Company’s consent, so long as such affiliate is a registered
broker-dealer.
15. Adjustments
for Share Splits. The parties acknowledge and agree that all share-related numbers contained in this Agreement shall be adjusted to
take into account any share split, share dividend or similar event effected with respect to the Common Stock.
16. Entire
Agreement; Amendment; Severability; Waiver. This Agreement (including all schedules (as amended pursuant to this Agreement) and exhibits
attached hereto and Placement Notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous
agreements and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement
nor any term hereof may be amended except pursuant to a written instrument executed by the Company and the Agent; provided, however,
that Schedule 2 of this Agreement may be amended by either party from time to time by sending a notice containing a revised
Schedule 2 to the other party in the manner provided in Section 13 and, upon such amendment, all references herein
to Schedule 2 shall automatically be deemed to refer to such amended Schedule 2. In the event that any one
or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable
as written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent
that it is valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal
or unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder
of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement. No implied waiver
by a party shall arise in the absence of a waiver in writing signed by such party. No failure or delay in exercising any right, power,
or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further
exercise thereof or the exercise of any right, power, or privilege hereunder.
17. GOVERNING
LAW AND TIME; WAIVER OF JURY TRIAL. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF
NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH PARTY HEREBY
IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING
OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.
18. Consent
to Jurisdiction. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the
City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection with any of the transactions contemplated
hereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum, or that the venue
of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process
being served in any such suit, action or proceeding by mailing a copy (certified or registered mail, return receipt requested) to such
party at the address in effect for notices under Section 13 of this Agreement and agrees that such service shall constitute good
and sufficient notice of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any manner permitted by law.
19. Construction.
(a) The
section and exhibit headings herein are for convenience only and shall not affect the construction hereof.
(b) Words
defined in the singular shall have a comparable meaning when used in the plural, and vice versa.
(c) The
words “hereof,” “hereto,” “herein” and “hereunder” and words of similar import, when used
in this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement.
(d) Wherever
the word “include,” “includes” or “including” is used in this Agreement, it shall be deemed to be
followed by the words “without limitation.”
(e) References
herein to any gender shall include each other gender.
(f) References
herein to any law, statute, ordinance, code, regulation, rule or other requirement of any governmental authority shall be deemed
to refer to such law, statute, ordinance, code, regulation, rule or other requirement of any governmental authority as amended, reenacted,
supplemented or superseded in whole or in part and in effect from time to time and also to all rules and regulations promulgated
thereunder.
20. Permitted
Free Writing Prospectuses. Each of the Company and the Agent represents, warrants and agrees that, unless it obtains the prior written
consent of the other party, which consent shall not be unreasonably withheld, conditioned or delayed, it has not made and will not make
any offer relating to the Placement Shares that would constitute an issuer free writing prospectus, or that would otherwise constitute
a free writing prospectus (as defined in Rule 405), required to be filed with the Commission. Any such free writing prospectus consented
to by the Agent or by the Company, as the case may be, is hereinafter referred to as a “Permitted Free Writing Prospectus.”
The Company represents and warrants that it has treated and agrees that it will treat each Permitted Free Writing Prospectus as an issuer
free writing prospectus, and that it has complied and will comply with the requirements of Rule 433 applicable to any Permitted Free
Writing Prospectus, including timely filing with the Commission where required, legending and record keeping.
21. Absence
of Fiduciary Relationship. The Company acknowledges and agrees that:
(a) the
Agent has been retained to act as sales agent in connection with the sale of the Placement Shares, the Agent has acted at arms’
length and no fiduciary or advisory relationship between the Company or any of its respective affiliates, stockholders (or other equity
holders), creditors or employees or any other party, on the one hand, and the Agent, on the other hand, has been or will be created in
respect of any of the transactions contemplated by this Agreement, irrespective of whether the Agent has advised or is advising the Company
on other matters and the Agent has no duties or obligations to the Company with respect to the transactions contemplated by this Agreement
except the obligations expressly set forth herein;
(b) the
Company is capable of evaluating, and understanding and understands and accepts, the terms, risks and conditions of the transactions contemplated
by this Agreement;
(c) neither
the Agent nor its affiliates have provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated
by this Agreement and it has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate;
(d) the
Company has been advised and is aware that the Agent and its affiliates are engaged in a broad range of transactions which may involve
interests that differ from those of the Company and that the Agent and its affiliates have no obligation to disclose such interests and
transactions to the Company by virtue of any fiduciary, advisory or agency relationship or otherwise, provided that the Agent hereby agrees
not to engage in any such transaction which would be prohibited under Regulation M; and
(e) the
Company waives, to the fullest extent permitted by law, any claims it may have against the Agent or its affiliates for breach of fiduciary
duty or alleged breach of fiduciary duty in connection with the transactions contemplated by this Agreement and agrees that the Agent
and its affiliates shall have no liability (whether direct or indirect) to the Company in respect of such a fiduciary claim or to any
person asserting a fiduciary duty claim on behalf of or in right of the Company, including stockholders (or other equity holders), creditors
or employees of the Company.
22. Recognition
of the U.S. Special Resolution Regimes. In the event that the Agent is a Covered Entity and becomes subject to a proceeding under
a U.S. Special Resolution Regime, the transfer from the Agent of this Agreement, and any interest and obligation in or under this Agreement,
will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and
any such interest and obligation, were governed by the laws of the United States or a state of the United States.
In the event that the Agent is a Covered Entity
and the Agent or a BHC Act Affiliate of the Agent becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights
under this Agreement that may be exercised against the Agent are permitted to be exercised to no greater extent than such Default Rights
could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state
of the United States.
For purposes of this Agreement, (A) “BHC
Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12
U.S.C. § 1841(k); (B) “Covered Entity” means any of the following: (i) a “covered entity” as that
term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b); (ii) a “covered bank” as that term
is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a “covered FSI” as that term is
defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b); (C) “Default Right” has the meaning assigned
to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable; and (D) “U.S.
Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and
(ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.
23. Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile or electronic
transmission. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal
ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com)
or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and
effective for all purposes.
24. Use
of Information. The Agent may not provide any information gained in connection with this Agreement and the transactions contemplated
by this Agreement, including due diligence, to any third party other than its legal counsel advising it on this Agreement and the transactions
contemplated by this Agreement unless expressly approved by the Company in writing.
25. Agent’s
Information. As used in this Agreement, “Agent’s Information” means solely the following information
in the Registration Statement and the Prospectus: the third sentence of the eighth paragraph and the tenth paragraph under the heading
“Plan of Distribution” in the ATM Prospectus.
All references in this Agreement to the Registration
Statement, the ATM Prospectus, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy
filed with the Commission pursuant to EDGAR. All references in this Agreement to financial statements and schedules and other information
that is “contained,” “included” or “stated” in the Registration Statement or the Prospectus (and all
other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information
that is incorporated by reference in the Registration Statement or the Prospectus, as the case may be.
All references in this Agreement to “supplements”
to the Prospectus shall include any supplements, “wrappers” or similar materials prepared in connection with any offering,
sale or private placement of any Placement Shares by the Agent outside of the United States.
[Remainder of Page Intentionally Blank]
If the foregoing correctly sets forth the understanding
between the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute
a binding agreement between the Company and the Agent.
|
Very truly yours, |
|
|
|
NEXTCURE, INC. |
|
|
|
|
|
By: |
/s/ Michael Richman |
|
|
Name: |
Michael Richman |
|
|
Title: |
President & Chief Financial Officer |
|
ACCEPTED as of the date first-above written: |
|
|
|
LEERINK PARTNERS LLC |
|
|
|
|
|
By: |
/s/ Peter M. Fry |
|
|
Name: |
Peter M. Fry |
|
|
Title: |
Head of Alternative Equities |
SCHEDULE
1
FORM OF
PLACEMENT NOTICE
From: |
[ ] |
|
[TITLE] |
|
NextCure, Inc. |
Cc: |
[ ] |
To: |
Leerink Partners LLC |
Subject: |
Leerink Partners LLC —At the Market Offering—Placement Notice |
Ladies and Gentlemen:
Pursuant to the terms and subject to the conditions contained in the
Sales Agreement, dated August 4, 2023 (the “Agreement”), by and between NextCure, Inc., a Delaware
corporation (the “Company”), and Leerink Partners LLC (the “Agent”), I hereby
request on behalf of the Company that the Agent sell up to [ ] shares of common
stock, $0.001 par value per share, of the Company (the “Shares”), at a minimum market price of $__________ per
share[; provided that no more than [ ] Shares shall be sold in any one
Trading Day (as such term is defined in Section 4 of the Agreement)]. Sales should begin [on the date of this Placement Notice] and
end on [DATE] [until all Shares that are the subject of this Placement Notice are sold].
SCHEDULE 2
The Company
mayerT@nextcure.com, cobourns@nextcure.com, IR@nextcure.com
The Agent
gabriel.cavazos@leerink.com, brian.swanson@leerink.com, atm@leerink.com
SCHEDULE 3
Compensation
The Company shall pay the Agent compensation in cash equal to 3.0%
of the gross proceeds from the sales of Placement Shares pursuant to the terms of the Sales Agreement of which this Schedule 3
forms a part.
Exhibit 8(m)
OFFICERS’ CERTIFICATE
Each of [·], the duly qualified and elected Chief Executive Officer
of NextCure, Inc., a Delaware corporation (the “Company”), and [·], the duly qualified and elected
Chief Financial Officer of the Company, does hereby certify in his respective capacity and on behalf of the Company, pursuant to Section 8(m) of
the Sales Agreement, dated August 4, 2023 (the “Sales Agreement”), by and between the Company and Leerink
Partners LLC, that, after due inquiry, to the best of the knowledge of the undersigned:
(i) The
representations and warranties of the Company in Section 7 of the Sales Agreement (A) to the extent such representations and
warranties are subject to qualifications and exceptions contained therein relating to materiality or Material Adverse Effect, are true
and correct on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof, and (B) to
the extent such representations and warranties are not subject to any qualifications or exceptions relating to materiality or Material
Adverse Effect, are true and correct in all material respects as of the date hereof as if made on and as of the date hereof with the same
force and effect as if expressly made on and as of the date hereof.
(ii) The
Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied pursuant to the Sales Agreement
at or prior to the date hereof.
(iii) As
of the date hereof, (A) the Registration Statement complies in all material respects with the requirements of the Securities Act
and does not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
in order to make the statements therein not misleading, (B) the Prospectus complies in all material respects with the requirements
of the Securities Act does not contain any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading
and (C) no event has occurred as a result of which it is necessary to amend or supplement the Registration Statement or the Prospectus
in order to make the statements therein not untrue or misleading or for clauses (A) and (B) above, to be true and correct.
(iv) There
has been no material adverse change, or any development that could reasonably be expected to result in a material adverse change, in the
condition (financial or otherwise), earnings, results of operations, business, properties, operations, assets, liabilities or prospects
of the Company and its Subsidiaries, taken as a whole, whether or not arising from transactions in the ordinary course of business, since
the date as of which information is given in the Prospectus, as amended or supplemented to the date hereof.
(v) The
Company does not possess any material non-public information.
(vi) The
maximum amount of Placement Shares that may be sold pursuant to each outstanding Placement Notice has been duly authorized by the Company’s
board of directors or a duly authorized committee thereof pursuant to a resolution or unanimous written consent in accordance with the
Company’s amended and restated articles of incorporation, amended and restated bylaws and applicable law.
Capitalized terms used but not defined herein shall
have the meanings ascribed to them in the Sales Agreement.
Cooley LLP and Sidley Austin LLP are entitled to
rely upon this certificate in connection with the opinions given by such firms pursuant to the Sales Agreement.
IN WITNESS WHEREOF, each of the undersigned, in
such individual’s respective capacity as Chief Executive Officer or Chief Financial Officer of the Company, has executed this Officers’
Certificate on behalf of the Company.
[Company Signature Page to Officer’s’
Certificate]
Exhibit 5.1
|
Sidley Austin LLP
787 Seventh Avenue
New York, NY 10019
+1 212 839 5300
+1 212 839 5599 Fax
AMERICA
• ASIA PACIFIC •
EUROPE |
|
August 4, 2023
NextCure, Inc.
9000 Virginia Manor Road
Suite 200
Beltsville, Maryland 20705
| Re: | Registration Statement on Form S-3 |
Ladies and Gentlemen:
We refer to the Registration Statement on Form S-3
(the “Registration Statement”) being filed by NextCure, Inc., a Delaware corporation (the “Company”),
with the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities
Act”), on August 4, 2023, relating to the registration of up to an aggregate total offering price of $180,000,000 of:
(a) shares
of the Company’s common stock, $0.001 par value per share (the “Common Stock”);
(b) shares
of the Company’s preferred stock, $0.001 par value per share (the “Preferred Stock”);
(c) warrants
to purchase Common Stock, Preferred Stock or Debt Securities (as defined below) (the “Warrants”);
(d) debt
securities of the Company (the “Debt Securities”);
(e) units
(the “Units”), each consisting of two or more types of the securities listed in clauses (a) through (d) above.
The Common Stock, the Preferred Stock, the Warrants, the Debt Securities
and the Units are collectively referred to herein as the “Securities.”
Unless otherwise specified
in the applicable prospectus supplement:
(1) the
Debt Securities will be issued under an indenture (the “Indenture”) to be entered into between the Company and a trustee
(the “Trustee”);
(2) the
Warrants will be issued under a warrant agreement (the “Warrant Agreement”) to be entered into between the Company
and a warrant agent (the “Warrant Agent”); and
Sidley Austin (NY) LLP is a Delaware limited liability partnership doing business as Sidley Austin LLP and practicing in affiliation with other Sidley Austin partnerships.
NextCure, Inc.
August 4, 2023
Page 2
(3) the
Units will be issued pursuant to one or more unit agreements (each, a “Unit Agreement”) to be entered into between
the Company and a unit agent (each, a “Unit Agent”); in each case substantially in the form that has been or will be filed
as one or more exhibits to the Registration Statement.
This opinion letter is being delivered in accordance
with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.
We have examined the Registration Statement, the
exhibits thereto, the certificate of incorporation of the Company, as amended to the date hereof (the “Charter”),
the bylaws of the Company, as amended to the date hereof (the “Bylaws”), and the resolutions (the “Resolutions”)
adopted by the board of directors of the Company (the “Board”) relating to the Registration Statement. We have also
examined originals, or copies of originals certified to our satisfaction, of such agreements, documents, certificates and statements
of the Company and others, and have examined such questions of law, as we have considered relevant and necessary as a basis for this
opinion letter. We have assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures, the
legal capacity of all persons and the conformity with the original documents of any copies thereof submitted to us for examination. As
to facts relevant to the opinions expressed herein, we have relied without independent investigation or verification upon, and assumed
the accuracy and completeness of, certificates, letters and oral and written statements and representations of public officials and officers
and other representatives of the Company.
Based on and subject to the foregoing and the
other limitations, qualifications and assumptions set forth herein, we are of the opinion that:
1. With
respect to an offering of shares of Common Stock covered by the Registration Statement, such shares of Common Stock will be validly issued,
fully paid and nonassessable, when: (i) the Registration Statement, as finally amended (including any necessary post-effective amendments),
shall have become effective under the Securities Act; (ii) a prospectus supplement with respect to the sale of such shares of Common
Stock, if any shall be required, shall have been filed with the SEC in compliance with the Securities Act and the rules and regulations
thereunder; (iii) the Board or a duly authorized committee thereof shall have duly adopted final resolutions in conformity with
the Charter, the Bylaws and the Resolutions authorizing the issuance and sale of such shares of Common Stock; and (iv) certificates
representing such shares of Common Stock shall have been duly executed, countersigned and registered and duly delivered in accordance
with the applicable definitive purchase, underwriting or similar agreement upon payment of the agreed consideration therefor in an amount
not less than the aggregate par value thereof or, if any such shares of Common Stock are to be issued in uncertificated form, the Company’s
books shall reflect the issuance of such shares of Common Stock in accordance with the applicable definitive purchase, underwriting or
similar agreement upon payment of the agreed consideration therefor in an amount not less than the aggregate par value thereof.
NextCure, Inc.
August 4, 2023
Page 3
2. The
issuance and sale of each series of Preferred Stock covered by the Registration Statement will be duly authorized, and each share of
such series of Preferred Stock will be validly issued, fully paid and nonassessable, when: (i) the Registration Statement, as finally
amended (including any necessary post-effective amendments), shall have become effective under the Securities Act; (ii) a prospectus
supplement with respect to the sale of such series of Preferred Stock shall have been filed with the SEC in compliance with the Securities
Act and the rules and regulations thereunder; (iii) the Board or a duly authorized committee thereof shall have duly adopted
final resolutions in conformity with the Charter, the Bylaws and the Resolutions establishing the designations, preferences, rights,
qualifications, limitations or restrictions of such series of Preferred Stock and authorizing the issuance and sale of such series of
Preferred Stock; (iv) the Company shall have filed with the Secretary of State of the State of Delaware a Certificate of Designations
with respect to such series of Preferred Stock in accordance with the General Corporation Law of the State of Delaware (the “DGCL”)
and in conformity with the Charter and such final resolutions; and (v) certificates representing such series of Preferred Stock
shall have been duly executed, countersigned and registered and duly delivered in accordance with the applicable definitive purchase,
underwriting or similar agreement to the purchasers thereof against payment of the agreed consideration therefor in an amount not less
than the aggregate par value thereof or, if any shares of such series of Preferred Stock are to be issued in uncertificated form, the
Company’s books shall reflect the issuance of such shares in accordance with the applicable definitive purchase, underwriting or
similar agreement upon payment of the agreed consideration therefor in an amount not less than the aggregate par value thereof.
3. Each
issue of Warrants covered by the Registration Statement will constitute valid and binding obligations of the Company when: (i) the
Registration Statement, as finally amended (including any necessary post-effective amendments), shall have become effective under the
Securities Act; (ii) a prospectus supplement with respect to such issue of Warrants and the Common Stock, Preferred Stock or Debt
Securities issuable upon exercise of such Warrants shall have been filed with the SEC in compliance with the Securities Act and the rules and
regulations thereunder; (iii) a Warrant Agreement relating to such issue of Warrants shall have been duly authorized, executed and
delivered by the Company and duly executed and delivered by the Warrant Agent named in the Warrant Agreement; (iv) the Board or
a duly authorized committee thereof shall have duly adopted final resolutions in conformity with the Charter, the Bylaws and the
Resolutions authorizing the execution and delivery of the Warrant Agreement and the issuance and sale of such issue of Warrants; (v) if
such Warrants are exercisable for Common Stock, the actions described in paragraph 1 above shall have been taken; (vi) if such Warrants
are exercisable for Preferred Stock, the actions described in paragraph 2 above shall have been taken; (vii) if such Warrants are
exercisable for Debt Securities, the actions described in paragraph 4 below shall have been taken; and (viii) certificates representing
such issue of Warrants shall have been duly executed, countersigned and issued in accordance with such Warrant Agreement and shall have
been duly delivered in accordance with the applicable definitive purchase, underwriting or similar agreement to the purchasers thereof
against payment of the agreed consideration therefor.
NextCure, Inc.
August 4, 2023
Page 4
4. The
Debt Securities of each series covered by the Registration Statement will constitute valid and binding obligations of the Company when:
(i) the Registration Statement, as finally amended (including any necessary post-effective amendments), shall have become effective
under the Securities Act and the Indenture (including any necessary supplemental indenture) shall have been qualified under the Trust
Indenture Act of 1939, as amended; (ii) a prospectus supplement with respect to such series of Debt Securities shall have been filed
with the SEC in compliance with the Securities Act and the rules and regulations thereunder; (iii) the Indenture shall have
been duly authorized, executed and delivered by the Company and the Trustee; (iv) all necessary corporate action shall have been
taken by the Company to authorize the form, terms, execution, delivery, performance, issuance and sale of such series of Debt Securities
as contemplated by the Registration Statement, the prospectus supplement relating to such Debt Securities and the Indenture and to authorize
the execution, delivery and performance of a supplemental indenture or officers’ certificate establishing the form and terms of
such series of Debt Securities as contemplated by the Indenture; (v) a supplemental indenture or officers’ certificate establishing
the form and terms of such series of Debt Securities shall have been duly executed and delivered by the Company and the Trustee (in the
case of such a supplemental indenture) or by duly authorized officers of the Company (in the case of such an officers’ certificate),
in each case in accordance with the provisions of the Charter, the Bylaws, final resolutions of the Board or a duly authorized committee
thereof and the Indenture; and (vi) the certificates evidencing the Debt Securities of such series shall have been duly executed
and delivered by the Company, authenticated by the Trustee and issued, all in accordance with the Charter, the Bylaws, final resolutions
of the Board or a duly authorized committee thereof, the Indenture and the supplemental indenture or officers’ certificate, as
the case may be, establishing the form and terms of the Debt Securities of such series, and shall have been duly delivered in accordance
with the applicable definitive purchase, underwriting or similar agreement to the purchasers thereof against payment of the agreed consideration
therefor.
5. With
respect to an offering of Units covered by the Registration Statement, such Units will constitute valid and binding obligations of the
Company when: (i) the Registration Statement, as finally amended (including any necessary post-effective amendments), shall have
become effective under the Securities Act; (ii) a prospectus supplement with respect to such Units and the Common Stock, Preferred
Stock, Debt Securities or Warrants, as the case may be, included as a component of such Units shall have been filed with the SEC in compliance
with the Securities Act and the rules and regulations thereunder; (iii) an Unit Agreement relating to such issue of Units shall
have been duly authorized, executed and delivered by the Company and duly executed and delivered by the Unit Agent named in the Unit
Agreement, (iv) the Board or a duly authorized committee thereof shall have duly adopted final resolutions in conformity with the
Charter, the Bylaws and the Resolutions authorizing the execution and delivery of the Units Agreement and the execution, delivery, issuance
and sale of such Units; (v) if such Units relate to the issuance and sale of Common Stock, the actions described in paragraph 1
above shall have been taken; (vi) if such Units relate to the issuance and sale of Preferred Stock, the actions described in paragraph
2 above shall have been taken; (vii) if such Units relate to the issuance and sale of Warrants, the actions described in paragraph
3 above shall have been taken; (viii) if such Units relate to the issuance and sale of Debt Securities, the actions described in
paragraph 4 above shall have been taken; and (ix) certificates representing such Units shall have been duly executed, countersigned
and registered and shall have been duly delivered to the purchasers thereof in accordance with the applicable definitive purchase, underwriting
or similar agreement against payment of the agreed consideration therefor.
NextCure, Inc.
August 4, 2023
Page 5
Our opinions are subject to bankruptcy, insolvency,
reorganization, moratorium, fraudulent conveyance, fraudulent transfer and other similar laws relating to or affecting creditors’
rights generally and to general equitable principles (regardless of whether considered in a proceeding in equity or at law), including
concepts of commercial reasonableness, good faith and fair dealing and the possible unavailability of specific performance or injunctive
relief. Our opinion is also subject to (i) provisions of law which may require that a judgment for money damages rendered by a court
in the United States of America be expressed only in United States dollars, (ii) requirements that a claim with respect to any Debt
Securities or other obligations that are denominated or payable other than in United States dollars (or a judgment denominated or payable
other than in United States dollars in respect of such claim) be converted into United States dollars at a rate of exchange prevailing
on a date determined pursuant to applicable law and (iii) governmental authority to limit, delay or prohibit the making of payments
outside of the United States of America or in a foreign currency.
For the purposes of this letter, we have assumed
that, at the time of the issuance, sale and delivery of any of the Securities:
(i) the
Securities being offered will be issued and sold as contemplated in the Registration Statement and the prospectus supplement relating
thereto;
(ii) the
execution, delivery and performance by the Company of each Indenture, each Warrant Agreement and each Unit Agreement, as applicable,
and the issuance sale and delivery of the Securities will not (A) contravene or violate the Charter or Bylaws, (B) violate
any law, rule or regulation applicable to the Company, (C) result in a default under or breach of any agreement or instrument
binding upon the Company or any order, judgment or decree of any court or governmental authority applicable to the Company, or (D) require
any authorization, approval or other action by, or notice to or filing with, any court or governmental authority (other than such authorizations,
approvals, actions, notices or filings which shall have been obtained or made, as the case may be, and which shall be in full force and
effect);
(iii) the
authorization thereof by the Company will not have been modified or rescinded, and there will not have occurred any change in law affecting
the validity, legally binding character or enforceability thereof; and
NextCure, Inc.
August 4, 2023
Page 6
(iv) the
Charter and the Bylaws, each as currently in effect, will not have been modified or amended and will be in full force and effect.
We have further assumed that each Warrant Agreement,
each Unit Agreement, each Warrant, each Unit, each Indenture, each indenture supplement to the Indenture and each Debt Security will
be governed by the laws of the State of New York.
With respect to each instrument or agreement referred
to in or otherwise relevant to the opinions set forth herein (each, an “Instrument”), we have assumed, to the extent
relevant to the opinions set forth herein, that (i) each party to such Instrument (if not a natural person) was duly organized or
formed, as the case may be, and was at all relevant times and is validly existing and in good standing under the laws of its jurisdiction
of organization or formation, as the case may be, and had at all relevant times and has full right, power and authority to execute, deliver
and perform its obligations under such Instrument; (ii) such Instrument has been duly authorized, executed and delivered by each
party thereto; and (iii) such Instrument was at all relevant times and is a valid, binding and enforceable agreement or obligation,
as the case may be, of, each party thereto.
This opinion letter is limited to the DGCL and
the laws of the State of New York (excluding the securities laws of the State of New York). We express no opinion as to the laws, rules or
regulations of any other jurisdiction, including, without limitation, the federal laws of the United States of America or any state securities
or blue sky laws.
We hereby consent to the filing of this opinion
letter as an Exhibit to the Registration Statement and to all references to our Firm included in or made a part of the Registration
Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7
of the Securities Act.
Very truly yours,
/s/ Sidley Austin LLP
Exhibit 5.2
|
SIDLEY
AUSTIN LLP 787 SEVENTH AVENUE NEW YORK, NY 10019 +1 212 839 5300 +1 212 839 5599 FAX
AMERICA · ASIA PACIFIC
· EUROPE |
August 4, 2023
NextCure, Inc.
9000 Virginia Manor Road
Suite 200
Beltsville, Maryland 20705
Re: | Registration Statement on Form S-3 |
Ladies and Gentlemen:
We refer to the Registration
Statement on Form S-3 (the “Registration Statement”), being filed by NextCure, Inc., a Delaware corporation
(the “Company”), with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities
Act”). Pursuant to the Registration Statement, the Company may from time to time issue up to an aggregate offering price of
$16,762,573 of shares (the “Shares”) of its Common Stock, $0.001 par value per share (the “Common Stock”).
The Shares are to be sold by the Company pursuant to a sales agreement, dated August 4, 2023 (the “Sales Agreement”)
between the Company and Leerink Partners LLC.
This opinion letter is being
delivered in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.
We have examined the Registration
Statement, the Company’s prospectus dated August 4, 2023 relating to the Shares (the “ATM Prospectus”), the Sales
Agreement, the Company’s certificate of incorporation (as amended and restated, the “Certificate of Incorporation”),
the Bylaws of the Company, as amended to the date hereof (the “Bylaws”) and the resolutions (the “Resolutions”)
adopted by the board of directors of the Company (the “Board”) and the Audit Committee of the Board, relating to the
Registration Statement and the Sales Agreement. We have also examined originals, or copies of originals certified to our satisfaction,
of such agreements, documents, certificates and statements of the Company and other corporate documents and instruments, and have examined
such questions of law, as we have considered relevant and necessary as a basis for this opinion letter. We have assumed the authenticity
of all documents submitted to us as originals, the genuineness of all signatures, the legal capacity of all persons and the conformity
with the original documents of any copies thereof submitted to us for examination. As to facts relevant to the opinions expressed herein,
we have relied without independent investigation or verification upon, and assumed the accuracy and completeness of, certificates, letters
and oral and written statements and representations of public officials and officers and other representatives of the Company.
Sidley Austin (NY) LLP is a Delaware limited liability partnership doing business as Sidley Austin LLP and practicing in affiliation with
other Sidley Austin partnerships.
NextCure, Inc.
August 4, 2023
Page 2
Based on the foregoing, we
are of the opinion that the Shares will be validly issued, fully paid and non-assessable when: (i) the Registration Statement, as
finally amended (including any necessary post-effective amendments), shall have become effective under the Securities Act, (ii) the Board
or a duly authorized committee thereof shall have duly adopted final resolutions in conformity with the Certificate of Incorporation,
the Bylaws and the Resolutions, setting the price of the Shares, and authorizing the issue and sale of the Shares, and (iii) certificates
representing such Shares shall have been duly executed, countersigned and registered and duly delivered to the purchasers thereof against
payment of the agreed consideration therefor in an amount not less than the par value thereof or, if any such Shares are to be issued
in uncertificated form, the Company’s books shall reflect the issuance of such Shares to the purchasers thereof against payment
of the agreed consideration therefor in an amount not less than the par value thereof, all in accordance with the Sales Agreement.
For the purposes of this opinion
letter, we have assumed that, at the time of the issuance, sale and delivery of Shares:
| (i) | the Shares being offered will be issued and sold as contemplated in the Registration Statement and the
ATM Prospectus relating thereto; |
| (i) | the authorization thereof by the Company will not have been modified or rescinded, and there will not have occurred any change in
law affecting the validity thereof; |
| (ii) | the Certificate of Incorporation and Bylaws, as currently in effect, will not have been modified or amended and will be in full force
and effect; and |
| (iii) | the Company will have sufficient authorized and unissued shares of Common Stock from which to issue as the Shares. |
This opinion letter is limited
to the General Corporation Law of the State of Delaware. We express no opinion as to the laws, rules or regulations of any other jurisdiction,
including, without limitation, the federal laws of the United States of America or any state securities or blue sky laws.
We hereby consent to the filing
of this opinion letter as an Exhibit to the Registration Statement and to all references to our Firm included in or made a part of the
ATM Prospectus. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under
Section 7 of the Securities Act.
Exhibit 23.1
Consent of Independent Registered Public Accounting
Firm
We consent to the reference to our firm under
the caption "Experts" in this Registration Statement (Form S-3) and related Prospectus of NextCure, Inc. for the registration
of common stock, preferred stock, debt securities, warrants and units and to the incorporation by reference therein of our report dated
March 2, 2023, with respect to the financial statements of NextCure, Inc. included in its Annual Report (Form 10-K) for
the year ended December 31, 2022, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Baltimore, MD
August 4, 2023
Exhibit 107
Calculation of Filing Fee Tables
Form S-3
(Form Type)
NextCure, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward
Securities
|
Security
Type |
Security
Class
Title |
Fee
Calculation
or Carry
Forward
Rule |
Amount
Registered |
Proposed
Maximum
Offering
Price Per
Unit |
Maximum
Aggregate
Offering
Price |
Fee
Rate |
Amount
of
Registration
Fee |
Carry
Forward
Form Type |
Carry
Forward
File
Number |
Carry
Forward
Initial Effective
Date |
Filing
Fee
Previously
Paid In
Connection
with
Unsold
Securities
to be
Carried
Forward |
Newly
Registered Securities |
Fees
to be Paid |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
|
|
|
|
Fees
Previously Paid |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
|
N/A |
|
|
|
|
Carry
Forward Securities |
Carry
Forward Securities |
Equity |
Common
Stock, par value $0.001 per share |
415(a)(6) |
N/A |
N/A |
N/A |
N/A |
|
|
|
|
|
Carry
Forward Securities |
Equity |
Preferred
Stock, par value $0.001 per share |
415(a)(6) |
N/A |
N/A |
N/A |
N/A |
|
|
|
|
|
Carry
Forward Securities |
Debt |
Debt
Securities |
415(a)(6) |
N/A |
N/A |
N/A |
N/A |
|
|
|
|
|
Carry
Forward Securities |
Other |
Warrants |
415(a)(6) |
N/A |
N/A |
N/A |
N/A |
|
|
|
|
|
Carry
Forward Securities |
Other |
Units |
415(a)(6) |
N/A |
N/A |
N/A |
N/A |
|
|
|
|
|
Carry
Forward Securities |
Unallocated
(Universal) Shelf |
Unallocated
(Universal) Shelf |
415(a)(6) |
$180,000,000(1) |
|
$180,000,000 |
|
|
S-3ASR |
333-241706 |
August 6,
2020 |
$19,638 |
|
Total
Offering Amounts |
|
$180,000,000 |
|
N/A |
|
|
|
|
|
Total
Fees Previously Paid |
|
|
|
N/A |
|
|
|
|
|
Total
Fee Offsets |
|
|
|
N/A |
|
|
|
|
|
Net
Fee Due |
|
|
|
N/A |
|
|
|
|
(1) | NextCure, Inc. (“the “Registrant”) previously
filed a Registration Statement on Form S-3ASR with the Securities and Exchange Commission (the
“SEC”) on August 6, 2020 (File No. 333-241706) (the “Prior Registration
Statement”), which was declared effective upon filing, that registered an indeterminate amount
of securities to be offered by the Registrant from time to time. In connection with Post-Effective
Amendment No. 1 to the Prior Registration Statement filed with the SEC on March 4, 2021,
the Registrant paid a filing fee of $19,638. All of the $180,000,000 of securities registered on the
Prior Registration Statement remain unsold. Pursuant to Rule 415(a)(6) under the Securities
Act, the $19,638 filing fee previously paid in connection with such unsold securities will continue
to be applied to such unsold securities. Pursuant to Rule 415(a)(6) under the Securities
Act of 1933, the offering of unsold securities under the Prior Registration Statement will be deemed
terminated as of the date of effectiveness of this registration statement. |
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From Apr 2024 to May 2024
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From May 2023 to May 2024